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Abstract 
 
Background 
Chronic kidney disease (CKD) continues to increase worldwide. Professional organisations have 
committed themselves to developing clinical practice guidelines to manage and prevent disease 
progression. People with diabetes and hypertension are at greater risk of developing CKD, but other 
risk factors include smoking, obesity, family history of CKD and being Aboriginal/ Torres Strait 
Islander or other ethnic minority. In order to prevent disease progression and other complications 
such as heart attack or stroke, people with early stage CKD must adhere to treatment regimes and 
make lifestyle modifications. Patients need to be active participants in their own care however their 
involvement may be limited by lack of awareness and understanding of CKD. Educational 
interventions may facilitate learning and provide patients with the knowledge and skills to better 
manage their condition.   
 
Aims 
The overarching aim of this thesis was to explore guideline recommendations about the 
management of patients with early stage CKD, identify ways in which patients could improve their 
knowledge and participation in self-care and discover strategies to educate them. The 
recommendations provided in clinical practice guidelines are crucial to patient care, therefore we 
sought to assess and compare guideline quality, scope, content and consistency. This was followed 
by identifying patients’ level of awareness about CKD, their information needs, perspectives and 
beliefs about managing and living with the disease and its associated complications. Finally we 
assessed the effectiveness and quality of educational interventions for primary and secondary 
prevention of CKD.   
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Methods and Results 
In Chapter 3 the Appraisal of Guidelines for Research and Evaluation (AGREE) II instrument and 
textual synthesis was used to appraise and compare the recommendations. Fifteen guidelines and 
one consensus statement were identified and included. The methodological rigour across guidelines 
was variable and there were some evident inconsistencies across the recommendations. Some 
inconsistencies included variation in the definition thresholds for protein and albumin creatinine 
ratios and proteinuria, protein intake recommendations, blood pressure targets and the use of anti-
hypertensives as either combined or monotherapy. Salt intake was recommended by most, but 
psychosocial and education recommendations were recommended by few.  
 
In Chapter 4 participants with CKD Stages 1-5 were purposively sampled to participate in a mixed 
methods study. There were nine focus groups and participants had the opportunity to complete a 
survey on CKD risk factors. Thirty eight participants completed the survey, where 70 – 90% of 
participants recognised hypertension, diabetes, family history and obesity as risk factors for CKD. 
Heart attack, stroke and premature mortality were considered 20 – 40% lower risk in people with 
CKD than those with pre-existing cardiovascular disease (CVD) or diabetes. Five themes were 
identified which reflected reasons for patients choices: invisibility (asymptomatic disease), 
invincibility (refused to believe they were sick), lacking awareness, cumulative comorbidities (risks 
of associated diseases) and inevitability of death (CKD has no cure). 
 
Focus group discussions were also used in Chapter 5. Transcripts were transcribed verbatim and 
thematically analysed. A total of 38 participants were included. Six major themes were identified: 
medical attentiveness (shared decision making, rapport, indifference and insensitivity); learning 
self-management (diet and nutrition, barriers to physical activity, medication safety); 
contextualizing comorbidities (prominence of chronic kidney disease, contradictory treatment); 
prognostic uncertainty (hopelessness, fear of disease progression, disbelief regarding diagnosis); 
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motivation and coping mechanisms (engage in research, pro-active management, optimism, feeling 
normal); and knowledge gaps (practical advice, access to information, comprehension of pathology 
results and CKD diagnosis, education for general practitioners).  
 
In Chapter 6 we systematically searched the literature for educational interventions in people with 
Stages 1-5 CKD in the community and hospital setting. Study quality was assessed using the 
Cochrane Collaboration risk of bias tool. Twenty-five studies, 12 trials and 13 observational studies, 
involving 5,345 participants were included. Risk of bias was high in most studies. Interventions 
were multifaceted, including face-to-face teaching (25 studies), written information (19 studies) and 
telephone follow-up (13 studies). Nineteen studies involved one-on-one patient/educator interaction 
and 13 incorporated group sessions. Nine studies showed improved outcomes for quality of life, 
knowledge and self-management; eight had improved clinical endpoints; and two studies showed 
improvements in both patient reported and clinical outcomes. Characteristics of effective 
interventions included teaching sessions that were interactive - workshops/practical skills (12/14 
studies); integrated negotiated goal setting (9/12 studies); involved groups of patients (11/13 
studies), their families (4/4 studies) and a multidisciplinary team (6/6 studies); and had frequent 
[weekly (4/5 studies) or monthly (7/7 studies)] participant/educator encounters.  
 
Conclusions  
CKD guidelines were consistent in scope but were variable with respect to their recommendations, 
coverage and methodological quality. Participants were found to have limited understanding of the 
risk factors and comorbidities associated with CKD and therefore perceived CKD to be less of a 
threat to life compared with CVD and diabetes. Patients’ ability to delay the progression of CKD 
may be affected by their lack of knowledge about the disease, its comorbidities, psychosocial 
influences and their ability to communicate effectively with their health care provider. Interactive, 
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frequent, and multifaceted educational interventions that include both individual and group 
participation appear to improve knowledge, self-management and patient outcomes. 
 
To promote effective primary and secondary prevention of CKD, regularly updated guidelines that 
are based on the best available evidence and augmented with healthcare context-specific strategies 
for implementation are warranted. Implementation strategies would include patient education 
interventions which address CKD risk factors, comorbidities and outcomes, and may also increase 
awareness and foster better self-management for people with CKD. Support from a 
multidisciplinary care team, combined with provision of comprehensive, accessible and practical 
educational resources may enhance patients’ ability and motivation to access and adhere to 
therapeutic and lifestyle interventions to retard progression of CKD.   
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Chapter 1. Introduction 
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Chapter 1 Introduction 
 
1.1 Background 
 
On a global scale, chronic kidney disease (CKD) is affecting an ever increasing number of people 
[1, 2]. CKD increases the risk of end-stage kidney disease (ESKD) as well as cardiovascular disease 
(CVD) and other complications such as premature death [3-5]. Evidence suggests that early 
detection and treatment of CKD, that is guided by trustworthy guidelines [6, 7], can slow the 
progression of disease [2, 8, 9]. To be effective for use in clinical practice, guidelines should be 
rigorously developed, be consistent with the available scientific evidence, accessible, transparent, 
unbiased and acceptable to clinicians [6, 10]. If these factors are not met, the recommendations may 
be ineffective and potentially dangerous to clinical care [6]. 
 
The increased rates of diabetes, hypertension, and an ageing population are the main contributors to 
the rising prevalence of CKD and the increase in cardiovascular death [4, 11-13]. This increased 
risk is well known to healthcare providers but may not be so well known amongst patients. Lack of 
awareness about CKD has been found to persist in patients throughout the disease continuum [14]. 
This may limit their abilities and willingness to actively participate in self-management to prevent 
disease progression and treat their comorbidities. Some studies have assessed patients’ awareness 
about the risk factors and comorbidities for CKD. While one identified that 92% of participants 
believed hypertension and diabetes (86%) were risk factors for CKD [15], others demonstrated that 
up to 36% of patients believed excessive alcohol intake was a major cause of CKD [16, 17] and 
25% thought it was inadequate diet [17] and 40% were unsure [16]. However the reasons for 
patients’ perception on risk factors and comorbidities are unknown. 
 
The asymptomatic nature of early stage CKD and lack of public awareness about the disease [17, 
18], also mean that patients may be reluctant to accept the diagnosis, lack insight into factors that 
Chapter 1. Introduction 
2 
may drive progression and be at risk of non-adherence to recommended therapies. Therefore they 
need to be informed about the benefits of maintaining a healthy lifestyle and adhering to medication 
to reduce proteinuria, hypertension and diabetes [19]. Studies show that patients have very limited 
knowledge about CKD and the prevention of ESKD [14], they also experience depression and 
anxiety, and have limited participation in treatment planning, and poor quality of life [20, 21]. 
Effective education interventions can improve symptoms, survival, quality of life and reduce 
hospitalization rates and progression to ESKD [20, 22-24]. 
 
An essential element for the care of people with CKD is to educate them about the risk factors and 
their management, to ensure effective primary and secondary prevention [25-29]. Systematic 
reviews, focused on diet and fluid management, have shown that educational interventions may be 
effective in pre-dialysis and dialysis patients [30] and self-management programs in stages 1-4 
CKD have shown some improvement in knowledge and quality of life [31]. However, previous 
systematic reviews were primarily focused on dialysis patients, or were limited to self-management 
interventions, rather than educational interventions more broadly.  
 
Effective strategies to prevent CKD progression requires understanding the views, concerns, and 
needs of patients, so that educational interventions address their information needs and promotes 
their capacity to make lifestyle changes.  
 
1.2 Aims 
 
The primary aims of the research described in this thesis are: 
1. To identify current clinical management for people with CKD, provide evidence of the need 
for increased education and health promotion, outline educational and preventive strategies 
for patients and include suggestions future strategies.   
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2. To compare the quality, scope, and consistency of clinical practice guidelines on the 
prevention, detection and management of stage 1-3 CKD. The published guidelines were 
also assessed for their methodological consistency and comprehensiveness. 
3. To assess and describe patients’ awareness and perceptions of the risk factors and 
comorbidities related to CKD. 
4. To describe the experiences and perspectives of patients with early stage CKD, with a 
specific focus on their information needs in managing and living with CKD and its related 
complications.  
5. To evaluate the effectiveness of education interventions for primary and secondary 
prevention of CKD, and to identify the individual characteristics of the more effective 
educational interventions. 
 
1.3 Thesis overview 
 
The overall objective of this thesis was to expand on the current evidence for the management of 
patients with early stage CKD by identifying patients’ perceptions and beliefs about their disease, 
and their thoughts regarding the risk factors and associated comorbidities. To inform the 
development and implementation of educational interventions for the primary and secondary 
prevention of progression of CKD, and also to inform treatment that is based on good quality and 
evidence based guidelines. 
 
Chapter 2 is a narrative review of the evidence covering current clinical management of people with 
CKD as recommended by clinical practice guidelines. The review also includes the a summary of 
the literature regarding patient awareness of CKD, their information and education needs and 
suggestions for education strategies used to promote awareness and patient knowledge about 
management and prevention of progression. 
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Chapter 3 is a systematic review of clinical practice guidelines that are used worldwide for the 
management, detection and prevention of CKD. The guidelines were assessed for quality, 
comprehensiveness and scope. The methodological quality of the guidelines was conducted using 
the Appraisal of Guidelines for Research and Evaluation (AGREE) II instrument [32]. This 
instrument has been internationally validated and consists of six domains which include, scope and 
purpose, stakeholder involvement, rigour of development, clarity and presentation, applicability and 
editorial independence.  
 
Chapters 4 and 5 were based on the study I conducted to identify patients’ educational needs and 
awareness about CKD. This was a qualitative study which involved the recruitment of patients from 
three major hospitals in NSW to take part in focus group discussions. Focus group discussions 
facilitate group interaction and allow participants to explore and clarify their individual and shared 
experiences [33]. Chapter 4 was a mixed-methods study where knowledge and awareness of the risk 
factors and comorbidities associated with CKD was assessed using a self-administered survey that 
was given to all participants during the focus group discussions. The qualitative component 
provided the evidence to support their choices in the survey. Chapter 5 was solely a qualitative 
study, involving the identification of themes related to education and information needs.  
 
Chapter 6 was a systematic review of educational interventions for patients with early stage CKD. 
The interventions were assessed for risk of bias using the Cochrane tool for randomised studies [34] 
and the Effective Practice and Organisation of Care (EPOC) Review Group Criteria for controlled 
before and after studies [35]. A detailed analysis of the intervention characteristics was done using a 
taxonomy framework for educational interventions. This framework assesses the setting (one-on-
one, group), delivery style (face-to-face, telecommunication, written), teaching method (didactic, 
goal setting, situational), intensity (frequency, number of episodes, duration), content and personnel 
[36]. This framework has been previously used in diabetes education interventions.  
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Chapter 7 provides an overall discussion of this work, encompassing main findings, strengths and 
limitations, comparisons with other studies, implications for clinical practice and research, and 
conclusions. 
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Chapter 2 Self-management of chronic kidney disease through 
effective educational strategies 
 
2.1 Abstract  
 
The incidence and prevalence of chronic kidney disease (CKD) continues to rise worldwide, leading 
to a substantial health and financial burden, on individual patients and societally more generally. 
This occurs because of the direct effect of CKD and its treatment, and indirectly, by leading to 
cardiovascular disease, cancer and other comorbidities.  Given the chronic nature of the condition, 
self-management is increasingly recognised as critical to improving the outcomes of people with 
CKD, and effective educational strategies are required to ensure this happens. If substantial 
improvements in the outcomes for people are to occur, prevention of progression needs to be the 
focus, rather than simply improving the care of people who need renal replacement therapy.  
Patients with early-stage CKD are required to make lifestyle modifications and adhere to treatment 
regimens to prevent disease progression and complications. This can only occur if patients 
understand their disease and what they can do to prevent its progression and effective educational 
strategies are central to this framework. The aims of this narrative review are to identify current 
clinical management for people with CKD, provide evidence of the need for increased education 
and health promotion, outline educational and preventive strategies for patients and suggest future 
strategies.   
 
2.2 Introduction 
 
The burden of chronic kidney disease (CKD) patients is increasing worldwide [3]. Kidney disease is 
associated with other acute and chronic diseases including cardiovascular disease, diabetes, chronic 
pulmonary disease and cancer [4]. Complications from CKD include all-cause and cardiovascular 
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mortality, acute kidney injury, progression of kidney disease, anaemia, mineral bone disorders, 
fractures and cognitive decline [5]. Preventing CKD and delaying its progression to end-stage 
kidney disease (ESKD) will also impact upon complications and will decrease the disease burden 
overall, directly and indirectly.   
 
Introducing and incorporating preventive strategies such as early detection, patient education and 
promoting awareness about CKD in the community are methods that may reduce this global 
epidemic. There is evidence indicating that the ESKD incidence has been reduced in communities 
where comprehensive management strategies have been implemented [5]. 
 
Problems affecting the management of early stage CKD include its asymptomatic nature. 
Individuals with the disease may not be aware they have it and therefore fail to recognise the 
importance of treatment [6]. Improved awareness of the associated risk factors of CKD such as 
diabetes, hypertension, obesity and family history, may assist early detection. 
 
The aims of this narrative review are to identify the current management and prevention strategies 
for CKD; to investigate patients’ current needs about CKD management and prevention; explore the 
level of patients’ awareness of CKD risk factors and comorbidities and factors affecting patients’ 
willingness to make changes. Current CKD management policies and suggestions for future patient 
education strategies will also be discussed.  
 
2.3 What is chronic kidney disease? 
Definition, classification and epidemiology  
 
Chronic kidney disease is defined as having a glomerular filtration rate (GFR) of <60 
ml/min/1.73m2 , or the presence of albuminuria for ≥ 3 months or more [7]. There are six 
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progression stages of CKD which can be seen in Figure 2.1. The combination  of estimated 
glomerular filtration rate (eGFR) and albuminuria determines the stage and severity of the disease, 
and places the individual at an increased risk of CKD progression at all ages, compared with those 
with only low GFR, albuminuria or proteinuria [1]. 
 
Worldwide, the prevalence of CKD is estimated to be 8-16% [5]. In Australia, kidney disease 
currently affects an estimated 1.7 million people (10%) aged 18 years of age and older. 
Approximately 4% of all adults are in Stage 1, 2.5% are in Stage 2 and less than 1% are in Stages 4-
5 [8]. This means that up to 92.5% of patients may potentially have Stage 3 CKD (eGFR 30-60) 
whereby the majority will be cared for by their general practitioner rather than by nephrologists. 
Which means that CKD management and patient education is not only of concern for nephrologists, 
but for primary care physicians as well. Prevalence of CKD increases with age as only 5.5% of 
people under the age of 55 years had indicators of CKD compared to 42.2% of people aged 75 years 
and over [8]. Similar prevalence rates are found worldwide. In the USA, data from the National 
Health and Nutrition Examination Survey indicates a prevalence rate of 15% for CKD stages 1-4 
for the period 2007 – 2012 [9].  
 
2.3.1 What causes CKD?  
Risk factors, comorbidities and complications 
 
Diabetes and hypertension are the main causes of CKD in developed and many developing 
countries. In developing countries, infectious diseases continue to contribute to the burden of CKD, 
whereas in developed countries the problem has shifted to lifestyle-related diseases which include 
hypertension and diabetes [5, 7]. Along with obesity and smoking, diabetes and hypertension are 
regarded as modifiable risk factors which, when addressed, may minimise the risk of CKD. The 
non-modifiable risk factors for CKD include increasing age, family history of CKD and ethnicity. 
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Ethnic minority groups include Indigenous Australians, Pacific and Torres Strait Islanders, Maori 
people, South American Aborigines, First Nation Canadians, black and Asian people in the United 
Kingdom, and black, Hispanic and Native Americans in the United States [1, 5, 7]. 
 
Hypertension and diabetes are not only risk factors for CKD but also regarded as comorbidities 
which increase the rate of progression of CKD, mortality and morbidity. The prevalence of 
hypertension in adults has been estimated to increase to 1.56 billion by 2025 [10]. The current rates 
for treatment and control of hypertension is low, with 29% and 10% respectively in men, and 41% 
and 17% respectively in women [11]. The global prevalence of diabetes is estimated to be 6.4%, 
affecting 285 million adults. This is projected to increase to 7.7%, affecting 439 million adults in 
2030 [12]. Diabetes may be the leading cause of CKD and end-stage kidney disease (ESKD) in the 
US. Strategies that address the control of hypertension and diabetes are necessary to decrease the 
risk and rate of progression of CKD [2].  
 
A series of health complications arise from having CKD.  Some of these begin to develop during 
the earlier stages of the disease such as anaemia, while others appear later; calcium-phosphorus 
mineral and bone disorder, metabolic acidosis, hypoalbuminaemia, malnutrition, dyslipidaemia and 
the development of cardiovascular disease (CVD) [2]. Results from the Framingham cohort study 
showed that patients with mild CKD had almost double the prevalence of CVD compared to those 
with no CKD [2]. In 2010, more than 40% of deaths worldwide were due to CVD, CKD and 
diabetes where high blood pressure was the leading risk factor. High body mass index (BMI) and 
glucose were responsible for about 15% of deaths each, and high cholesterol for more than 10% 
[13]. 
 
2.3.2 Current clinical management of CKD 
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Current clinical practice for CKD management is guided by clinical practice guidelines (CPG) 
which provide guidance for the detection and management of CKD and prevention of progression 
[14]. While there have been 523 guidelines on kidney disease published to date [14], 15 of them 
address the detection, management and prevention of CKD [15]. Guidelines help clinicians and 
patients make informed choices about their care, ultimately leading to improved patient outcomes 
and quality of care [16] .  
 
The current Australian and New Zealand guideline for the management of early CKD recommends 
lifestyle modification and nutrition interventions, along with medical therapies for blood pressure 
control, glucose control, lipid management, anti-platelet , uric acid and vitamin D [1]. Management 
of blood pressure mainly involves the use of angiotensin-converting enzyme inhibitors (ACEi) or 
angiotensin receptor blockers (ARB) as first line therapy. The blood pressure target is ≤140/90 or 
≤130/80 for people with micro or macro albuminuria [1]. Both these medications have been shown 
to slow the progression of CKD [17]. 
 
The guideline also recommends dietary modification of protein, salt, phosphate and potassium, and 
other specific diets. Lifestyle changes include increasing physical activity, cessation of smoking and 
moderate consumption of alcohol, carbonated beverages and fluid intake [1]. Although early 
detection and management of CKD can prevent disease progression, studies have shown that 
current management is inadequate. This can be attributed to the asymptomatic nature of early CKD 
and lack of preventive care, such as monitoring modifiable risk factors in high-risk patients [18]. 
 
The guideline also recommends dietary modification of protein, salt, phosphate and potassium, and 
other specific diets. Lifestyle changes include increasing physical activity, cessation of smoking and 
moderate consumption of alcohol, carbonated beverages and fluid intake [1]. Although early 
detection and management of CKD can prevent disease progression, studies have shown that 
Chapter 2. Self-management of chronic kidney disease through effective educational strategies 
15 
current management is inadequate. This can be attributed to the asymptomatic nature of early CKD 
and lack of preventive care, such as monitoring modifiable risk factors in high-risk patients [18]. 
 
Recommendations for the early detection of CKD include screening people with risk factors such as 
diabetes, smoking, hypertension, obesity, established CVD, family history and Aboriginal or Torres 
Strait Islander origin, assessing kidney function (estimated glomerular filtration rate eGFR) and 
urine (albumin:creatinine ratio ACR). If the kidney function is <60ml/min/1.73m2, the test needs to 
be repeated within two weeks, and twice again within the next three months if the second test 
remains below <60ml/min/1.73m2. Likewise the urine test needs to be repeated if values exceed 
>2.5 and >3.5 mg/mmol for males and females respectively.  If the renal function remains low, the 
individual needs to be referred to a nephrologist [1]. The presence of albuminuria is of prognostic 
importance as studies have shown that patients with eGFR >60 ml/min/1.73m2 and moderately 
elevated proteinuria (ACR of 30/300 mg/g) have significantly worse outcomes than those with an 
eGFR <60 ml/min/1.73m2 but no proteinuria. These adverse outcomes include increased risk of 
CVD, hospitalisation, infections and all-cause mortality [19]. Other guidelines have defined similar 
management regimes however there are some variations with respect to recommendations for 
albumin creatinine ratios and proteinuria definition thresholds [15]. 
 
2.4 Prevention of progression of CKD 
 
Aside from screening and early management of CKD, preventive strategies include effective self-
management through patient education and behaviour modification, and multidisciplinary care. 
Patient education should provide information about the management of risk factors and 
comorbidities for CKD, strategies to improve self-management for blood pressure and glucose 
control, medication adherence and lifestyle changes. These involve promoting active lifestyle, 
weight control, and smoking cessation. Educational programs should take into consideration the 
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patient’s stage of CKD, individual health requirements and cultural and social backgrounds. The 
care provided should be multidisciplinary involving a doctor, nurse, dietician and social worker [1]. 
A clinical algorithm adapted from Johnson et al [1] (Figure 2.2) demonstrates the pathway for the 
screening and education of patients with CKD.  
 
The implementation of prevention programs has shown some improvements in countries such as 
Cuba, Chile, Uruguay and Taiwan. These have included screening and management, continuing 
education for nephrologists, general practitioners and other health professionals, increased 
nephrology services and surveillance. Since their commencement the incidence and prevalence of 
end-stage renal disease have declined [5]. 
 
2.4.1 Early intervention programs 
Community awareness programs 
 
There are several programs which promote awareness and improve screening that are being 
implemented worldwide. The National Institute of Diabetes and Digestive and Kidney Diseases 
(NIDDK) developed the National Kidney Disease Education Program (NDKEP), which aims to 
increase awareness of CKD amongst primary care providers and people at high risk. The program 
comprises three areas of care: laboratory screening for CKD and management of risk factors such as 
hypertension; public awareness particularly for African American individuals and program 
evaluation [17, 20]. The Kidney Early Evaluation Program (KEEP) initiated by the National Kidney 
Foundation, targets high risk individuals and their relatives with diabetes or hypertension and 
provides free health screening. This program offers blood and urine testing, on-site physician 
consultation, referrals to appropriate health care providers and follow-up for those with abnormal 
findings [17, 20]. The Kidney Check Australia Taskforce (KCAT) is responsible for Kidney Health 
Australia’s health professionals’ education program. KCAT produced a CKD Management in 
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General Practice booklet, which provides guidance and clinical information to help general 
practitioners identify and manage patients at high risk of CKD [21].  
 
2.5 Patient awareness about CKD 
 
Patient awareness involves having general knowledge about CKD, its risk factors, complications, 
and an understanding of their own CKD stage and associated risks. Awareness has been found to be 
consistently low [22, 23]. Up to a third of participants believed that alcohol was the main cause for 
CKD and 2.8% and 8.6% respectively identified hypertension and diabetes as risk factors. 
Additionally, participants being treated for hypertension were not more aware of the risk of CKD 
compared to patients who were normotensive (3.3% versus 2.7%), but those diagnosed as having 
diabetes did have greater awareness of the risks of CKD compared to those without diabetes (25.7% 
versus 4.2%) [23]. Tuot et al. have shown that up to 90% of individuals with two or three markers 
of CKD were unaware of their condition. These markers included hyperkalaemia, 
hyperphosphataemia, uraemia, nitrogen, acidosis, albuminuria, anaemia and hypertension. 
However, individuals with albuminuria had greater awareness of their disease compared to those 
without (P<0.01) [24].  
 
Awareness of the relationship between CKD and other comorbidities such as CKD and diabetes is 
also limited. Individuals with coronary heart disease (CHD) have an increased prevalence of CKD 
and vice versa. The Reasons for Geographical and Racial Differences in Stroke (REGARDS) cohort 
study showed that among participants with both CHD and CKD, 5% were aware of their CKD 
compared to 2% in those without CHD. Among participants with a GFR <60ml/min/1.73m
2
, 10% 
reported having been told by a physician that they had kidney disease [25]. Similarly patients with 
uncontrolled hypertension or diabetes were shown to have a poor perception of the likelihood of 
developing CKD [26]. 
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In patients with CKD and hypertension, knowledge of the blood pressure target is independently 
associated with lower systolic blood pressure [27]. However, in a study of the treatment needs of 
primary care patients 41% of individuals were unaware of their CKD diagnosis and up to 33% 
required improved blood pressure control. Almost 10% of patients needed advice to investigate 
anaemia or to stop nephrotoxic drugs [28]. Thus is can be seen that patients have limited awareness 
about their CKD status and even in those who were aware, their blood pressure management 
remained inadequately controlled.  
 
Patient awareness and treatment adherence 
 
The association between patient awareness of CKD and adherence to therapy was examined in a 
study involving adults with CKD who participated in the National Health and Nutrition 
Examination Surveys 2003-2008. Results indicated that there was no difference in blood pressure 
control and ACEi/ARB use between individuals who were aware of their CKD and those that were 
not, adjusted odds ratio 0.91 (95%CI 0.52-1.58) and 0.75 (0.44-1.30) respectively. Also, glycaemic 
control was not associated with increased CKD awareness AOR 0.41 (0.14-1.18) [29]. Awareness 
of the condition alone does not promote behaviour change or ensure adequate management. 
Education interventions to improve patient knowledge may be the key to promoting increased 
awareness, management and participation in self-care. 
 
2.5.1 Patient education needs  
 
Knowledge of patient information needs is fundamental to the development of patient education 
programs and services. Patient information need is defined as the ‘recognition that their knowledge 
is inadequate to satisfy a goal, within the context/situation that they find themselves at a specific 
point in the time’ [30, 31]. The terms information need and education need have been used 
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synonymously, however these should be differentiated. Both terms imply a knowledge deficit, 
however education need refers to a cognitive deficit that is objectively measured (by an external 
individual) and that is aimed at modifying health behaviour. Information need is a 
subjective/cognitive knowledge deficit recognized by the individual [31-33]. 
 
Providing information to patients gives them the opportunity to improve their understanding of 
CKD, self-management, decreases concerns and promotes the maintenance of a normal life [34]. In 
a systematic review about the education needs of patients with CKD, the  topics of interest 
included: information – physiology, symptoms, disease progression, complications; CKD 
management – medical and renal replacement therapy; diagnostic tests; lifestyle and dietary 
management; family, social and psychosocial impact; patient experiences, support groups and 
service provision [34]. Ormandy et al. conducted semi-structured interviews of pre-dialysis and 
dialysis patients to identify their information needs. Of highest priority were information needs 
about how kidney disease may affect patients, how to recognise symptoms and what to expect. 
Patients in full or part-time employment were most concerned with how to manage their condition, 
complications, side effects and the impact it will have on their lifestyle. Most participants identified 
information about the causes of CKD, its progression and understanding what to expect in the future 
as necessary information for all new patients [35, 36]. 
 
In a focus group study on patients with CKD and hypertension, six themes about blood pressure 
control were identified: lack of basic knowledge about blood pressure (BP); conflicting advice 
given by doctors; delay in diagnosis due to lack of symptoms; changes in BP management; self-
management – BP monitoring; and views on the patient-health professional relationship. Increasing 
patient knowledge and motivation helped to address the confusion experienced by the participants 
[37].  
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These studies have shown that patients desperately need more information and education about their 
disease, its management and prevention. Patients want to know what future outcomes they should 
expect and how this will affect them, their families and social sphere. Providing patients with the 
necessary information has been shown to assist in managing stress, improve well-being, compliance 
with treatments and self-care, and reduced dependency on health care services [31, 33, 38].    
 
2.5.2 The process of patient education 
 
The process of patient education involves five stages. These are: 1. Assess current knowledge, 
learning abilities, misconceptions, attitudes and motivation; 2. Identify their learning needs and 
barriers; 3. Plan the education intervention with patient input including their goals, frequency, type 
of education, who will provide the education and how; 4. Deliver the education intervention; 5. 
Evaluate the patient’s needs and the effectiveness of the program [39]. In a study by Wright-Nunes, 
the association between knowledge and patient satisfaction with physician communication was 
assessed. Perceived knowledge was associated with higher odds (2.13) and objective knowledge 
was associated with lower odds (0.91) of patient satisfaction with physician communication [40]. 
We need to be aware of what patients believe they know and what they actually know in order to 
tailor education to their needs.  
 
2.6 Education for chronic kidney disease 
What is health education? 
 
Health education is any combination of learning experiences designed to help individuals and 
communities improve their health, by increasing their knowledge or influencing their attitudes [41]. 
The main purpose of health education is to produce a positive change in patient behaviour which 
promotes health. However, to be effective, health education programs need to consider the target 
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audience, their social characteristics, beliefs, attitudes, skills and past behaviours [42]. Knowledge 
increases perceived control and improves the patient’s ability to adapt to the chronic-illness role and 
self-care behaviour such as modification of diet and fluid intake, increased exercise and medication 
adherence and attending physician appointments [39]. 
 
2.6.1 Theoretical basis  
Education theories and models of care 
 
The use of theory in health education facilitates research and practice. It can be applied during the 
planning, implementation and evaluation stages of an intervention. Theories help explain behaviour 
and suggest ways to modify it [42]. Models on the contrary, draw from a number of theories to aid 
in understanding a specific problem in a particular context or setting [43]. The most commonly used 
theories and models in health education are the Social Cognitive Theory, the Theory of Reasoned 
Action, the Health Belief Model and the Trans-theoretical Model [42]. However the model that 
would most likely be used in a future CKD educational intervention would be the Trans-theoretical 
Model. This model has been applied to some of the more resistant behaviours to change such as 
smoking cessation, diet and weight control, addictive and life-threatening behaviours [44], all of 
which are factors associated with CKD. 
 
Transtheoretical Model of Behaviour Change 
 
Prochaska’s model of behaviour change focuses on the transition points in the process and the 
underlying factors that facilitate movement between stages. It helps us to understand how an 
individual will progress through the stages of behaviour change until the behaviour becomes a habit 
[45].  The six stages of change are [42]: Pre-contemplation – the individual does not intend to take 
action in the next six months; Contemplation – the individual intends to change within the next six 
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months and are aware of the costs and benefits; Preparation – the individual intends to take action 
within the next month. They have a plan of action to make a change; Action – the individual has 
made obvious changes in the past six months; Maintenance – the individual strives to prevent 
relapse but does not apply change processes as often as people in the action stage; Termination – 
the individual is no longer tempted by old habits and has complete self-efficacy. 
 
2.6.2 Barriers to patient education 
Health-care provider barriers 
 
Identifying the barriers and enablers to change is necessary for the implementation of education 
interventions. Interventions addressing the barriers may improve patient care and outcomes [46]. 
Consideration should be given to patient and physician characteristics as well as the social, 
economic, organizational and political circumstances [47].  Barriers preventing the dissemination of 
health promotion innovations and implementation include: access to information – sometimes 
physicians and  health-care providers may not be aware of the available information; physician 
beliefs regarding the effectiveness of the intervention; organizational priorities; behavioural 
intervention skills – physicians may feel inadequately prepared to provide advice; inappropriate 
expectations in assuming a complex health problem could be controlled through health promotion 
alone; lack of sociocultural relevance – ethnic, minority and other subcultural groups need to be 
considered [48]. 
 
Patient barriers 
 
Sometimes underlying issues may affect a patients’ willingness to adhere to an education program. 
In a focus group study [49] involving 54 chronically ill people, the perceived barriers to active self-
management included depression, weight problems, fatigue, difficulty exercising, poor physician 
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communication, low family support, pain and financial problems. Medication adherence has been 
found to depend on patients’ beliefs about the necessity of taking their medication versus concerns 
about its side effects [50]. Similar results were identified in another study which assessed adherence 
to a low sodium diet. Adherence was associated with greater perceived benefits and fewer perceived 
barriers [51]. 
 
Lack of awareness about a disease can affect an individual’s willingness to engage in education. In 
a study involving 2017 African Americans it was identified that only 24% had been screened for 
kidney disease and of the 44% who had a risk factor, only 2.8% reported that CKD was an 
important health concern. Participants who perceived themselves at increased risk, and had been 
screened for CKD, had diabetes, hypertension, a family history of kidney disease, a tertiary 
education and who had also spoken with a medical professional or their family [52].  
 
Cultural barriers   
 
People’s abilities to modify their lifestyle can be impeded by their cultural and health beliefs. Such 
was the case amongst Bangladeshi people with CKD whose dietary customs and culturally-
established taste for salt made it difficult for them to restrict their salt intake. Once these barriers 
were identified, appropriate interventions such as cooking with less salt were introduced to promote 
dietary changes [53].  
 
2.6.3 Known strategies – education programs 
 
Effective management and prevention of CKD requires multiple interventions. Education of health 
care personnel is essential to improve awareness of the disease. Educating patients and their 
families about preventive strategies, risk factors, diabetes, hypertension and obesity is necessary to 
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slow the progression [54]. Cueto-Manzano et al. [55] conducted an educational intervention 
involving a multidisciplinary health team aimed at improving the outcomes for patients with 
diabetes, hypertension and obesity. It involved patient education in health-related problems, 
nutritional advice from a dietician, counselling from a social worker and exercise guidance from a 
physical trainer. Participants significantly reduced their BMI, waist circumference, reduced glucose 
in diabetics and increased GFR. Hypertensive patients reduced their systolic blood pressure and also 
increased their GFR, though only slightly. In another study, a disease management programme 
involving patients with Stages 4-5 CKD, demonstrated significantly improved systolic and diastolic 
blood pressure, cholesterol levels and improved eGFR. The median decrease in eGFR prior to the 
programme was 3.69 ml/min/1.73m
2
 compared to 0.32 ml/min/1.73m
2
 in the 12 months after 
enrolment (P<0.001). The programme was delivered by a community based team of nurses, 
dietician and social worker and involved patient education, medicine management, dietetic advice 
and clinical management to achieve clinical targets [56].  
 
2.7 Future implications 
Education interventions 
 
Education interventions for patients with CKD vary in terms of their methodology, intervention 
type and outcomes. Some studies have used education tools such as worksheets to teach patients 
about CKD. The one-page worksheet proved effective in that patients who took part in the study 
had an improved their knowledge about their diagnosis, their kidney function and eGFR compared 
to controls [57]. Another study involved a multidisciplinary team for the care of pre-dialysis 
patients. The program was beneficial but it required: early patient referral to the nephrology centre, 
adequate resources for staff and infrastructure, and available resources for patients with ESKD [58].  
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Patients and health-care providers continuously access health information online. Not all 
information is reliable therefore it is important that patients are directed to the right sources. These 
sources are generally associated with a Professional Nephrology association or consumer 
organisations that have links to professional organisations. Some of these include the National 
Kidney Disease Education Program (NKDEP), The National Kidney Foundation, Kidney Health 
Australia, National Kidney Federation, The Kidney Foundation of Canada and Pró Renal from 
Brasil. Their website addresses can be found in Table 2.1. These organisations provide evidence-
based patient information and resources along with a platform for patients to communicate with 
others.  
  
The future of education interventions will most likely involve face-to-face interaction between 
patient and health-care provider combined with information technology (IT) [59]. The current high 
internet and mobile phone use means that patients have the technology to access information, 
however the target patient population and the type of technology used should be considered. In the 
iNephro study it was identified that users of the ‘Medication Plan’ smart phone application were 
predominantly middle-aged, well-educated and relatively healthy males [59]. The target population 
for CKD is generally people over the age of 50 who may also have other comorbidities such as 
diabetes, hypertension or CVD. The application and health programs need to be user friendly and 
preferably interactive to enable patient feedback.  
 
Other IT delivery methods include Telehealth interventions such as the delivery of telephone-based 
educational materials and prompts via landline and video-conferencing of clinical visits. Interactive 
voice response system (IVRS) applications are easy to use, can be accessed from any phone and 
may therefore appeal more to an older patient group. Personal health record (PHR) for use by 
patients to communicate with their health care provider are becoming more widely used, but the 
implications of these initiatives have yet to be determined [59]. A recent study on electronic 
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personal health records (ePHR) identified that patients with internet access and post-secondary 
education were more likely to indicate their intentions to use an ePHR. They indicated ePHR would 
facilitate greater involvement in their own care and improve access to lab results and health 
information. Privacy concerns were reported but they were not associated with intent to use an 
ePHR [60].  
 
Educators 
 
Teaching should take place in either a primary, secondary or combined health-care setting. This 
would allow key stakeholders to provide adequate patient care and education and a greater access to 
resources for patients. Educators should include primary care physicians, nephrologists, nurses and 
allied health care professionals including pharmacist, nutritionist, psychologist, social worker and 
physiotherapist. Education should begin once the patient has surpassed the initial diagnosis stage so 
they are more receptive to the information given. It should also be frequent as there is a vast amount 
of information to be acquired [39].  A study on patient priorities has shown that patients identified 
the hospital consultant as the most useful resource followed by the dietitian, renal community nurse 
and renal unit nurse. The General Practitioner, self-help groups / patient associations, pharmacists, 
family and friends were seldom used as sources of information. Participants valued face to face 
education interaction the most, on their own and with their family [35].  
 
In order for education to be standardised and taught in a diverse setting, National Standards for 
CKD education will need to be developed. These standards could be based on the diabetes self-
management education standards which focuses on: programme structure - key stakeholders, 
participants, providers, curriculum, resources; the process of education, assessment and the 
outcomes including quality improvement measures [61]. 
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Patients and carers 
 
It is apparent that patients are not satisfied with the amount of education being given as their 
information needs have not been met. Patients’ awareness about CKD, its management, and 
knowledge about preventing its progression is also limited [62]. This issue has been ongoing for 
decades and is not isolated to the CKD community but within general patient education [63]. 
Possibly the main barriers to the implementation of patient education interventions is the lack of 
coordination of services, inadequate preparation of physicians, nurses and educators and lack of 
interest from administration [63].Coordinating education programs with other established 
institutions such as the Diabetes Association and the Heart Foundation may be an effective way of 
delivering information to CKD patients.  
 
2.7.1 Other future strategies for CKD 
 
The World Health Organization (WHO) has developed a non-communicable diseases action plan to 
be implemented from 2013 to 2020. This focuses on reducing four modifiable risk factors, namely 
tobacco use, unhealthy diet, physical inactivity and harmful use of alcohol. There are nine target 
areas to be addressed by 2025 which include: reducing premature death of CVD, cancer, diabetes or 
chronic respiratory diseases by 25% in those aged between 30 to 70; reduce harmful alcohol intake 
by 10%; reduce prevalence of physical inactivity by 10%, salt intake by 30%, tobacco use by 30%, 
the prevalence of high blood pressure by 25%, stop the rise in diabetes and obesity, increase 
availability of preventive therapy for heart attacks and strokes for 50% of people, and an 80% 
availability of affordable technology and medicine to treat non-communicable diseases. It is 
estimated that the cost of implementing the Global Action Plan will be $11 billion per year, while 
the estimated loss of productivity and health care cost without taking action will be $7 trillion over 
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the next 20 years. By taking action against the four risk factors, the resulting reduction in CVD, 
cancer, diabetes and chronic respiratory diseases [64] will directly affect the incidence of CKD.  
 
CKD promotion needs to be escalated in the national agenda so that changes to the Australian 
health care system can be implemented. General practitioners will have a key role to play in the 
early detection of the disease and in coordinating continuity of care. Healthcare education needs to 
incorporate learning outcomes that include symptom control and quality of life matters [65]. 
Research that focuses on the prevention of CKD and the reduction of symptoms should be included 
in the research priority list [66]. 
 
2.8 Conclusion 
 
This review has identified the relevant issues that are important for the effective care of patients 
with early stage CKD. Clinical care of these patients focuses on management of blood pressure, 
glucose control and minimisation of cardiovascular events and complications such as anaemia. 
Preventive management focuses on lifestyle modification such as smoking cessation, physical 
activity and weight management, salt reduction and glucose management for patients with diabetes. 
Strategies to improve the detection and awareness of CKD include screening patients at high risk; 
that is, those with diabetes, hypertension or a family history of CKD. Patient education strategies 
are also recommended to improve patient knowledge of the risk factors and comorbidities of CKD 
and awareness of the management and prevention of progression of the disease. Although there is 
consensus to promote and improve prevention, the amount of educational strategies conducted in 
this group of patients is limited. More research in this field is required to improve the current 
educational methods and interventions used.  
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Abbreviations: eGFR – estimated glomerular filtration rate; CKD – chronic kidney disease; ACR – albumin : creatinine ratio 
 
Figure 2.1. Classification of chronic kidney disease.  
Green is low risk of CKD, yellow is moderate, orange is high and red is very high risk.  
Adapted from Johnson et al. 2013 [1] . 
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Figure 2.2. Chronic kidney disease patient management and education pathway.  
Kidney Check component was adapted from Johnson et al [1] .  
Ideas for the patient education component were obtained from St Peter et al.[2]   
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Table 2.1 Patient information websites  
Country of Origin Name of organization Website address 
United States of America National Kidney Disease 
Education Program (NKDEP) 
http://nkdep.nih.gov/ 
United States of America National Kidney Foundation https://www.kidney.org/ 
Australia Kidney Health Australia (KHA) http://www.kidney.org.au/ForPatients/Recommendedweblinks/tabid/619/Default.aspx 
United Kingdom British Kidney Patient 
Association 
http://www.britishkidney-pa.co.uk/patient-info 
United Kingdom National Health Services (NHS) http://www.nhs.uk/Livewell/Kidneyhealth/Pages/Advicefornewpatients.aspx 
United Kingdom National Kidney Federation http://www.kidney.org.uk/help-and-information/ 
United Kingdom Renal Medicine http://www.renalmed.co.uk/patient-information 
Canada  The Kidney Foundation of 
Canada 
http://www.kidney.ca/detection-and-prevention 
Brazil Pró Renal http://pro-renal.org.br/educacao.php 
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Chapter 3. Prevention, detection and management of early 
chronic kidney disease: a systematic review of clinical practice 
guidelines 
 
3.1 Abstract  
 
Aim: In response to the increase in Chronic Kidney Disease (CKD) worldwide, several professional 
organisations have developed clinical practice guidelines to manage and prevent its progression. 
This study aims to compare the scope, content and consistency of published guidelines on CKD 
Stages I-III.  
 
Methods: Electronic databases of the medical literature, guideline organisations, and the websites 
of nephrology societies were searched to November 2011. The Appraisal of Guidelines for 
Research and Evaluation (AGREE) II instrument and textual synthesis was used to appraise and 
compare recommendations.  
 
Results: One consensus statement and 15 guidelines were identified and included. Methodological 
rigour across guidelines was variable, with average domain scores ranging from 24% to 95%. For 
detection of CKD, all guidelines recommended estimated glomerular filtration rate measurement, 
some also recommended serum creatinine and dipstick urinalysis. The recommended protein and 
albumin creatinine ratios and proteinuria definition thresholds varied (>150-300mg/day to 
>500mg/day). Blood pressure targets ranged (<125/75 to <140/90mmHg). Angiotensin converting 
enzyme inhibitor and angiotensin receptor blockers were recommended for hypertension, as 
combined or as monotherapy. Protein intake recommendations varied (no restriction or 
0.75g/kg/day1.0g/kg/day). Salt intake of 6g/day was recommended by most. Psychosocial support 
and education were recommended by few but specific strategies were absent.  
Chapter 3. Prevention, detection and management of early chronic kidney disease: a systematic review of clinical 
practice guidelines 
40 
Conclusions: CKD guidelines were consistent in scope but were variable with respect to their 
recommendations, coverage and methodological quality. To promote effective primary and 
secondary prevention of CKD, regularly updated guidelines that are based on the best available 
evidence and augmented with healthcare context-specific strategies for implementation are 
warranted. 
 
3.2 Introduction  
 
Chronic kidney disease (CKD) is a rapidly increasing public health problem worldwide [1]. CKD 
predisposes to end-stage kidney disease (ESKD) and is a risk factor for cardiovascular disease, the 
leading cause of premature death in the CKD population. The rising prevalence of CKD is largely 
attributable to increased rates of diabetes and hypertension, as well as the ageing population [2].  
 
Despite evidence demonstrating that early detection and treatment of CKD can slow the progression 
of disease and other adverse outcomes [1, 3, 4], there is still a steady increase in the number of 
incident patients with ESKD requiring dialysis or kidney transplantation [5, 6]. Of greater concern 
is the continued rise in the number of patients with earlier stages of CKD [3]. In 1999-2000, 9.7% 
of Australian adults in the general population were identified as having renal impairment [6]. This 
proportion increased at a rate of 1% per annum in five years [7]. 
 
Prevention of progression can be achieved through early detection [8] and appropriate patient 
management that is guided by trustworthy clinical practice guidelines [9, 10]. To be effective for 
use in clinical practice, guidelines should be rigorously developed and be consistent with the 
available scientific evidence [11]. They should also be unbiased, transparent, accessible and 
acceptable to clinicians [12]. If guideline developers fail to consider these factors, the 
recommendations may be ineffective and potentially dangerous to clinical care [11].    
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This study aims to compare the quality, scope, and consistency of clinical practice guidelines on the 
prevention, detection and management of early stage I - III CKD. The published guidelines were 
also assessed for their methodological consistency and comprehensiveness.  
 
3.3 Methods  
Selection criteria 
 
Guidelines defined as "systematically developed statements to assist practitioner and patient 
decisions about appropriate health care for specific clinical circumstances" [13] and consensus 
statements that primarily focussed on the prevention, detection, and management of early chronic 
kidney disease (stages 1-3; defined as >30 mL/min per 1.73m
2
) were included. Non-English 
publications were included if resources for translation were available. Guidelines relevant to late 
stage 4 - 5 CKD such as, bone mineral disease, anaemia or renal replacement therapy, draft 
unpublished guidelines, previous guideline versions, clinical protocols and research articles were 
excluded. 
 
Search for guidelines and consensus statements  
 
Medical terms and Subject Heading (MeSH) terms and text words for chronic kidney disease were 
combined with MeSH terms and text words relating to clinical practice guidelines and consensus 
statements. The searches were conducted in Medline (1948 to November Week 3 2011) and 
Embase (1980 to week 50 2011).  Guideline organisations, including the Guidelines International 
Network and the National Guideline Clearinghouse, Intercollegiate Guidelines Network (SIGN); 
National Collaborating Centre for Chronic Conditions (NICE) and professional nephrology society 
websites were also searched (Supplementary material). PLV screened the titles and abstracts and 
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discarded those that were ineligible. Full texts of potentially relevant articles were obtained and 
examined for eligibility. 
 
Appraisal of guidelines and consensus statement 
 
The Appraisal of Guidelines for Research and Evaluation (AGREE) II Instrument [14] was used to 
assess the methodological quality of the guidelines. The 23-item instrument has been internationally 
validated and consists of six domains: scope and purpose, stakeholder involvement, rigour of 
development, clarity and presentation, applicability and editorial independence. A definition of 
these domains can be found in Appendic A - Table A3. Each guideline was independently appraised 
by PLV and AT.  Each item within the six domains was rated by allocating a value from 1 to 7 (1 = 
‘Strongly Disagree’; 7 = ‘Strongly Agree’) based on the specific assessment criteria provided. 
Major discrepancies in the scores were discussed and independently reassessed. Domain scores 
were calculated as per the AGREE II user’s manual, whereby a total quality score was obtained for 
each domain by summing up the scores of each item [14]. A maximum possible score for each 
domain was calculated by multiplying the number of appraisers by the number of items for that 
domain and multiplying by seven (value for ‘strongly agree’). A minimum possible score for each 
domain was calculated by multiplying the number of appraisers by the number of items for that 
domain and multiplying by one (value for ‘strongly disagree’). The domain score was then 
standardised as a percentage using the following formula:   
Standardized domain score (%) = (total quality score – minimum possible score) x 100 
 (maximum possible score – minimum possible score) 
 
To measure inter-observer agreement across the ordinal categories for each guideline and consensus 
statement, a weighted kappa (κw) was calculated using SAS version 9.2 software. This takes into 
account the degree of disagreement between the observers by assigning less weight to agreement, as 
categories are further apart [15, 16]. An overall κw was also calculated across all guidelines and 
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consensus statement. A kappa value of <0.2 indicates poor agreement; 0.21- 0.4 fair; 0.41- 0.6 
moderate;.61 - 0.8 good and 0.81-1.0 very good agreement [17]. Due to resource limitations, only 
guidelines published or translated in English were appraised. 
 
Synthesis of guideline recommendations 
 
We conducted a textual descriptive synthesis to analyse the scope, content and consistency of the 
recommendations. Initially, the guidelines were read by PLV to gain an overall knowledge of 
guideline content. PLV inductively coded the text manually to identify domains covered by the 
guidelines. The inclusion of specific themes and domains were discussed with the team. These were 
cross-tabulated with the guidelines and recommendations were inserted into the corresponding cell. 
For each domain, we compared guideline recommendations to identify similarities and 
discrepancies.  
 
3.4 Results  
Search and guideline characteristics 
 
The search yielded 1266 citations of which 1218 were excluded because they did not fulfil the 
eligibility criteria, leaving 48 articles requiring full text analysis. Thirty two were excluded because 
they were guidelines replaced by an updated version, were guideline summaries, did not include 
recommendations for early stage CKD or were a duplicate. This left 15 clinical practice guidelines 
from Australasia [18, 19], Japan [20], France [21, 22], Netherlands [23], Italy [24, 25], United 
Kingdom[26-28] , Canada [29], U.S.A. [30], Chile [31] and Argentina [32], and one consensus 
statement from Spain [33] able to be included. (Fig A1. Appendix A) A total of 93 nephrology 
societies were identified in the web search (Table A2), but only seven societies had published 
guidelines available [20, 21, 24, 25, 28, 31-33]. 
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The characteristics and guideline development processes are provided in Table 3.1. The guidelines 
were published between 2002 and 2011. Seven (44%) guidelines [18, 19, 21, 22, 24, 25, 30] were 
published more than three years ago. All were peer reviewed and almost half included public 
consultation [18, 19, 21, 22, 26-30]. All guideline groups conducted a systematic literature search, 
however the methods used to extract the data and synthesise the evidence varied. Some guidelines 
graded the evidence [18, 19, 24-26], graded the strength of the recommendations [23, 29, 30], or 
both [20-22, 27, 28, 31-33]. The target users, as specified by guideline developers, included primary 
health care providers (general practitioners) and nephrologists.  
 
Methodological quality 
 
As part of the guideline appraisal, weighted kappa scores (κw) were calculated to determine the 
strength of agreement between the two assessors (AT and PLV). These values ranged from 
moderate κw=0.49, (95%CI: 0.17 to 0.82) to very good 0.85 (95%CI: 0.76 to 0.93). The overall 
inter-rater agreement was κw= 0.82 (95%CI: 0.78 to 0.85) indicating very good strength of 
agreement [15, 16]. 
 
Of the 16 guidelines, 11 (69%) were appraised [18-22, 26-30, 33] as they were written in English, 
the common language for both assessors. The domain scores for each guideline are shown in Table 
3.2. The average scores (and range) for the domains were: scope and purpose 75% (25% - 100%); 
stakeholder involvement 63% (14% - 97%); rigour of development 67% (20% - 96%); clarity of 
presentation 81% (64% - 94%); applicability 46% (10% - 90%) and editorial independence 67% 
(0% - 100%). Seven (64%) guidelines were independently assessed as ’recommended‘ for use [18, 
19, 26-30],  their quality scores ranged between 5 and 7, representing good to high quality 
guidelines. The other four (36%) guidelines were ‘recommended for use after modification’, they 
were given quality scores of 3 and 4 [20-22, 33].  
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Synthesis of recommendations 
 
We identified three major domains addressed by the guidelines including: early detection of CKD 
(identification of risk factors, diagnostic tests, proteinuria, albuminuria, haematuria, dyslipidaemia); 
medical management of early CKD (hypertension, proteinuria, glucose control, dyslipidaemia, 
antiplatelet therapy); and lifestyle modification and education (smoking cessation, weight 
management, exercise, protein restriction, salt restriction, psychosocial support and education). 
 
Early detection of CKD 
 
The recommendations for early detection of CKD are provided in Table 3.3. The key areas 
addressed included: who to test; details of diagnostic tests; proteinuria and albuminuria thresholds 
for renal dysfunction; tests for haematuria; and detection of dyslipidaemia. Almost all guidelines 
identified high blood pressure, diabetes, family history and cardiovascular disease as the main risk 
factors to be considered, with five (31%) guidelines also considering ‘chronic use of nephrotoxic 
drugs’ [21, 26, 30-32] and ‘prostatic syndrome/urological disease’ [19, 21, 23, 28, 32] as risk 
factors for CKD.  
 
Most guidelines recommended the referral of patients with more advanced disease and uncontrolled 
blood pressure. Seven (44%) guidelines [19, 23, 26, 28-30, 33]  recommended that patients should 
be referred to a nephrologist if they had an estimated glomerular filtration rate (eGFR) of < 30 
ml/min/1.73m
2
; or uncontrolled hypertension [19, 22, 26, 28, 30, 31, 33]; persistent proteinuria [19, 
26-31] or unexplained anaemia [19, 28, 33]. Some guidelines stated that the patient’s age [23, 30, 
33] and presence of unexplained haematuria [26-28, 33] should be considered as indicators for 
referral to a nephrologist. Two (13%) guidelines also recommended that patients with acute renal 
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failure [28, 29] should be referred as well as patients with other suspected genetic or rare cause of 
renal disease [26].  
 
Estimated glomerular filtration rate was the main diagnostic test recommended by all guidelines, 
while some also recommended serum creatinine and/or dipstick urinalysis as adjunct tests. Six 
(38%) guidelines [18, 20, 23, 28, 30, 33] specified morning urine as the preferred method of urine 
collection, while two (13%) guidelines also suggested 24hr urine collection [20, 21]. Most 
guidelines gave recommendations for proteinuria, albuminuria, protein creatinine ratio (PCR) and 
albumin creatinine ratio (ACR) marker levels of renal dysfunction. Eight (50%) guidelines 
recommended proteinuria values which consisted of: >150-300 mg/day [19], >300mg/day [21, 33]  
or >500 mg/day [20, 26-29] and four (25%) recommended an albuminuria value of >300 mg/day 
[19, 23, 27, 31].. Three (19%) guidelines recommended a PCR value of >23 mg/mmol [21, 30, 31] 
and two (13%)  recommended a level ≥34 mg/mmol [32, 33]. ACR levels for diabetes were 
recommended by seven (44%) guidelines, these were >2 mg/mmol [21, 29]  or >3.4 mg/mmol [26, 
30-33]  and two (13%) guidelines also specified an ACR value of  >30 mg/mmol [26, 27] for non-
diabetes.   
 
The use of dipstick urinalysis was recommended by nine (56%) guidelines [20, 21, 23, 26-28, 30-
32] for the detection of haematuria, three (19%) also recommended microscopy [20, 21, 31] and 
four (25%) also recommended sediment analysis [23, 30-32]. The detection of dyslipidaemia was 
recommended by only four (25%) guidelines [25, 28, 29, 33]. 
 
Medical management of early CKD 
 
Recommendations for the medical management of early CKD are provided in Table 3.4. All the 
guidelines provided recommendations for medical management of hypertension and proteinuria. 
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Angiotensin converting enzyme inhibitor (ACEi) and angiotensin receptor blockers (ARB) were 
recommended by most guidelines as first line of therapy, singly or in combination, for the 
management of hypertension. However one (6%) guideline [31], recommended lifestyle changes as 
the first line of therapy followed by medication (thiazide diuretics, beta-blockers, calcium channel 
blockers [CCBs], ACEi and ARBs). Only two (13%) guidelines [23, 26]  specified ACEi as first 
line and ARBs as second line therapy. Diuretics followed by CCBs and beta-blockers, either alone 
or in combination, were the preferred choice for second line therapy by most guidelines. Non-
dihydropyridine CCBs, CCBs and beta-blockers were recommended as third line therapy by five 
(31%) guidelines [19, 22, 24, 30, 33].  
 
Recommendations for blood pressure control targets were included in all guidelines however the 
targets varied depending on diabetic status and/or presence of proteinuria. The majority of the 
guidelines indicated a target value of <130/80 mmHg for non-diabetics [20, 22-24, 29, 30, 33], but 
four (25%) guidelines [26, 28, 31, 32]  recommended a higher target of <140/90mmHg. Three 
(19%) guidelines recommended a target of <125/75 mmHg if proteinuria >1 g/day [19, 20, 32], one 
(6%) guideline recommended <125/75 if proteinuria >500 mg/g [33]  and another guideline 
recommended a systolic blood pressure of 130 mmHg if proteinuria >1 g/day [27]. A value of 
130/80mmHg was recommended for diabetes [20, 26, 28, 31, 32].   
 
For the management of proteinuria in non-diabetes, ACEi alone or in combination with ARBs was 
recommended by 12 (75%) guidelines [19, 22-24, 26-33]. However, four (25%) stated this was 
conditional and depended on the level of proteinuria detected [23, 26, 28, 30]. For diabetes, two 
(13%) guidelines recommended ACEi alone [19, 24] and five (31%) guidelines recommended 
either ACEi or ARBs or in combination [26-29, 32]. Combination therapy (ACEi and/or ARBs) was 
recommended for non-diabetes by all guidelines except for one [20]. Eight (50%) guidelines 
recommended an HbA1c target ranging from <6.5 % to <7.5 % [19, 20, 28-33], but most 
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recommended a target of <7 %. Three (19%) also recommended a target fasting blood glucose level 
between 4.4 to 6.7 mmol/L [19, 29, 30]. Avoidance of oral hypoglycaemics (metformin in 
particular) was recommended by three (19%) guidelines [29, 31, 33]. Statins were recommended by 
most guidelines for all patients with dyslipidaemia with or without diabetes, for the prevention of a 
cardiovascular event, whilst five (31%) guidelines [20, 25, 31-33] also provided a threshold level 
for low density lipoprotein (LDL), which varied across guidelines from <100 mg/dl to ≤120 mg/dl. 
Aspirin was recommended as antiplatelet therapy for patients with diabetic nephropathy [20] and to 
prevent cardiovascular complications [23, 26, 27, 31, 33]. 
 
Lifestyle modification and education 
 
For the recommendations on lifestyle modification and education (Table 3.5), all guidelines except 
for two [24, 25]  recommended smoking cessation, while 10 (63%) guidelines recommended weight 
management to prevent CKD progression [19, 23, 25-29, 31-33] and exercise to prevent 
cardiovascular disease [19, 20, 25-29, 31-33]. Other recommended lifestyle modifications included: 
reduction in alcohol intake [20, 29, 31], restriction of fluid and energy intake [22], carbohydrate-
restricted diet for diabetic nephropathy [19], reduction in saturated fat and cholesterol intake [25, 
31], increase fruit and vegetables in the diet [31]  and avoidance of non-steroidal anti-inflammatory 
drugs (NSAIDs) [33]. Four (25%) guidelines stated that restricting protein from the diet was not 
recommended or that it should be considered for later stages of CKD [20, 27, 32, 33]. In contrast, 
five (31%) guidelines recommended protein restriction ranging between 0.75 and 1.0 g/kg/day [19, 
22, 23, 29, 30] and one (6%) guideline also recommended 0.75g/kg/day for diabetic nephropathy 
[19]. Three (19%) guidelines [20, 22, 28] mentioned referral to a dietitian for advice regarding 
protein intake.  Eight (50%) guidelines recommended salt restriction to reduce the risk of 
cardiovascular events [20, 22, 27-31, 33] although the recommended amount of salt intake was the 
same, it was expressed in different terms (sodium: 2.4g/day; salt: 6g/day and <100mmol/day). 
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Three (19%) guidelines recommended psychosocial support and education [19, 26, 27]. However, 
specific strategies or tools for implementing health promotion and education recommendations were 
not provided in any of the guidelines. 
 
3.5 Discussion  
 
Overall, guidelines on early CKD are comprehensive and consistent in scope covering early 
detection of CKD, medical management, and lifestyle modification and education. However the 
extent of coverage varied due to implicit and explicit discrepancies in recommendations, 
particularly for diagnostic testing of eGFR, protein and albumin excretion, blood pressure targets, 
treatment of hypertension and proteinuria, glucose control targets, and dietary protein intake. The 
importance of health promotion and education was highlighted, but to a lesser extent, and was not 
supported with tools or specific strategies for implementation. Most guidelines appeared to be 
methodologically robust, but not all guidelines were consistent in the way they were developed, also 
almost half were out of date. All guidelines conducted a systematic review of the literature to search 
for evidence but there were clear differences in the way the literature was synthesized and graded. 
Thus the discrepancies between guideline recommendations can be attributed, at least in part, to the 
methodology employed by the guideline groups and to the evidence available at the time of 
guideline development.  
 
There was general consensus on the recommendations for detection of early CKD in terms of the 
risk factors, which may be reflective of current epidemiological data supporting the association 
between obesity, hypertension, cardiovascular disease, and chronic kidney disease [34, 35]. There 
were implicit inconsistencies across guideline recommendations for PCR, ACR, proteinuria and 
albuminuria. SI units of measurement used varied between the guidelines and this was most likely 
attributed to the different laboratories used. A recent study has found no consensus on the 
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diagnostic cut-off levels, sampling procedures and on the units used in laboratory reports when 
reporting on proteinuria [36].  
 
The recommendations for the treatment of hypertension and proteinuria were consistent in that they 
recommended ACEi or ARBs as first line therapy. However there were explicit inconsistencies in 
the regimens recommended. Some guidelines recommended ACEi or ARBs as monotherapy but 
other guidelines recommended that they be used in combination. Combination therapy is no longer 
recommended as recent studies have shown that patients on combined ACEi and ARBs therapy 
were at increased risk of cardiovascular death, increased risk of hypotension, syncope, renal 
dysfunction and hyperkalaemia [37, 38]. This evidence however was not available at the time of 
guideline development for most of the guidelines. There were also inconsistencies in the agents 
recommended for use as second and third line therapy which may be explained by the limited 
evidence on the efficacy of combined treatment with other agents including non-dihydropyridine 
CCBs and thiazide diuretics. Blood pressure targets varied depending on the presence of other risk 
factors, such as: diabetes; over 50 or under 50 years of age; proteinuria ≥1g/day; or ACR >500mg/g. 
Current evidence suggests that a blood pressure target below 125/75 to 130/80mmHg provides no 
extra benefit than a target of <140/90 for patients with CKD [39]. However, a lower blood pressure 
may be of benefit for patients with diabetes mellitus or impaired glucose tolerance [40]. While the 
majority of the guidelines recommended a blood pressure target of <130/80 mmHg for non-
diabetes, there were a few that were consistent with the more recent recommendation of <140/90 
mmHg. 
 
More than half of the guidelines explicitly recommended glucose control although the HbA1c target 
varied from 6.5 to 7.5%. With the exception of one guideline, recommendations for HbA1c below 
7% were inconsistent with the current evidence. Glycaemic control has been shown to slow the 
progression of CKD in the diabetic population, however there is concern about the potential 
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complications associated with intensive glucose lowering including hypoglycaemia [41, 42]. 
Almost all guidelines recommended statin therapy to reduce cardiovascular risk. Evidence suggests 
that while statin therapy may reduce mortality and cardiovascular events in the early CKD setting, 
the effect on CKD progression is still uncertain [43, 44].  Similarly, there is some weak evidence 
suggesting that the benefits of antiplatelet therapy such as reduced myocardial infarction and 
mortality may be outweighed by the potential risks of major and minor bleeding in patients with 
CKD  [45]. 
 
All guidelines provided recommendations for lifestyle modification. Inconsistencies were evident 
with regard to protein intake where the recommendations ranged from, no restriction to up to 
1.0g/kg/day. There is no conclusive evidence to demonstrate that long-term protein reduction delays 
CKD progression, therefore specific dietary protein restriction cannot be recommended [46, 47]. 
Recommendations for salt restriction ranged from no recommendation to < 6 g/day to reduce 
cardiovascular risk in the Stage 1-4 CKD population. Although there is no clinical evidence that salt 
reduction slows the progression of CKD, there is some evidence that a low-sodium diet reduces 
blood pressure and proteinuria [48-50]. Psychosocial support and education were recommended by 
three guidelines but specific tools or strategies were not included or referenced, therefore limiting 
the applicability of the recommendations.  
  
Our study is the first to systematically review clinical practice guidelines for CKD. We used the 
AGREE II instrument, a validated and reliable instrument, to appraise the guidelines and consensus 
statements and achieved good agreement between reviewers. Non-English guidelines (published in 
Italian, Dutch and Spanish) were included in the review, but their methodological rigour was not 
assessed with the AGREE II instrument due to resource limitations. The guidelines were assessed 
by two reviewers who were affiliated with the KHA-CARI guideline group. This may be seen as a 
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potential geographical bias however, the AGREE II instrument is solely focussed on the guideline 
development and reporting methodology, making geographical bias unlikely.   
 
Based on our assessment, we identified that guidelines scored consistently low in the applicability 
domain. This domain covers four questions which refer to: the barriers and facilitators to 
implementation; provision of advice or tools to implement the recommendations; consideration of 
potential resource implications; and the provision of auditing and/or monitoring criteria [14]. To 
improve guideline uptake and implementation, we recommend that guidelines include facilitators 
and barriers to consider additional resources with specific plans or strategies for guideline 
implementation (e.g. quality indicators, algorithms, links to manuals), economic evaluations and 
cost analysis. Also, some guidelines scored particularly low for specific domains such as editorial 
independence and stakeholder involvement because they did not address or define these domains. 
Editorial independence covers two aspects referring to: the views of the funding body; and 
competing interests of the guideline development group members. Stakeholder involvement 
addresses the individual members of the guideline development group; the views and preferences of 
the target population; and the target users [14]. These aspects should be made explicit in the 
guideline document.  
 
Consumer involvement in guidelines has been widely advocated to ensure that guidelines are 
relevant to consumers. This can promote guideline uptake and implementation, and lead to 
improved patient outcomes. In a study by Tong et al [51] patients and carers identified seven main 
topics that they considered important to be included in guidelines for early stage CKD. These topics 
included: patient education, nutrition and exercise, CKD monitoring, managing fatigue, medication 
interactions and side effects, financial and emotional support for patients and carers, and health-care 
services. We suggest that guideline developers facilitate active consumer involvement in guideline 
development, and incorporate topics and outcomes that patients believe are important. 
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Chronic kidney disease is a global health problem and the development of methodologically robust 
guidelines that are applicable in the community and clinical setting is warranted. Current guidelines 
addressing early stage chronic kidney disease cover early detection, medical management and 
lifestyle modification and education. While comprehensive, there are implicit and explicit 
discrepancies across guidelines in regards to detection of CKD, targets for management of risk 
factors, dietary intake of protein and inconsistencies in the SI units used. Combination therapy 
(ACEi and ARB) for blood pressure and proteinuria management and recommendations for 
antiplatelet therapy are also inconsistent with current evidence. These recommendations are 
potentially harmful to patient care and should be revised. Specific tools or strategies to implement 
guideline recommendations were mostly absent, limiting guideline applicability. We acknowledge 
that implementation strategies and action plans would need to be context-specific given the 
variation of resources, disease prevalence, and health care structures across geographical areas.  
 
Guideline developers must ensure, where possible, that recommendations are graded and 
underpinned by the best available evidence. We suggest using the GRADE system (Grading of 
Recommendations Assessment, Development and Evaluation) which promotes evaluation of the 
quality of the evidence and judgement about the strength of the recommendation, leading to a more 
structured and transparent approach to decision making [52]. Application of the eight Standards for 
developing trustworthy clinical practice guidelines as set out by the Institute of Medicine [53] 
should also be considered. This in turn, may lead to more effective primary and secondary 
prevention of CKD. 
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Table 3.1 Characteristics of the included guidelines  
Guideline 
Organisation
/Society 
Guideline Name/s Year/s of 
publication 
Target Users Guideline 
Writers 
Guideline Review Methods Support Evidence 
Base 
Level of 
Evidence† 
Grade of 
recommendation 
‡ 
Asia Pacific          
KHA-CARI 
[18, 19] 
 
Prevention of progression 
of kidney disease; Urine 
protein as diagnostic test 
2004, 
2006, 2007 
Clinicians, 
Healthcare 
professionals 
Multidisciplinary Expert review, 
public consultation 
Editorial team Systematic 
literature 
review 
I to IV  NS 
JSN [20] Evidence-based Practice 
Guideline for the Treatment 
of CKD  
2009 General physicians Nephrologists  Peer review NS Systematic 
literature 
review 
1 to 4 A to C 
Europe          
ANAES/ 
HAS   
[21, 22] 
Diagnosis of chronic renal 
failure in adults; Treatment 
strategies to slow the 
progression of chronic renal 
failure in adults  
2002; 2004 Nephrologists, 
primary health care 
providers, service 
providers 
Multidisciplinary Public, 
stakeholder 
consultation, peer 
review 
NS Systematic 
reviews and 
narrative 
synthesis of 
the literature 
1 to 4 A to C 
NfN  [23] 
 
Guideline for the treatment 
of patients with chronic 
kidney disease 
2009 Professionals 
involved in primary 
and secondary care 
of patients with 
chronic kidney 
disease 
Multidisciplinary Dutch association 
for general 
practitioners 
(NHG), Dutch 
association for 
internists (NIV) 
Dutch federation 
for Nephrology  
 
Systematic 
literature 
review 
A to C  NS 
SIN  [24, 25] Use of statins for 
preventing cardiovascular 
and renal outcomes in 
patients with chronic kidney 
disease excluding dialysis); 
Antihypertensive agents for 
the prevention of chronic 
kidney disease progression 
2006 Nephrologists, 
primary health care 
providers, service 
providers 
 
Nephrologists Peer review NS Systematic 
literature 
review 
 
1 to 4 NS 
 
NICE[26]  
 
Chronic kidney disease: 
national clinical guideline 
for early identification and 
management in adults in 
primary and secondary 
care   
2008 Healthcare 
professionals in 
primary and 
secondary care, 
patients and carers, 
commissioning 
organisations, 
service providers 
Multidisciplinary Public, 
stakeholder 
consultation 
Technical team 
(Chair, clinical 
advisor, 
information 
scientist, research 
fellow, health 
economist, project 
manager) 
Systematic 
literature 
review 
1++ to 4  NS 
SIGN [27] 
 
Diagnosis & management 
of chronic kidney disease 
2008 Healthcare 
professionals in 
primary and 
secondary care, 
patients and carers 
Multidisciplinary Public, 
independent 
experts, SIGN 
editorial group 
SIGN information 
officer 
Systematic 
literature 
review 
1++ to 4  A to D  
SEN  [33] 
 
SEN-sem FYC consensus 
document on chronic 
2008 Primary and 
secondary care 
Nephrologists Peer review NS Literature 
review 
High, 
moderate, 
A to C  
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Guideline 
Organisation
/Society 
Guideline Name/s Year/s of 
publication 
Target Users Guideline 
Writers 
Guideline Review Methods Support Evidence 
Base 
Level of 
Evidence† 
Grade of 
recommendation 
‡ 
kidney disease 
 
health care 
practitioners 
low level 
evidence  
UK RA[28] 
 
Renal association clinical 
practice guideline on 
detection, monitoring and 
management of patients 
with CKD  
 
2011 Renal medical, 
nursing and 
technical staff, other 
health professionals 
caring for patients 
with renal disease 
Nephrologists Expert review, 
public, 
stakeholder 
consultation 
NHS Centre for 
Reviews and 
Dissemination 
Systematic 
literature 
review  
A to D  GRADE (1 or 2)
 
 
North 
America 
         
CSN [29] 
 
Guidelines for the 
management of chronic 
kidney disease  
 
2008 Nephrologists, 
primary caregivers 
(GPs), 
endocrinologists, 
cardiologists, 
Multidisciplinary Expert review, 
CSN members 
and stakeholders 
(other guideline 
groups) 
Canadian Society 
of Nephrology 
Implementation 
Committee 
Systematic 
literature 
review 
NS A to D, opinion  
KDOQI [30] 
 
Clinical practice guidelines 
for chronic kidney disease: 
evaluation, classification 
and stratification  
 
2002 Health care 
providers, patients 
and carers, service 
providers 
(manufacturers, 
laboratories) 
Multidisciplinary Internal and 
external review 
(advisory board, 
experts, NKF 
board members) 
Independent 
evidence review 
team 
(nephrologists and 
methodologists) 
Systematic 
literature 
review and 
Work group 
consensus 
NS S, C, R, O  
South 
America 
         
SCN  [31] 
 
Clinical guidelines on 
identification, management 
and complications of 
chronic kidney disease 
(Supplement)  
2009 Primary health care 
providers  (medical 
community) 
Nephrologists Expert review Guideline writers 
working group 
Systematic 
literature 
review  
1 to 4  A, B, C, I  
SAN  [32] Clinical practice guideline 
on the early prevention and 
detection of chronic kidney 
disease in adults at the 
primary health care level  
2010 Primary health care 
practitioners and 
other health care 
professionals 
Multidisciplinary Expert review NS Systematic 
literature 
review 
1++ to 4  A – D, I, BP  
KHA-CARI - Kidney Health Australia – Caring for Australasians with Renal Impairment; JSN - Japanese Society of Nephrology; ANAES/HAS - Agence Nationale d’Accreditation et d’Evaluation en Sante/ L’Haute 
Autorite de Santé: (France); NfN – The Netherlands Federation of Nephrology; SIN - Societa Italiana di Nefrologia (Italian); NICE - National Institute for Health and Clinical Excellence & National Collaborating Centre 
for Chronic Conditions; SIGN - Scottish Intercollegiate Guidelines Network; SEN – Sociedad Española de Nefrologia (Spain); UK RA – UK Renal Association;  CSN - Canadian Society of Nephrology; KDOQI - 
Kidney Disease Outcomes Quality Initiative; SCN - Sociedad Chilena de Nefrologia (Chilean society of Nephrology); SAN – Sociedad Argentina de Nefrologis (Argentinian Society of Nephrology) 
 
†Level of evidence 
Level 1++: High quality meta-analysis, systematic reviews of randomised controlled trials (RCTs), or RCTs with a very low risk of bias 
Level 1+: Well conducted meta-analysis, systematic reviews of RCTs, or RCTs with a low risk of bias 
Level 1 or Level A: RCTs of high power; meta-analyses of RCTs; systematic reviews; well executed study with very strong effects or well performed RCT; high quality evidence 
Level 2++: High quality systematic reviews of case-control or cohort studies. High quality case-control or cohort studies with a very low risk of confounding bias and a high probability that the relationship is causal 
Level 2+: Well-conducted case-control or cohort studies with a low risk of confounding, bias or chance and a moderate probability that the relationship is causal 
Level 2 or Level B: RCTs of low power; at least one properly designed RCT; properly conducted non-RCTs; cohort studies; RCTs with serious flaws; moderate quality evidence; significant risk that the relationship is 
not causal  
Level 3 or Level C: Case-control studies; descriptive and cohort studies; controlled trials with serious limitations; low quality evidence; non-analytic studies 
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Level 4 or Level D: Comparative studies with major bias; retrospective; case studies; expert opinion; very low quality evidence  
High evidence: Subsequent research is unlikely to change confidence in effect estimation 
Moderate evidence: Subsequent research may have an impact on effect estimation and this estimation may change 
Low or very low evidence: Subsequent research is likely to have a significant impact on effect estimation 
 
‡Grade of the recommendation 
Grade A: Based on scientific evidence established by trials of high level evidence, RCTs of high power and free of major bias, and/or meta-analyses of RCTs or decision analyses based on properly conducted 
studies 
Grade B: Based on scientific evidence from studies of intermediate level evidence, RCTs of low power, well-conducted non-RCTs or cohort studies 
Grade C: Based on studies of lower level evidence, such as case-control studies or case series; expert opinion; composition of original articles 
Grade D: Based on evidence level 3 or 4; or extrapolated evidence from well-conducted case-control or cohort studies with a low risk of confounding 
Grade I: Insufficient information to formulate a recommendation 
Grade S: Analysis of individual patient data from a single large, generalizable study of high methodological quality  
Grade R: Review of reviews and selected original articles 
Grade O: Opinion 
Grade BP: Group consensus 
Grade 1: Strong recommendation (benefits outweigh the risks) 
Grade 2: Weak recommendation (benefits and risks are more uncertain) 
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Table 3.2 Guideline assessment according to the Appraisal of Guidelines for Research and Evaluation (AGREE II) instrument  
 
Guideline 
Organisation/Society 
Domain Scores (%) 
Agreement between 
appraisers 
Mean 
domain 
scores (%)  Scope and 
Purpose  
Stakeholder 
Involvement  
Rigour of 
Development 
Clarity and 
Presentation 
Applicability Editorial 
Independence  
Weighted kappa 
coefficient (k, 95% CI) 
Asia Pacific  
KHA-CARI [18, 19] 81 69 83 86 29 96 0.78 (0.63 – 0.92) 74 
JSN [20] 25 14 20 64 10 8 0.77 (0.63 – 0.91) 24 
Europe  
ANAES/HAS  [21, 22] 81 53 59 78 23 0 0.80 (0.71 – 0.90) 49 
NICE [26] 100 97 96 94 81 100 0.74 (0.45 – 1.00) 95 
SIGN [27] 100 94 90 81 90 96 0.49 (0.17 – 0.82) 92 
SEN  [33] 44 47 42 86 25 17 0.81 (0.70 – 0.91) 44 
UK Renal Association [28] 75 56 69 81 58 100 0.69 (0.54 – 0.84) 73 
North America  
CSN  [29] 92 61 60 86 23 92 0.85 (0.76 – 0.93) 69 
KDOQI [30] 81 75 80 72 79 96 0.69 (0.51 – 0.87) 81 
KHA-CARI - Kidney Health Australia – Caring for Australasians with Renal Impairment; JSN - Japanese Society of Nephrology; ANAES/HAS - Agence Nationale d’Accreditation et d’Evaluation en Sante/ 
L’Haute Autorite de Santé: (France); NICE - National Institute for Health and Clinical Excellence & National Collaborating Centre for Chronic Conditions; SIGN - Scottish Intercollegiate Guidelines Network; 
SEN – Sociedad Española de Nefrologia (Spain); UK RA – UK Renal Association;  CSN - Canadian Society of Nephrology; KDOQI - Kidney Disease Outcomes Quality Initiative;  
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Table 3.3 Guideline recommendations for detection of early stage chronic kidney disease 
Criteria Guideline Recommendations CARI 
[18, 19] 
JSN 
[20] 
ANAES 
[21, 22] 
NfN 
[23] 
SIN 
[24, 25] 
NICE 
[26] 
SIGN 
[27] 
SEN 
[33] 
UK Renal 
[28] 
CSN 
[29] 
KDOQI 
[30] 
SCN 
[31] 
SAN 
[32] 
Who to test for chronic kidney disease 
 High blood pressure              
Diabetes              
Family history              
Cardiovascular disease              
Prostatic syndrome/ Urologic disease              
Use of nephrotoxic drugs              
Tests used to diagnose chronic kidney disease 
 eGFR              
Serum creatinine              
Dipstick urinalysis              
Morning urine†              
24hour urine*              
Protein and albumin thresholds for renal dysfunction 
Proteinuria  
 >150 - 300 mg/day              
>300 mg/day              
>0.5 g/day (50 mg/mmol)              
Protein creatinine ratio  
 >23 mg/mmol (>200 mg/g)              
≥34 mg/mmol (>300 mg/g)              
Albuminuria  
 >300 mg/day              
Albumin creatinine ratio (diabetes) 
 >2 mg/mmol (>20 mg/g)              
>3.4 mg/mmol (>30 mg/g)               
Albumin creatinine ratio (non-diabetes) 
  >30 mg/mmol               
Detection of haematuria 
 Dipstick urinalysis              
Microscopy              
Sediment analysis              
Detection of dyslipidaemia 
 LDL              
HDL              
Total cholesterol              
Fasting lipid profile              
KHA-CARI - Kidney Health Australia – Caring for Australasians with Renal Impairment; JSN - Japanese Society of Nephrology; ANAES/HAS - Agence Nationale d’Accreditation et d’Evaluation en Sante/ L’Haute Autorite de 
Santé: (France); NfN – The Netherlands Federation of Nephrology; SIN - Societa Italiana di Nefrologia (Italian); NICE - National Institute for Health and Clinical Excellence & National Collaborating Centre for Chronic Conditions; 
SIGN - Scottish Intercollegiate Guidelines Network; SEN – Sociedad Española de Nefrologia (Spain); UK RA – UK Renal Association;  CSN - Canadian Society of Nephrology; KDOQI - Kidney Disease Outcomes Quality 
Initiative; SCN - Sociedad Chilena de Nefrologia (Chilean society of Nephrology); SAN – Sociedad Argentina de Nefrologis (Argentinian Society of Nephrology) 
 eGFR – estimated glomerular filtration rate; LDL – low-density lipoprotein; HDL – high-density lipoprotein 
Note: urinary protein/albumin to creatinine (mg/g) was converted to (mg/mmol) by multiplying by 0.113; blank cells indicate no recommendations were available  
† Methods of urine collection 
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Table 3.4 Guideline recommendations for medical management of early stage chronic kidney disease 
Criteria Guideline 
Recommendations 
CARI 
[18, 19] 
JSN 
[20] 
ANAES 
[21, 22] 
NfN 
[23] 
SIN 
[24, 25] 
NICE 
[26] 
SIGN 
[27] 
SEN 
[33] 
UK Renal 
[28] 
CSN 
[29] 
KDOQI 
[30] 
SCN 
[31] 
SAN 
[32] 
Hypertension treatment 
First line 
therapy 
ACEi &/or ARBs              
ACEi or ARBs              
ACEi              
ARBs (type II diabetics)              
Lifestyle changes              
Second line 
therapy 
Beta-blockers              
Diuretics              
Thiazide diuretic              
Loop diuretic              
CCB              
DHP- CCB              
Non-DHP CCB              
Long-acting CCB              
ARBs              
ACEi              
Third line 
therapy 
Non-DHP CCB              
Beta -blockers              
CCB              
Blood pressure targets 
Diabetes ≤130/80mmHg              
Non-diabetes <130/80mmHg              
<140/90mmHg              
<125/75 If proteinuria >1g/day              
Proteinuria treatment 
Diabetes ACEi              
ACEi & ARBs              
ACEi or ARBs              
Non-diabetes ACEi &/or ARBs              
Glucose control 
HbA1c target  <6.5%              
<7.0%              
<7.5%              
Other FBG 4.4-6.7 mmol/L              
Dyslipidaemia treatment and targets 
Treatment Statins              
LDL- 
cholesterol  
<100 mg/dL              
≤120 mg/dL              
Antiplatelet treatment 
Treatment Aspirin              
KHA-CARI - Kidney Health Australia – Caring for Australasians with Renal Impairment; JSN - Japanese Society of Nephrology; ANAES/HAS - Agence Nationale d’Accreditation et d’Evaluation en Sante/ L’Haute Autorite de 
Santé: (France); NfN – The Netherlands Federation of Nephrology; SIN - Societa Italiana di Nefrologia (Italian); NICE - National Institute for Health and Clinical Excellence & National Collaborating Centre for Chronic Conditions; 
SIGN - Scottish Intercollegiate Guidelines Network; SEN – Sociedad Española de Nefrologia (Spain); UK RA – UK Renal Association;  CSN - Canadian Society of Nephrology; KDOQI - Kidney Disease Outcomes Quality 
Initiative; SCN - Sociedad Chilena de Nefrologia (Chilean society of Nephrology); SAN – Sociedad Argentina de Nefrologis (Argentinian Society of Nephrology) 
ACEi and ARBs: Angiotensin Converting Enzyme inhibitors & Angiotensin Receptor Blockers; CCB- Calcium Channel Blockers; DHP- Dihydropyridine; Non-DHP – Non-dihydropyridine; FBG: Fasting Blood Glucose;  
CKD: Chronic Kidney Disease; LDL: Low Density Lipoprotein Cholesterol.  Note: fasting blood glucose (mg/dL) was converted to (mmol/L) by dividing by 18; blank cells indicate no recommendations available   
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Table 3.5 Guideline recommendations on lifestyle modification and education  
Criteria Guideline Recommendations CARI 
[18, 19] 
JSN 
[20] 
ANAES
[21, 22] 
NfN 
[23] 
SIN 
[24, 25] 
NICE 
[26] 
SIGN 
[27] 
SEN 
[33] 
UK 
Renal 
[28] 
CSN 
[29] 
KDOQI
[30] 
SCN 
[31] 
SAN 
[32] 
Lifestyle changes 
 Smoking cessation              
Weight management              
Exercise               
Other lifestyle and dietary changes 
 Reduce alcohol intake              
Fluid intake approx. (1.5L/day)              
Energy intake 30-35 kcal/kg/day               
CR-LIPE diet for diabetic nephropathy              
Reduce saturated fat and cholesterol              
Increase fruit and vegetables in diet              
Avoid use of NSAIDs              
Protein restriction 
 Diabetic nephropathy: 0.75 g/kg/day              
0.75 – 1.0 g/kg/day               
Dietician advice              
Not recommended for Stage 1-3 CKD              
Salt restriction 
 <6 g/day [<100 mmol/day; <2.4g/day 
(sodium)] 
             
Psychosocial Support /Education 
 Pre end-stage-kidney-disease program              
Information, education, lifestyle advice              
Pre-dialysis psycho-education              
KHA-CARI - Kidney Health Australia – Caring for Australasians with Renal Impairment; JSN - Japanese Society of Nephrology; ANAES/HAS - Agence Nationale d’Accreditation et d’Evaluation en Sante/ L’Haute 
Autorite de Santé: (France); NfN – The Netherlands Federation of Nephrology; SIN - Societa Italiana di Nefrologia (Italian); NICE - National Institute for Health and Clinical Excellence & National Collaborating Centre 
for Chronic Conditions; SIGN - Scottish Intercollegiate Guidelines Network; SEN – Sociedad Española de Nefrologia (Spain); UK RA – UK Renal Association;  CSN - Canadian Society of Nephrology; KDOQI - 
Kidney Disease Outcomes Quality Initiative; SCN - Sociedad Chilena de Nefrologia (Chilean society of Nephrology); SAN – Sociedad Argentina de Nefrologis (Argentinian Society of Nephrology) 
CR-LIPE- carbohydrate restricted low-iron available polyphenol-enriched diet; DN – diabetic nephropathy; NSAIDs – non-steroidal anti-inflammatory drugs 
Note: blank cells indicate no recommendations were available 
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Chapter 4. Patient awareness and beliefs about the risk factors 
and comorbidities associated with chronic kidney disease – a 
mixed-methods study. 
 
4.1 Abstract  
 
Background: Diabetes, hypertension and smoking may contribute to the development and progression 
of chronic kidney disease (CKD) and its complications. The aim of this study was to assess patients’ 
awareness and beliefs about risk factors associated with CKD.  
 
Methods: Participants with CKD Stages 1-5 were purposively sampled to participate in a mixed 
methods study. This involved nine focus groups who completed a survey on CKD risk factors and 
discussed the reasons for their choices. Thematic analysis was used to analyse the qualitative data.  
 
Results: Of the 38 participants, the proportion who identified hypertension, family history, diabetes 
and obesity as risk factors for CKD were 89%, 87%, 87% and 70% respectively. Only 54% and 38% 
recognised that smoking and Aboriginal or Torres Strait Islander status were also risk factors. 
Participants considered the risks of heart attack, stroke and premature mortality to be 20 to 40% lower 
in people with CKD than those with diabetes or pre-existing CVD. Five themes reflecting reasons for 
their choices were identified: invisibility (lack of signs and symptoms of CKD), invincibility 
(participants did not feel they were at risk), lacking awareness (identified not knowing much about 
their disease), cumulative comorbidities (concerned about the increased risks of associated diseases) 
and inevitability of death (there is no cure for CKD).  
 
Conclusion: Participants had limited understanding of the risk factors and comorbidities associated 
with CKD. Compared to diabetes and CVD, CKD was perceived to pose less of a threat to life. Patient 
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education that addresses CKD risk factors, comorbidities and outcomes may increase awareness and 
foster better self-management for people with CKD. 
 
4.2 Introduction 
 
It is well established that people with chronic kidney disease (CKD) have three times the risk of major 
cardiovascular events compared to people without CKD [1]. Those with stages 2 and 3 CKD are also 
20-times more likely to die than to progress to end-stage kidney disease (ESKD) [2]. CKD also causes 
cognitive decline, poor quality of life, and directly and indirectly leads to inpatient care [3-10]. Risk 
factors such as diabetes, systolic hypertension and smoking in people with CKD have been shown to 
independently increase cardiovascular death [11-13].  
 
This excess risk is well known to healthcare providers but may not be so well known amongst patients. 
Lack of awareness about CKD has been found to persist in patients throughout the disease continuum, 
who have shown to have limited knowledge about their condition and about renal replacement therapy 
[14]. Poor knowledge about CKD may limit patients’ motivation and willingness to participate actively 
and effectively in self-management to prevent disease progression and treat their comorbidities. 
Patients’ awareness about the risk factors and comorbidities for CKD has been assessed using self-
administered questionnaires [15-17]. One study found that 92% of participants believed that 
hypertension and diabetes (86%) were risk factors for CKD and that CKD increased the risk of dying 
(90%) and having a heart attack (89%) [15]. While others have shown that approximately one-third of 
patients believed that excessive alcohol intake was a major cause of CKD [16, 17], a quarter thought 
that it was inadequate diet [17] and close to half were unsure [16]. However the reasons for their 
perception on risk factors and comorbidities are unknown. 
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The aim of this study was to assess and describe patients’ awareness and perceptions of the risk factors 
and comorbidities related to CKD, to inform the development and implementation of education 
interventions for patients with early stage CKD.   
 
4.3 Methods 
 
This was a mixed-methods study which included a survey and focus groups.  
 
Participant selection 
 
Patients with Stages 1-5 CKD, who were 18 years of age or older, English-speaking and able to give 
informed consent were eligible to participate. Participants were recruited from three hospitals in New 
South Wales, Australia. Purposive sampling was done to include patients with a variety of 
demographic and clinical characteristics (gender, age, time since diagnosis, cultural background and 
education). Participants not able to speak or read English, or not able to provide informed consent were 
excluded. We aimed to recruit six to eight participants per focus group as recommended [18]. A list of 
eligible patients was provided by a nephrologist at each unit. The primary investigator (PLV) then 
contacted patients and posted written information to those interested in being involved. A 
reimbursement of AUD$30 was offered to participants to cover travel and parking expenses. Ethical 
clearance was obtained from all participating institutions. 
 
Data collection 
 
Participant knowledge and awareness of the risk factors for and comorbidities of CKD was assessed 
using a self-administered survey which was given to all participants during the focus group session. 
The development of the survey was based on a literature review of the risk factors for CKD and its 
related comorbidities [2, 3, 19] as well as with discussion among the research team. It consisted of four 
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sections: one on risk factors for CKD, and three sections on comorbidities which included hypothetical 
scenarios based on three medical conditions, diabetes, CKD and cardiovascular disease (CVD). Each 
scenario presented a set of related comorbidities namely heart attack, stroke, kidney disease, cancer 
and death. In the section on risk factors, participants were asked to indicate the factors that they 
thought would increase their chances of developing CKD. Participants were also asked to indicate the 
proportion of people they believed would develop a heart attack, stroke, kidney disease and cancer in 
their lifetime, as well as the excess risk of death due to each condition (Appendix B1).  
 
Nine focus group discussions were conducted in March/April 2011, in which participants discussed the 
reasons for their choices and what they knew about the risk factors for CKD, complications of the 
disease, diagnosis, prevention and management. Each two-hour focus group was facilitated by the 
primary investigator (PLV). An observer (RK, NV, AT or MH) was also present during each session to 
record field notes on participant interactions, characteristics and group dynamics. Discussions were 
recorded with a digital voice recorder and transcribed verbatim.   
 
Analysis 
 
Survey results were recorded and then analysed using SPSS Version 21. Median and inter-quartile 
ranges were calculated for continuous variables and proportions were represented in box plots. The 
Kruskal-Wallis test for independent samples was used to calculate the statistical significance of the 
differences in the reported event rates for stroke, heart attack, cancer and death across the three 
scenarios.  
 
All transcripts were downloaded into HyperRESEARCH (Version 3.0.3. Research Ware Inc. 
Randolph, MA, USA) for coding and analysis. Using the consolidated criteria for reporting focus 
groups [20] and the principles of grounded theory [21] PLV coded and grouped similar concepts and 
developed preliminary themes that captured patients’ beliefs and awareness of the comorbidities and 
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risk factors for CKD. After discussion with AT, the themes were discussed among the research team 
and refined.  
 
4.4 Results 
 
Participant demographics 
 
Of the 97 participants eligible to attend, 38 (39%) participated in the study. Reasons for non-
participation included disinterest / unaware of being diagnosed with CKD (19%), non-attendance 
(13%), work and family commitments (10%), poor health (10%) and transport difficulties (8%), The 
participant characteristics are provided in Table 4.1.  The mean age was 54 years (range 20 to 79 
years), 23 (60.5%) were male, and 25 (66%) were diagnosed with CKD for more than 1 year. Causes 
of CKD included inherited 6 (16%), diabetes 5 (13%), autoimmune disease 4 (11%), hypertension 
4(11%), other causes 5 (13%), and 11 (29%) participants did not know the cause of their disease. 
Twenty (53%) patients reported that they had received information about CKD prior to the study 
commencement.  
 
Survey responses  
 
Risk factors (Figure 4.1): The proportion who indicated that hypertension, diabetes and obesity were 
modifiable risk factors for CKD were 89%, 87%, and 70% respectively. Only 54% of participants 
identified smoking as a risk factor. For the non-modifiable risk factors however, 87% of participants 
identified family history whilst 41% and 38%, respectively, regarded age and being of Aboriginal or 
Torres Strait Islander descent as risk factors. Up to 70% and almost 50% respectively considered 
inadequate fluid intake and alcohol as risk factors for CKD. 
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Comorbidities (Figure 4.2): The box plots showed consistently narrow inter-quartile ranges and the 
results for most outcomes appeared to be of normal distribution except for death and stroke which 
tended to be either positively or negatively skewed. In scenario A, participants indicated that 50% 
(IQR: 40 – 70%) of people with Type 2 diabetes would develop kidney disease, 50% (30 - 67.5%) 
experience a heart attack, and 40% (23 - 60%) have a stroke. The excess risk of death was considered 
to be 30% as was the risk of developing cancer. Participants perceived that having chronic kidney 
disease (scenario B) would increase the chances of having a heart attack by 30% (20 - 40%), while 
having a stroke and cancer would increase by 20%. The excess risk of dying was also 20%. Having 
cardiovascular disease (scenario C) was evidently considered to have the worst outcomes. Participants 
believed that 70% (60 - 80%) of people with CVD would have a heart attack in their lifetime, 60% (48 
- 80%) a stroke and 55% (30 - 73%) would have an excess risk of dying. The increased likelihood of 
developing kidney disease was 45% (30 - 60%) and having a cancer 25% (13 - 38%). The condition 
which participants reported as having the highest risk was heart attack.  Cancer was consistently rated 
low, while excess death rates were variable. Overall there were significant differences identified for 
stroke P < 0.001, heart attack P < 0.001 and death P <0.001 across the three scenarios. The median 
reported risks for stroke, heart attack, cancer and excess death were rated consistently lower for CKD 
compared to CVD and diabetes.  
 
Thematic analysis 
 
We identified five themes: invisibility, invincibility, cumulative comorbidities, lacking awareness and 
inevitability of death; these are described in the following section. Selected illustrative quotations for 
each theme are provided in Table 4.2.  
 
Invisibility: Participants described kidney disease as invisible as many had not experienced any signs 
or symptoms and had not felt sick – ‘They just told me that I had kidney disease. I was sort of 
surprised but I didn’t feel any different, I still don’t.’  Some participants also stated that because the 
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disease was not physically noticeable, it went unnoticed by their family and friends. This was 
especially true for those whose lifestyle was unaffected by their disease – ‘People are more concerned 
of the ones [diseases] that have more physical effect where they can see it happening to you. With 
kidney disease, they don't see anything.’ Due to its nature, participants felt their disease was not well 
understood and for some, the opportunity to learn more about it occurred mainly when they became 
unwell – ‘It was only until he started running into a problem that we started to realise what it was all 
about. Even now we're still learning about what his problem is’. 
 
Invincibility: Some male participants felt invincible and fearless. They preferred to ignore the risk 
factors regardless of the potential consequences. One participant had a family history of cardiovascular 
disease and hypertension, yet he had refused to monitor his blood pressure, until the day he ended up 
in hospital – ‘… I felt like I was going to die, my heart was racing, my blood pressure was really 
high… I thought I was invincible’. Another participant with diabetes was aware of the risk of 
developing kidney disease - ‘…an inevitable result, but like all brave males’ preferred not to ‘worry 
about it’ as there was nothing he could do to prevent it.  
 
Lacking awareness: Even though there were participants with CKD for several years, they rarely 
thought about their disease and potential consequences because they felt well. They only realised the 
gravity of their condition when they experienced a critical event and needed specialist care – ‘…I 
absolutely thought nothing of the kidneys because I felt nothing… then I turned 18, the doctor visits 
were every four months or so ... I slurred off and ended up in hospital… I didn’t think it was serious 
until then.’ Some participants regretted not being more pro-active about their medical treatment 
particularly during the early stages. They felt they could have prevented disease progression if they 
had asked for a more thorough explanation of their condition as they were not aware of the related 
comorbidities, risk factors and complications of kidney disease – ‘I don't think the relationship 
between high blood pressure and kidney disease is known at all. So consequently, I didn't take that 
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seriously enough, which I regret…’ While participants responded to the survey they discussed the risk 
factors and comorbidities for CKD. 
 
 ‘Just because you’ve got kidney disease, it doesn’t mean you’re going to have a heart 
attack, stroke or die.’ (Female, 56 years, Stage 3) 
 
 ‘What’s type one diabetes? I don’t really understand. How are you at risk if you’re 
Aboriginal or Torres Strait Islander? How does that increase your risk?’ (Female, 39 
years, Stage 3) 
 
Cumulative comorbidities: Participants with multiple comorbidities including diabetes, hypertension 
and now kidney disease were concerned about their prognosis and about what other risk factors they 
may have – ‘...I’m seeing a cardiologist now as well, my heart lining is getting thicker. So now I’m 
going, the kidney, the heart, what else is going to go wrong? They [doctors] said, you’re a diabetic 
and all these things will happen.’  
Others were also concerned and wondered that if they had kidney disease, it was possible they could 
have another condition which they were not aware of – ‘...If this is going wrong, what else is going 
wrong? Am I more prone to heart disease? Am I more prone to whatever? It does worry you quite a 
lot.’  
 
Inevitability of death: Older participants accepted that they may be at a higher risk of early death 
compared to those without kidney disease. They believed that nothing could be done to increase their 
survival time – ‘that’s the trouble with it [CKD], there’s nothing people can do. My first reaction 
[when diagnosed] was I’m not going to live very long’. Others did not think kidney disease would 
increase their risk of dying. One participant, after having had a heart attack, coronary artery bypass 
surgery, an aortic abdominal aneurysm repaired and a defibrillator implanted, concluded that some 
comorbidities were less serious than others and did not warrant immediate action. Thus, kidney disease 
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would not put him at greater risk of dying compared to having a heart attack or a ruptured aorta – ‘… 
it’s just another problem. I can’t do anything very much about it. It hasn’t affected me too much 
really.’  
 
4.5 Discussion 
 
Our study has shown that participants were aware that hypertension, diabetes, family history and 
obesity were risk factors for CKD, but were unsure about how smoking, Aboriginal / Torres Strait 
Islander descent, age, alcohol and fluid intake could affect them. Participants also believed that that the 
outcomes for people with diabetes and cardiovascular disease were poorer than those with kidney 
disease. These findings are in part explained by participants’ perceptions about CKD, as ‘invisible’, 
with many demonstrating limited understanding of the risk factors and comorbidities associated with 
CKD. Participants were not generally aware of the consequences of CKD progression, and its multiple 
comorbidities, and were therefore anxious about the future. Some participants were more accepting of 
death as they believed nothing could be done to better manage their condition and prevent its 
progression.  
 
Although about half the participants had received information about CKD, the majority still had 
limited knowledge about the disease and its related risk factors and comorbidities. Almost half thought 
alcohol was a risk factor and about three quarters also believed that inadequate fluid intake was a risk 
factor. Previous studies have also reported participants’ belief that alcohol misuse caused kidney 
disease [16, 17]. Although alcohol intake is not a risk factor, some studies have demonstrated that 
more than two drinks per day was associated with CKD and ESRD [22, 23]. Likewise, inadequate 
fluid intake is not a risk factor for CKD, but a recent study found that participants with adequate fluid 
intake had a significantly lower risk of having the disease [24].  
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Patients appear to regard diabetes and CVD as more serious conditions than having CKD. They 
consistently indicated higher event rates for stroke, heart attack and death when associated with 
diabetes and CVD. According to the American Heart Association 2014 Report, individuals with earlier 
stages of CKD are at significantly increased risk of CVD, independent of other CVD risk factors [25]. 
It has been demonstrated that the predicted lifetime risk for cardiovascular disease is considerably 
increased in the presence of two or more major risk factors 68.9% compared with no risk factors 5.2% 
for men, and 50.2% versus 8.2% for women [26]. These risk factors included diabetes, smoking, 
obesity and hypertension, all of which are associated with CKD. In a study by Tan et al [15] 
participants identified diabetes and hypertension as the main risk factors for CKD. Their perceptions 
about CKD-related complications were assessed, but their beliefs with regard to diabetes and CVD 
associated complications were not evaluated.  
 
For most participants, the process of learning about their condition commenced too late. They felt they 
could have prevented CKD if they had been more aware of the effects of having diabetes and 
hypertension and wished they had managed them better.  Previous studies have shown that patients 
with earlier stages of CKD or with fewer symptoms, perceived their disease to be less threatening 
compared to those with advanced disease, and that patients’ perceived knowledge improved with 
disease progression [14, 27]. These studies have identified patients’ knowledge gap about CKD 
however, patients’ perceptions about CKD-related co-morbidities were not assessed. 
 
In this study, we have shown how patients’ perceive the risks and comorbidities associated with CKD 
compared with diabetes and cardiovascular disease. Patients’ attitudes and beliefs about the risk factors 
of CKD and comorbidities, and thoughts about their future health were also described. Our study had 
some limitations. The survey was not pilot tested and the sample size was small, however this can be 
attributed to the difficulty in recruiting patients with early stage CKD. Patients did not consider they 
were at risk nor believed they had kidney disease. Although the study was cross-sectional and only 
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English speaking participants were included, participants from different ethnic populations were 
included. 
 
To slow CKD progression, it may be necessary for patients to be better educated during the early 
stages of the disease. In our study, it was evident that participants had limited awareness about risk 
factors and comorbidities, even though 40% of them had been diagnosed for more than five years. An 
education program needs to be implemented where patients’ needs are met and where patient barriers 
to learning are identified and addressed. Educational interventions that are based on a health care 
model or theory may facilitate the learning process. One such model is the Health Belief Model which 
is based on the premise that a person will take action in response to a health concern if they believe 
they are susceptible, they understand the severity of the disease, they understand the benefits and 
barriers of taking action, are able to identify when to take action and show self-efficacy [28, 29].  
 
There is also a need to improve awareness of the risk factors and comorbidities associated with CKD, 
especially for people at high risk. One such national public awareness program is the Kidney Early 
Evaluation Program (KEEP) developed by the National Kidney Foundation [30] which aims to screen 
and educate patients with high blood pressure, diabetes or a family history of kidney failure. Consumer 
/ professional organisations such as Kidney Health Australia (KHA) [31], the National Institute of 
Diabetes and Digestive and Kidney Diseases (NIDDK) [32], The Renal Association in the UK [33] 
and The Kidney Foundation of Canada [34] provide evidence based information for patients and health 
care providers and this should be more vastly promoted.    
 
It has been previously demonstrated that patients with diabetes have a greater awareness of the risk of 
developing CKD compared to those without diabetes (25.9% versus 7.3% respectively, P<0.001). This 
was not the case however for patients being treated for hypertension, as only 3.3% knew that this was a 
risk factor for CKD compared to 2.7% of participants with normal blood pressure (P= not significant) 
[17]. Therefore, research should aim to facilitate patient learning by identifying their learning needs 
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and capabilities followed by educational interventions that are suited to their needs. Strategies that are 
important to early stage CKD patients such as self-management interventions including dietary 
modification, medication adherence, weight management, blood pressure monitoring, smoking 
cessation and patient education about CKD, its risk factors and comorbidities should be considered.  
 
In conclusion, participants perceived diabetes and CVD as more serious conditions compared to CKD. 
Most participants were not aware of the interaction between having kidney disease and developing a 
heart attack or stroke. This was partly due to the nature of the disease, participants’ lack of awareness 
and their attitude about accepting that they have a disease. Implementation of education interventions 
during the earlier stages of CKD, that address patients’ beliefs about health and illness as well as 
education about risk factors and CKD-related comorbidities is needed.  
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Table 4.1 Participant characteristics (n = 38) 
Characteristics Number (%) 
Gender   
  Males 23 (60.5) 
  Females 15 (39.5) 
Age (years)  
20-29 5 (13) 
30-39 5 (13) 
40-49 4 (10.5) 
50-59 6 (15.8) 
60-69 9 (23.7) 
70-79 9 (23.7) 
Time diagnosed with CKD (years)  
  ≤ 1  5 (13) 
> 1 ≤ 5  10 (26) 
>5  15 (39.5) 
Uncertain 8 (21) 
Cause of CKD  
Diabetes 5 (13) 
Hypertension 4 (10.5) 
Cancer / Radiotherapy 3 (7.9) 
Hereditary  6 (15.8) 
Autoimmune  4 (10.5) 
Other  5 (13) 
Uncertain 11 (29) 
Stage of CKD  
I 1 (2.6) 
II 6 (15.8) 
III 21(55) 
IV 9 (23.7) 
V
†
 1 (2.6) 
Level of education   
Primary 4 (10.5) 
Secondary  15 (39.5) 
Tertiary  19 (50) 
English as first language  
Yes 31 (81.5) 
No 7 (18.4) 
Country of birth  
Oceania (Australia / New Zealand) 25 (65.8) 
Europe (Austria, Italy, Portugal, United Kingdom) 5 (13.2) 
Asia (India, Iraq, Philippines) 4 (10.5) 
Africa (Mauritius, South Africa) 3 (7.9) 
South America 1 (2.6) 
Level of employment  
Full-time 8 (21) 
Part-time 5 (13) 
Other (home duties, unemployed, student, retired) 25 (66) 
Received CKD information  
Yes 20 (53) 
No 18 (47) 
Source of information  
Specialist 14 (36.8) 
General Practitioner 9 (23.7) 
Nurse 7 18.4) 
Self 5 (13.2) 
Other (family) 3 (7.9) 
Abbreviations: CKD – chronic kidney disease 
†
At the time of the focus groups, one participant had progressed to CKD Stage 5 
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Table 4.2 Illustrative quotations 
 
Theme Quotes 
Invisibility ‘I didn't feel any different. They just told me that I had kidney disease. I was sort of surprised but I didn't feel any different, I still don't. 
Every time I go there [see nephrologist] - your kidneys - they haven't got any better but they haven't got any worse’ (Male, 68 years, 
Stage 4)  
‘I wouldn’t say I was concerned when it hasn’t really impacted the family, I don’t think so. I mean, when I have a blood test I always get a 
copy of it and it would be two pages of tests and the only thing not in the normal is my creatinine, everything else is in the normal range. 
So, I don’t think it impacts it at the moment because I feel fine and I play tennis, and I walk and I do things so I don’t really feel I’m sick’ 
(Female, 60 years, Stage 3) 
‘People are more concerned of the ones that have more physical effect where they can see it happening to you. With kidney disease, 
they don't see anything. You can tell them about it, they won't remember it unless something really bad happens’ (Female, 22 years, 
Stage 3) 
‘Well back when it started, you didn't really get much of any information whatsoever. It was only until he started running into a problem 
that we started to realise what it was all about. Even now we're still learning about what his problem is’ (Female – carer) 
Invincibility  ‘I felt like I was going to die, it felt like my heart was racing… So i called my father and my father and mother suffer from high blood 
pressure… [patient’s father] took my blood pressure and it was really pretty high…went to the G.P. he took my blood pressure and they 
immediately told my father – ‘take him to the hospital now’… they [medical team] found out what I have today, IgA nephropathy’ (Male, 
33 years, Stage 3) 
‘[participant was asked if concerned about hypertension since he has a family history] Yes, but I thought I was invincible’ (Male, 33 
years, Stage 3)  
‘[participant questioned if kidney disease was ever mentioned since has diabetes] Well it was mentioned as an inevitable result, but like 
all brave males, thought I’d put that at the back of the line, can’t do anything about it so I won’t worry about it’ (Male, 72 years, Stage 4) 
Lacking awareness 
 
‘For the five years or six years I absolutely thought nothing of the kidneys; because I felt nothing. Maybe because I was seeing a child 
paediatric nephrologist, I saw her often and didn’t get sick for very long. Then when I turned 18, the doctor visits were every four months 
or so... That's when I slurred off and I realised how sick I could get. I ended up in hospital for a week. I didn't think it [kidney disease] was 
serious until then’ (Female, 22 years, Stage 3) 
‘I don't think the relationship between high blood pressure and kidney disease is known at all. So consequently, I didn't take that 
seriously enough, which I regret. But I have to say also, I'm someone who doesn't like to take medicines anyway and so I was somewhat 
resistant to it. But I didn't ask the fundamental question which was, what's the consequences of not [taking medication]’ (Female, 76 
years, Stage 4) 
‘Well the thing is, maybe we should have been better educated - and we're not blaming it on any of the doctors, it's just that we didn't 
look for more information. When he became a diabetic, we never thought ahead that it would lead to the insulin stage and when it got to 
the insulin stage, we never thought it would end up with the problem of the kidneys. So in other words, right at the beginning, instead of 
learning as you go - in other words, really we didn't know the consequences of what can happen at the end’ (Female – carer) 
‘ Just because you’ve got kidney disease, it doesn’t mean you’re going to have a heart attack, stroke or die [participant answering 
survey]’ (Female, 56 years, Stage 3) 
‘Smoking doesn’t give you kidney disease does it? [participant answering survey]’ (Female, 67 years, Stage 4) 
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Theme Quotes 
‘What’s type one diabetes? I don’t really understand. How are you at risk if you’re, Aboriginal or Torres Strait Islander descent? How 
does that increase your risk? [participant answering survey]’ (Female, 39 years, Stage 3) 
‘It’s a bit of guesswork this, isn’t it?’ (Male, 74 years, Stage 3) 
‘It just goes to show how ill-informed we are. It’s like a needle in the haystack’ (Female, 58 years, Stage 4). 
‘Type two diabetes is the obesity related?’ (Male,39 years, Stage 3) 
‘Ah, the risk factors, and what are the risk factors?’ (Male, 51 years, Stage 4) 
Cumulative 
comorbidities  
‘At the moment, because my blood pressure is always really high up to 200/120. I’m seeing a cardiologist now as well... and they found 
that my heart lining is getting thicker as well. So, now I’m going, the kidney, the heart, what else is going to go wrong? Because they 
[doctors] said, you’re diabetic and all these things will happen... and I go, mm yeah ok’ (Male, 38 years, Stage 2) 
‘Also the impact of this on other aspects of one's health is really a concern. If this is going wrong, what else is going wrong? Am I more 
prone to heart disease? Am I more prone to whatever? It does worry you quite a lot. You don't understand the links 100 per cent. It is 
concerning’ (Male, 69 years, Stage 3) 
Inevitability of 
death 
 
‘That’s the trouble with it, there’s nothing people can do.... I think my really first reaction was I’m not going to live very long... no, I don’t 
want to die, I’m not saying that. But I just had that you know, that was just my first reaction’ (Female, 56 years, Stage 3) 
 ‘I had a coronary in 1986; In 2002 I had the abdominal aortic aneurism repaired, lucky that they found that. In 2003 I had open heart 
surgery and (five) bypasses. At the end of 2003, I had a defibrillator inserted and when I was told that I had a kidney disease, I just sort 
of thought oh well, it's just another problem. I just accepted the fact that I can't do anything very much about it. It hasn't affected me too 
much really’ (Male, 70 years, Stage 3) 
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Figure 4.1 Proportion of participants who identified risk factors for chronic kidney disease 
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Figure 4.2 Patient reported event rates for the three hypothetical scenarios: A. Type 2 diabetes;  
B. chronic kidney disease; C. cardiovascular disease 
Chapter 4. Patient awareness and beliefs about the risk factors and comorbidities associated with chronic kidney disease – a 
mixed-methods study 
84 
4.6 References  
 
1. Brantsma AH, Bakker SJ, Hillege HL, de Zeeuw D, de Jong PE, Gansevoort RT. Cardiovascular 
and renal outcome in subjects with K/DOQI stage 1–3 chronic kidney disease: the importance of 
urinary albumin excretion. Nephrol Dial Transplant. 2008;23(12):3851-8. 
2. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and 
outcomes among a population with chronic kidney disease in a large managed care organization. 
Arch Intern Med. 2004;164(6):659-63. 
3. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, et al. Chronic kidney 
disease and the risk for cardiovascular disease, renal replacement, and death in the United States 
Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005;16(2):489-95. 
4. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJL, Mann JF, et al. 
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. 
Lancet. 2013;382(9889):339-52. 
5. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C-y. Chronic kidney disease and the risks of 
death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296-305. 
6. Herzog CA, Asinger RW, Berger AK, Charytan DM, Díez J, Hart RG, et al. Cardiovascular 
disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global 
Outcomes (KDIGO). Kidney Int. 2011;80(6):572-86. 
7. James MT, Hemmelgarn BR, Tonelli M. Early recognition and prevention of chronic kidney 
disease. Lancet. 2010;375(9722):1296-309. 
8. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: 
global dimension and perspectives. Lancet. 2013;382(9888):260-72. 
9. Mujais SK, Story K, Brouillette J, Takano T, Soroka S, Franek C, et al. Health-related Quality of 
Life in CKD Patients: Correlates and Evolution over Time. Clin J Am Soc Nephrol. 
2009;4(8):1293-301. 
Chapter 4. Patient awareness and beliefs about the risk factors and comorbidities associated with chronic kidney disease – a 
mixed-methods study 
85 
10. Tonelli M, Muntner P, Lloyd A, Manns BJ, Klarenbach S, Pannu N, et al. Risk of coronary 
events in people with chronic kidney disease compared with those with diabetes: a population-
level cohort study. Lancet. 2012;380(9844):807-14. 
11. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and 
progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study 
(UKPDS 64). Kidney Int. 2003;63(1):225-32. 
12. Fox CS, Matsushita K, Woodward M, Bilo HJG, Chalmers J, Heerspink HJL, et al. Associations 
of kidney disease measures with mortality and end-stage renal disease in individuals with and 
without diabetes: a meta-analysis. Lancet. 2012;380(9854):1662-73. 
13. Shlipak MG, Fried LF, Cushman M, Manolio TA, Peterson D, Stehman-Breen C, et al. 
Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk 
factors. JAMA. 2005;293(14):1737-45. 
14. Finkelstein FO, Story K, Firanek C, Barre P, Takano T, Soroka S, et al. Perceived knowledge 
among patients cared for by nephrologists about chronic kidney disease and end-stage renal 
disease therapies. Kidney Int. 2008;74(9):1178-84. 
15. Tan AU, Hoffman B, Rosas SE. Patient perception of risk factors associated with chronic kidney 
disease morbidity and mortality. Ethn Dis. 2010;20(2):106-10. 
16. Burke M, Kapojos J, Sammartino C, Gray N. Kidney disease health literacy among new patients 
referred to a nephrology outpatient clinic. Intern Med J. 2014;44(11):1080-6. 
17. White SL, Polkinghorne KR, Cass A, Shaw J, Atkins RC, Chadban SJ. Limited knowledge of 
kidney disease in a survey of AusDiab study participants. Med J Aust. 2008;188(4):204. 
18. Krueger RA, Casey MA. Focus groups: A practical guide for applied research: Sage 
Publications, Inc.; 2000. 
19. Tong B, Stevenson C. Comorbidity of cardiovascular disease, diabetes and chronic kidney 
disease in Australia: Australian Institute of Health and Welfare; 2007. 
20. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): 
a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349-57. 
Chapter 4. Patient awareness and beliefs about the risk factors and comorbidities associated with chronic kidney disease – a 
mixed-methods study 
86 
21. Strauss A, Corbin J. Basics of Qualitative Research. 2nd ed. Thousand Oaks, Califormia: Sage 
Publications; 1998. 
22. Perneger TV, Whelton PK, Puddey IB, Klag MJ. Risk of end-stage renal disease associated with 
alcohol consumption. Am J Epidemiol. 1999;150(12):1275-81. 
23. Shankar A, Klein R, Klein BE. The association among smoking, heavy drinking, and chronic 
kidney disease. Am J Epidemiol. 2006;164(3):263-71. 
24. Strippoli GF, Craig JC, Rochtchina E, Flood VM, Wang JJ, Mitchell P. Fluid and nutrient intake 
and risk of chronic kidney disease. Nephrology. 2011;16(3):326-34. 
25. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and 
stroke statistics--2014 update: a report from the American Heart Association. Circulation. 
2014;129(3):e28. 
26. Lloyd-Jones DM, Leip EP, Larson MG, d’Agostino RB, Beiser A, Wilson PW, et al. Prediction 
of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 
2006;113(6):791-8. 
27. Pagels AA, Klang B, Susanne Heiwe S. Differences in illness representations in patients with 
chronic kidney disease. J Ren Care. 2015:1-10. 
28. Glanz K, Rimer BK, Lewis FM, Editors. Health behavior and health education: theory, 
research, and practice. 3rd ed. San Francisco, CA: John Wiley & Sons; 2002. 
29. Lorig K, Associates. Patient education: a practical approach. Thousand Oaks, California: Sage; 
2001. 
30. National Kidney Foundation. Kidney Early Evaluation Program (KEEP) 2015 [cited 2015 22 
May]; Available from: https://www.kidney.org/news/keep. 
31. Kidney Health Australia (KHA). Support.   [cited 2015 22 May]; Available from: 
http://www.kidney.org.au/ForPatients/tabid/581/Default.aspx. 
32. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Health Information.  
2015 [cited 2015 22 May]; Available from: http://www.niddk.nih.gov/health-
information/healthcare-professionals/Pages/default.aspx. 
Chapter 4. Patient awareness and beliefs about the risk factors and comorbidities associated with chronic kidney disease – a 
mixed-methods study 
87 
33. The Renal Association. Information for Patients.  2015 [cited 2015 22 May]; Available 
from:http://www.renal.org/information-resources/information-for-
patients#sthash.QR2EhCY4.dpbs. 
34. The Kidney Foundation of Canada. Your Kidneys.  2015 [cited 2015 22 May]; Available from: 
http://www.kidney.ca/your-kidneys. 
 
Chapter 5. Knowledge deficit of patients with stage 1-4 CKD – a focus group study 
88 
Chapter 5. Knowledge deficit of patients with stage 1-4 CKD - a 
focus group study. 
 
5.1 Abstract  
 
Background: Patients with early-stage chronic kidney disease (CKD) must make lifestyle 
modifications and adhere to treatment regimens to prevent their progression to end-stage kidney 
disease. The aim of this study was to elicit the perspectives of patients with stage 1-4 CKD about their 
disease, with a specific focus on their information needs in managing and living with CKD and its 
sequelae.  
 
Methods: Patients with CKD stages 1-4 were purposively sampled from three major hospitals in 
Sydney, Australia to participate in focus groups. Transcripts were thematically analysed. 
 
Results: From nine focus groups including 38 participants, six major themes were identified: medical 
attentiveness (shared decision making, rapport, indifference and insensitivity); learning self-
management (diet and nutrition, barriers to physical activity, medication safety); contextualizing 
comorbidities (prominence of chronic kidney disease, contradictory treatment); prognostic uncertainty 
(hopelessness, fear of disease progression, disbelief regarding diagnosis); motivation and coping 
mechanisms (engage in research, pro-active management, optimism, feeling normal); and knowledge 
gaps (practical advice, access to information, comprehension of pathology results and CKD diagnosis, 
education for general practitioners).  
 
Conclusion: Patients capacity to slow the progression of CKD may be limited by their lack of 
knowledge about the disease, its comorbidities, psychosocial influences and their ability to interact and 
communicate effectively with their health care provider. Support from a multidisciplinary care team, 
combined with provision of comprehensive, accessible and practical educational resources may 
Chapter 5. Knowledge deficit of patients with stage 1-4 CKD – a focus group study 
89 
enhance patients’ ability and motivation to access and adhere to therapeutic and lifestyle interventions 
to retard progression of CKD.   
 
5.2 Introduction 
 
Prevention of chronic kidney disease (CKD) and its progression to end-stage kidney disease (ESKD) 
requires complex care, because it involves both specific CKD management and the management of 
comorbidities such as hypertension and diabetes. The asymptomatic nature of early stage CKD and 
lack of public awareness about the disease [1, 2], also mean that patients may be reluctant to accept the 
diagnosis, lack insight into factors that may drive progression and be at risk of non-adherence to 
recommended therapies. An effective patient and provider partnership is important to optimize patient 
care [3] in preventing disease progression [3, 4].   
 
To delay ESKD and its complications including cardiovascular disease, cancer, increased 
hospitalization, and premature death [5-8], patients must make lifestyle modifications and adhere to 
treatment regimens. Patients with CKD need to be informed about the benefits of maintaining a 
healthy lifestyle and adhering to medication to reduce proteinuria, hypertension and diabetes, all of 
which are risk factors for CKD [9, 10]. However, a recent study found that 35% of patients stated they 
had very limited or no knowledge at all about CKD and the prevention of ESKD [11]. Patients 
diagnosed with early CKD have also reported poor coping skills, depression and anxiety, limited 
participation in treatment planning, and poor quality of life [12, 13]. Effective patient education can 
improve symptoms, quality of life, coping mechanisms [12, 14], patient survival, and reduce rates of 
hospitalizations and progression to ESKD [15, 16].  
 
Effective strategies to prevent CKD progression requires understanding the views, concerns, and needs 
of patients, so that educational interventions address their information needs and promotes their 
capacity to make lifestyle changes. This study aims to describe the experiences and perspectives of 
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patients with early CKD to inform treatment and education strategies for primary and secondary 
prevention of progression of CKD. 
 
5.3 Methods 
 
We conducted nine focus groups from March to April 2011. Focus groups capitalize on group 
interaction which allows participants to explore and clarify their individual and shared perspectives 
[17]. Each focus group lasted two hours and was facilitated by the primary investigator (PLV).  
A field observer (RK, NV, AT or MH) was also present during each session. No researcher had prior 
contact with, or knowledge of, the participants. Three focus groups were conducted for each of the 
three participating institutions (Westmead Hospital, Royal Prince Alfred Hospital and Royal North 
Shore Hospital). Ethics approval was obtained from all sites. 
 
Participant selection 
 
Participants were eligible to participate if they were diagnosed with CKD (Stages 1-4), aged 18 years 
or older, English-speaking, and able to give informed consent. Patients were purposively sampled to 
include a range of demographic and clinical characteristics including age, sex, cultural backgrounds, 
time since diagnosis and education. A nephrologist or a CKD coordinator from each institution 
identified eligible patients. PLV invited patients to participate by telephone, written information about 
the study including consent form was sent to those who were interested in taking part. Participants 
were offered AUD$30 reimbursement to cover travel and parking expenses.  
 
Data collection 
 
The primary investigator developed a question guide based on a literature review [18] current 
guidelines [19, 20] and discussion among the research team. Topics included experiences of being 
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diagnosed with CKD, concerns about CKD, knowledge about CKD diagnosis and management, and 
specific information needs (Table C1). During the focus group, participants were shown a range of 
information pamphlets and booklets about CKD which have been developed by various organizations 
(Table C2). The participants were asked to comment on the content (for example, type and amount of 
information), and format (layout, readability and appeal). Using a standardised template, an observer 
recorded field notes on participant interactions and characteristics, body language and group dynamics. 
To facilitate open discussion between the participants, the focus groups were conducted in a hotel 
meeting room. The focus group sessions were recorded with a digital voice recorder and transcribed 
verbatim. Data collection ceased when theoretical saturation was reached, that is, when little or no new 
concepts were raised by the participants.   
 
Analysis 
 
All transcripts were downloaded into HyperRESEARCH (Version 3.0.3. Research Ware Inc. 
Randolph, MA, USA) a software package used to facilitate coding and analysis of qualitative data. 
Using the principles of grounded theory [21] PLV coded and recorded concepts inductively, grouped 
similar concepts, and developed preliminary themes. After discussion with AT, the themes were 
refined until all relevant concepts relating to patient perspectives and experiences of early CKD were 
captured. The FreeMind software 0.9.0 Beta 14 (Source Forge, Mountain View, California, USA) was 
used to map the interrelationships between themes and to develop analytical themes. The preliminary 
findings and themes were discussed among the research team, and then incorporated into subsequent 
revisions of the analytical thematic schema.  
5.4 Results 
 
Participant demographics 
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Of the 99 patients contacted, 38 (38%) participated in the study. Reasons for non-participation 
included family and work commitments, transport difficulties, poor health, disinterest, unaware of 
being diagnosed with CKD, and limited English. The participant characteristics are provided in Table 
5.1.  The mean age of participants was 54 years (range 20 to 79 years), 23 (60.5%) were male, and 25 
(66%) were diagnosed with CKD for more than 1 year. Causes of CKD included inherited 6 (16%), 
diabetes 5 (13%), autoimmune disease 4 (11%), hypertension 4(11%), and other causes 5 (13%), with 
11 (29%) participants not knowing the cause of their disease. There were 28 (73.6%) stage 1-3 CKD 
patients. Twenty (53%) patients reported that they had received information about CKD prior to the 
study commencement. 
 
Thematic analysis 
 
We identified six themes: medical attentiveness (shared decision making, indifference and 
insensitivity, rapport); learning self-management (diet and nutrition, barriers to physical activity, 
medication safety); contextualizing comorbidities (prominence of chronic kidney disease, 
contradictory treatment); prognostic uncertainty (defeat and hopelessness, disease progression, 
disbelief regarding diagnosis); motivation and coping mechanisms (engage in research, pro-active 
management, optimism, feeling normal); and knowledge gaps (practical advice, access to information, 
pathology results, diagnostic ambiguity). Selected illustrative quotations for each theme are provided 
in Table 5.2. The conceptual links and thematic schema are depicted in Figure 5.1.  
 
Medical attentiveness  
Shared decision making:  
 
Participants who had been diagnosed with CKD for a longer period of time were aware that dialysis 
and transplant were the options for renal replacement therapy. They wanted involvement in treatment 
decisions, particularly in choosing between dialysis types and transplantation. Some participants did 
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not want a kidney transplant in order to preserve “body wholeness.” One older participant stated that 
patients should not be forced to have dialysis especially if the quality of life benefits do not outweigh 
survival gain. She felt conservative therapy should be discussed more often with patients and that they 
should be allowed to make their own choices. 
 
Indifference and insensitivity:  
 
Some participants felt ignored by their general practitioner in that their concerns about their symptoms 
were not addressed and thus were forced to advocate for themselves to get a diagnosis. They were 
frustrated about receiving a “delayed diagnosis” and felt their opinions were not being heard. Some 
also felt a lack of empathy from their general practitioner who they believed should have provided 
more advice about prevention of progression and treatment, rather than providing an estimate of 
survival.  
 
Rapport:  
 
Some participants felt intimidated and anxious when they saw their specialist. They were hesitant to 
ask questions as they were uncertain about what was relevant to ask. Others felt their specialists did 
not provide adequate information about their health, which made them feel bewildered and 
exasperated. During consultation, some participants felt their concerns were not addressed and at times 
ignored. 
 
Learning self-management 
 
New diet and nutritional goals:  
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The participants believed that they could prevent disease progression by maintaining a specific diet 
and monitoring fluid intake. They felt frustrated as they perceived a lack of or contradictory dietary 
advice, and were concerned that the wrong foods and inadequate amounts of fluid will aggravate their 
condition. They wanted practical advice about meal preparation and foods to avoid. 
 
Barriers to physical activity:  
 
Although participants perceived it was important to maintain a healthy weight, some felt helpless as 
they were unable to participate in physical activity due to comorbidities, pain, or older age. Other 
participants who had increased their physical activity and lost weight, became discouraged and 
unmotivated when their blood pressure and kidney function had not improved.  
 
Apprehension about medication safety:  
 
Some participants considered that medication was damaging to their kidneys. They felt hesitant about 
taking medications and concerned about medication interactions, how it worked, and side effects. 
Some were anxious about the toxicity of medications particularly if they were taken orally or over a 
long period of time. 
 
Contextualizing comorbidities 
 
Prominence of chronic kidney disease: 
 
Participants had to contend with multiple comorbidities such as systematic lupus erythematosus, 
diabetes and hypertension as well as their kidney disease. They expressed a feeling of anxiety and ill-
fate due to having multiple afflictions. Some participants realized that their kidney disease was a direct 
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outcome of their high blood pressure and diabetes, and wished they had known earlier that adequate 
blood pressure management could retard disease progression. 
 
Contradictory treatment:  
 
Having to manage both prevention of CKD and treatment for other comorbidities was challenging and 
overwhelming. Participants were concerned about potential drug interactions and adverse effects; and 
some felt confused about taking medications for their kidneys if it was primarily indicated for another 
health condition, for example high blood pressure or cholesterol. 
 
Prognostic uncertainty 
 
Defeat and hopelessness:  
 
Participants felt overwhelmed as they believed that CKD progression to ESKD was inevitable. There 
was a sense of fear and of hopelessness in knowing that no therapeutic cure was available for CKD, a 
disease they perceived as life threatening.  
 
Anxiety about disease progression:  
 
Participants were anxious about being unable to predict how quickly their disease would progress and 
how this would affect their health, lifestyle and family. They felt they had no control over their kidney 
function which fluctuated over time.  They were fearful about dialysis and believed they would no 
longer be able to work, and worried about the impact this would have on their family.  
Disbelief regarding diagnosis: 
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One participant did not want to accept her diagnosis of polycystic kidney disease as she felt healthy 
and well at the time. Other participants were shocked when diagnosed with kidney disease as they had 
not experienced any physical symptoms. They were also not aware of any predisposing risk factors or 
health problems and therefore their diagnosis was completely unexpected.  
 
Motivation and coping mechanisms 
 
Engage in research:  
 
Participants were optimistic about new treatments to prevent ESKD. Some felt that patients needed 
more awareness about current research and about how they could get involved in clinical trials and 
access research findings. Research gave them hope of finding a cure to prevent their offspring from 
developing the disease,  one participant felt taking part in research studies would give him the 
opportunity to contribute to a cause.  
 
Pro-active management:  
 
A sense of empowerment was felt by participants who were able to discuss changes to treatment with 
their physician. It motivated them to take more control in managing their disease. They emphasized the 
importance of having adequate blood pressure management and would seek other advice if they felt 
their current treatment was ineffective. One participant experimented with alternate natural therapies, 
such as grape seed oil which he felt helped to stabilize his diabetes and kidney function. Their trust in 
alternative therapies was strengthened as they observed improvements with their condition.  
 
Optimism:  
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Participants believed that a positive outlook about life and life’s circumstances enabled them to cope 
with their illness and enjoy life. Others were hopeful of a bright future and felt reassured and 
encouraged by their physician to make lifestyle changes to improve their health.  
 
Feeling normal:  
 
Some participants felt they could continue living “normally” as CKD was not perceived to be affecting 
their daily lives. Their general well-being was unchanged and they considered themselves to be 
healthy. They would consider learning more about their health management once the signs and 
symptoms become more evident.  
 
Blame and resentment: 
 
One participant with hereditary CKD blamed his parents when he was diagnosed. He was young at the 
time, but had learnt to come to terms with the condition and with the concept of dying. It helped to 
know that he has a milder form of polycystic kidney disease and he has had years to learn more about 
the condition.  
 
Knowledge gaps 
 
Prioritize practical advice:  
 
Most participants sought practical advice which they could apply in their daily lives and enhance their 
self-management skills. Participants wanted specific information about CKD such as the physiology of 
the kidneys, causes of kidney disease, and more importantly how it is managed and what could they do 
to prevent its progression. Some participants felt they could benefit from patient support groups where 
they could meet people in similar circumstances to share experiences and knowledge about CKD.    
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Limited access to information:  
 
Participants believed information should be readily available in nephrology and general practice clinics 
as well as in community settings such as pharmacies. They urged that information about CKD be 
published or reported in the public media to target the general population and the younger generation.  
They felt information should be delivered in various formats such as in print and electronic media.  
Many participants expressed the need for general practitioners to be educated about CKD and other 
genetic kidney diseases, as they would be a great source of information for them if they were better 
informed.   
 
Perplexing pathology results:  
 
Many participants felt bewildered as they were unable to understand` their pathology results. The 
results were “meaningless” to them and felt that their physicians should interpret and explain the 
pathology report.  
 
Diagnostic ambiguity: 
 
Some participants thought that only those with polycystic kidney disease were the ones who end up 
having dialysis. They had not realized that CKD can be caused by other conditions and risk factors. 
Some perceived that they lacked knowledge about what kidney function meant and how it related to 
CKD. 
 
5.5 Discussion 
 
We have shown that chronic kidney disease is a very difficult diagnosis for patients to comprehend. 
What to nephrologists appears routine and self-evident, appears very different and complex to patients. 
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Participants in our study felt overwhelmed, confused and unable to control their condition. Many had 
fears and anxieties about inevitable disease progression, the impending burden of dialysis, and 
premature mortality. Despite being willing to be proactive in their own healthcare, they have limited 
confidence in disease management, due to a perceived potential harm of prescribed medications and 
lack of knowledge about their condition, or strategies to improve their outcomes. 
 
Patients urged for early, comprehensive and practical information to enable them to regain a sense of 
control over their condition. Their priorities for educational information focused on learning about 
dietary advice, medication safety and side effects, managing multiple co-morbidities, and kidney 
function. Patients with inherited CKD appeared better prepared, were more aware of their disease and 
actively sought information to improve their outcomes, as compared to participants who developed 
CKD due to other comorbidities such as diabetes and hypertension. 
 
As has been reported elsewhere, we found that patients want to know more about the biological 
function of the kidneys, signs and symptoms of the disease, and what means to prevent or delay 
progression are available [18, 22-25]. Patients want specific advice regarding diet and fluid 
management and safety of medications [18].  The need for better patient-physician communication, 
and more public awareness to de-stigmatize kidney disease have also been identified [22]. Patients 
with other chronic diseases have also emphasized the importance of shared-decision making and 
effective communication between physicians and patients [26, 27]. Patients in our study felt uncertain 
and intimidated about forming “relevant” questions to ask during consultations and they also sensed 
that consultations were too limited in time to permit questions.   
 
Our study provides insight on the perspectives of patients with early CKD, their information priorities 
and reasons underpinning their preferences for information and treatment. However, there are some 
limitations. Patient recruitment was challenging as some patients with CKD Stage 1-3 did not identify 
as having CKD. Participants from primary care settings were not recruited. It is uncertain whether 
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patients managed in primary care have different perspectives. Also, Non-English speaking patients 
were excluded to maintain the flow of the focus group discussions. Therefore the transferability of 
our findings may be limited particularly for patients of culturally and linguistically diverse 
backgrounds.  
 
The diagnosis of CKD can have a detrimental psychosocial impact on patients [28, 29]. Patients with 
genetic predisposition to CKD may experience fear and resentment. If the diagnosis was unexpected, 
patients can feel overwhelmed by prognostic uncertainty [29], lifestyle changes, hopelessness and loss 
of control. We suggest that health care providers acknowledge patients’ concerns, encourage open 
communication, suggest positive coping strategies, and provide access to psychosocial support.  
 
Patient support and self-management education promote their active role in shared decision making in 
healthcare, which has been shown to improve patient health outcomes and treatment satisfaction [3, 4]. 
In chronic kidney disease, lack of education for patients and carers can lead to inadequate awareness 
about the signs and symptoms of kidney disease, poor coping skills, depression and anxiety, faster 
progression of disease, reduced participation in treatment planning and inferior quality of life [13, 18].  
Several renal organizations have developed educational resources for both patients and primary care 
providers [30-32], but we suggest that more active and wider implementation and dissemination of 
these resources is needed. For example, the nephrology community could take further initiative in 
facilitating regular workshops and training for primary health care providers about CKD, including 
information specific to common inherited and autoimmune kidney diseases, such as polycystic kidney 
disease, IgA nephropathy and lupus nephritis.  
 
Dietary management and medications to prevent risk factors are key interventions in CKD prevention. 
We recommend that a renal dietician should be involved in the care of patients with CKD to provide 
education about diet and nutrition, focusing on practical recommendations such as recipes. Advice 
about medications should encompass information regarding possible side-effects, interactions with 
Chapter 5. Knowledge deficit of patients with stage 1-4 CKD – a focus group study 
101 
other medications, and clear explanation of its direct benefits in CKD prevention. As the diagnosis of 
CKD can be unexpected, education about CKD should be accessible in the primary healthcare setting 
particularly targeted at individuals with risk factors for CKD including diabetes and hypertension. 
Information should be disseminated at the community level to improve awareness among patients even 
prior to being referred to a nephrologist. 
 
More research is needed to develop and evaluate educational interventions for patients with stages 1-3 
CKD [33]. It is recommended that these interventions be multifaceted [33-35] incorporating interactive 
educational sessions supplemented with printed material such as an educational booklet or electronic 
medium such as a video. In assessing the effectiveness of an education program, we suggest that 
outcome measures  include: clinical parameters for renal function (estimated glomerular filtration 
rate), albumin/creatinine and protein/creatinine ratios, blood pressure and blood glucose levels; patient 
knowledge (improved CKD awareness and understanding); attitudes to CKD prevention,  quality of 
life, psychosocial factors; and behavioural factors such as lifestyle modification encompassing self-
management, increase in exercise, smoking cessation and  weight reduction.   
 
Development of comprehensive educational resources including practical lifestyle recommendations, 
such as adequate diet according to CKD stage and types of appropriate physical activities, combined 
with active multidisciplinary and physician engagement in prevention, are likely to promote patient 
satisfaction, positive coping mechanisms, and increase their ability and motivation to make lifestyle 
modifications for prevention of CKD progression.  
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Table 5.1 Participant characteristics (n = 38) 
Characteristics Number (%) 
Gender   
  Males 23 (60.5) 
  Females 15 (39.5) 
Age (years)  
20-29 5 (13) 
30-39 5 (13) 
40-49 4 (10.5) 
50-59 6 (15.8) 
60-69 9 (23.7) 
70-79 9 (23.7) 
Time diagnosed with CKD (years)  
  ≤ 1  5 (13) 
> 1 to 5  10 (26) 
>5  15 (39.5) 
Uncertain 8 (21) 
Cause of CKD  
Diabetes 5 (13) 
Hypertension 4 (10.5) 
Cancer / Radiotherapy 3 (7.9) 
Hereditary  6 (15.8) 
Autoimmune  4 (10.5) 
Other  5 (13) 
Uncertain 11 (29) 
Stage of chronic kidney disease  
I 1 (2.6) 
II 6 (15.8) 
III 21(55) 
IV 9 (23.7) 
V
†
 1 (2.6) 
Level of education   
Primary 4 (10.5) 
Secondary  15 (39.5) 
Tertiary  19 (50) 
English as first language  
Yes 31 (81.5) 
No 7 (18.4) 
Level of employment  
Full-time 8 (21) 
Part-time 5 (13) 
Other (home duties, unemployed, student, retired) 25 (66) 
Received CKD information  
Yes 20 (53) 
No 18 (47) 
Abbreviations: CKD – chronic kidney disease 
†
At the time of the focus groups, one participant had progressed to CKD Stage 5 
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Table 5.2 Illustrative quotations 
Theme Quotations 
Medical attentiveness 
Shared decision 
making 
 “My body, I take it as a temple I don’t want anybody to invade it. I would never have a transplant, even if I know that I’m going to die.” (Man, 75 years, CKD stage 3) 
“When they offered I should have dialysis, I said sorry no, I don't want to. But their insistence is really strong and because of my experience I said no. I'm not going through 
dialysis, it's my choice.” (Woman, 73 years, CKD stage 4) 
Indifference and 
insensitivity 
“From the age of 18 I'd been having undiagnosed pain. I went to my doctor about 20 years ago,…and said I wanted to be tested for polycystic kidneys. He actually just brushed it 
aside …and said nobody ever died of polycystic kidneys.” (Woman, 57 years, CKD stage 3) 
“In 2004, I noticed that most of the renal parameters rose where they shouldn’t and declined when they shouldn’t. My doctor was quite blasé about it. It was only until I told him 
that my creatinine had risen between 2004 and 2008 from 87 to 135 that I alerted him, that it’s obviously going the wrong way” (Man, 75 years, CKD stage 3) 
 “The last time I saw him [specialist] was last month and he just said ‘you got the disease’. The first thing I asked him was, ‘would I end up doing dialysis?’ He said, ‘probably in 5 
to 10 years’.” (Man, 38 years, CKD stage 2) 
“My GP [general practitioner] said to me, ’you’re not going to make 80’. He already told me that and I was 39 at the time.” (Woman, 56 years, CKD stage 3) 
Rapport “You know as soon as he [specialist] calls you, ah my God, I can feel my heart racing and I’m stressing out and you start sweating. Just shoots my blood pressure up… It’s just 
that they make you feel a bit stupid sometimes like you should know. It’s taken me 12 years to actually feel comfortable with him.” (Woman, 39 years, CKD stage 3) 
“Basically there is nothing they [doctors] can do, ‘just do what you’re doing’, that’s all they ever tell me. I say well what am I doing? I get no answers.” (Woman, 56 years, CKD 
stage 3) 
“It’s like the older [doctors] say ‘I know what I’m talking about and I live and breathe this every day, you don’t need to know the ins and outs.” (Man, 45 years, CKD stage 2) 
Learning self-management  
New diet and 
nutritional goals 
 “I suppose mine being genetic… It’s been very difficult to find what kind of diet you’re supposed to follow. You read one bit of information and it tells you this and you read 
another bit and it tells you don’t eat that, which the other one said you must eat… there’s no clear guideline on what it is you can or can’t eat.” (Man, 38 years, CKD stage 3) 
“Hydration levels and how to assess hydration. I would really like to get more information about that. I mean, I know you can look at the color of your urine but - I was a bit 
paranoid about hydration levels because of my kidneys.” (Man, 44 years, CKD stage 2) 
“When I go to the shop I look [food label] and if it's got too much saline, I can't buy that product. But the diet is a bit of a concern.” (Man, 69  years, CKD stage 3)  
“I don’t know what type of food is good for the kidney and is bad for the kidney. Like is chilli good for the kidney? I like to drink Scotch on Saturday.  Will that affect my kidney? 
Wine?” (Man, 75 years, CKD stage 3) 
Barriers to 
physical activity 
“We both find it difficult we used to love gardening… we had a small farm there for many years but neither of us can bend down anymore….we can’t walk the dogs for instance- 
And it’s very hard to exercise, if you know when you’re going to move it’s going cause you pain, so it tends to put you off a bit.” (Man, 72 years, CKD stage 2) 
“I’m a person 75 years old now, going on 76 in a few months, changing my lifestyle now?”(Man, 75 years, CKD stage 3) 
“I’ll go to weight watchers and follow a good diet, and I lost 20 kilos. I came to the specialist, he took my blood pressure and it’s still the same… I was really peeved off because I 
had done all this work and it didn’t help me…I looked better and I felt better but it still didn’t help my condition. You kind of get a bit disheartened as well.” (Woman, 39 years, 
CKD stage 3) 
Apprehension 
about medication 
safety 
“I am also very concerned with the medications I take (a) for my kidneys and (b) for other things, that they are having an effect on my kidneys. Especially when you're taking 
permanent long term medication….” (Man, 44 years, CKD stage 2) 
“I keep getting asked, just when I get a function check-up; ‘are you a regular taker of pain killers?’  But I take away from that, that pain killers are bad for your kidneys. So was 
being quite cautious with my son not to unnecessarily use pain killers and then I was subsequently told that Panadol affects the liver and not the kidneys(Man, 39 years) 
“Tablet has the residue; it’s poison, very light poison probably. If you take 5 or 6 of them in one go, they are going to cause some harm isn’t it?”(Man, 75 years, CKD stage 3) 
“I take 10 tablets in the morning and 9 tablets at night. I’ve been taking them for years and years it was for everything, definitely I think they attack your kidneys. Why don’t they 
give you injections anymore? It dissipates a lot faster, than tablets.” (Woman, 67 years, CKD stage 4) 
Contextualizing comorbidities 
Prominence of 
chronic kidney 
“At the moment, my blood pressure is always really high, up to 200/120. So, now I’m going, the kidney, the heart, what else is going to go wrong? Because they said [doctors], 
‘you’re diabetic and all these things will happen’.” (Man, 38 years, CKD stage 2) 
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Theme Quotations 
disease  
 
 “I don’t know why it’s hit me, it’s not a hereditary situation, I put it down to the fact that my blood pressure was too high for too long and that’s what killed my kidneys as it did my 
aneurysm, that’s why I acted on it.” (Man, 72 years, CKD stage 2) 
“I now think that although I was on blood pressure medication, it was not adequate. So it's my suspicion that's the major cause [of progression to end-stage kidney disease].” 
(Woman, 76 years, CKD stage 5)   
Contradictory 
treatment 
“The tablets that I’m on for my SLE affect my blood pressure… But if he [doctor] drops some of them [blood pressure medication], then my blood pressure goes up, but then my 
kidney function goes down. So I just say, you tell me what I have to take and I just take it.” (Woman 39 years, CKD stage 3) 
“About 4 years ago the doctor said to me, your kidney function, it’s a bit low. I said what could we do about it? She said ‘nothing really it’s your diabetes that caused it’. I said, 
well, give me some tablets to put my diabetes down then and she said, ‘yes take those tablets two in the morning and two in the evening’. I was taking the tablet, the diabetes 
went down, but my kidney went down as well.” (Man, 75 years, CKD stage 3) 
“I take another one for cholesterol but I haven’t got high cholesterol but they said it’s for my kidneys. I can’t understand why I take it.” (Woman, 60 years, CKD stage 3) 
Prognostic uncertainty 
Defeat and 
hopelessness  
 
“So I said if he dies [Kerry Packer] with kidney disease… what are they going do about me, I’m a poor man. His helicopter pilot gave him a kidney but it didn’t help him either. I 
ask my doctor, I said but nobody really could do anything about people sick with kidney? She said ‘no, they haven’t reached that point yet’…” (Man, 75 years, CKD stage 3) 
“I think it was 98 [creatinine] but maintained a fairly level playing field up until early last year, …it jumped almost a hundred points in three months. So the rate of decline has 
increased which, doesn’t excite me very much. But I can’t really put it down to anything in particular nor can any of the specialists or doctors.” (Man, 72 years, CKD stage 4) 
“I Google things and I don’t like what I read [about CKD], I might as well just go get a gun and shoot myself. If that’s going to be the end, like it’s not very encouraging.” (Woman, 
39 years, CKD stage 3) 
Anxiety about 
disease 
progression 
“I've got a double concern because I've got the lupus always in the background and it can affect any organ in your body, which that was fabulous news when I was told that.  So 
I've got pulmonary fibrosis in my lungs and then I've got the kidneys. I try not to think about it, but it's there.” (Woman, 68 years) 
“My GFR went down to 34/35, on my next visit it went up to 40. I don’t know why it just happens, I hadn’t changed anything. On my last visit it had gone up to 47… I’m due to go 
back in two weeks’ time and I’m starting to get anxious, has it gone up? Or have we slipped back down again. It’s that anxiety of not knowing.” (Woman, 66 years, CKD stage 3) 
“Well I'm sure there's a certain fear about the manner in which it's all going to eventually progress and end up. I’ve got a ten month old son, a bit of a concern that I've passed it 
on to him.” (Man 39 years) 
“When you've gotten married and you've got kids, it starts to affect you and you think oh crikey, in three or four years I won't be able to work, won’t be any money to pay for this 
and that. Who's going to drive me?” (Man, 51 years CKD stage 4).   
Disbelief 
regarding 
diagnosis 
 “Had the results and sort of floored me a bit.  It was sort of out of the blue, I didn't comprehend.  When they said, you'll have to have both kidneys out and go on dialysis, it still 
wasn't penetrating that much, but obviously starting to now.” (Man, 71 years) 
”I didn't think anyone knew what they were talking about. It really didn't present that many problems to me. So I guess I was in denial really, because it wasn't affecting me. I 
knew, at the back of my mind, that I had it” (Woman, 62 years, CKD stage 4) 
“Last November I just got sick and I didn't know what was wrong with me and the next thing I found out that I had kidney disease.  A bit of a kick in the butt, but I think I'm getting 
over it.” (Man, 69 years CKD stage 3) 
Motivation and coping mechanisms 
Engage in 
research 
“How do you find out whether you can volunteer for tests or studies? Couldn’t we have been given an opportunity to try on them?  I mean in my case, because it’s genetic my 
son’s got the disease as well, and he’s 8 now. But you’re hoping, probably for me it’s too late but maybe there’s something they can do for him.” (Man, 38 years, CKD stage 3) 
“I’ve probably got about 10 years left on the kidneys and then they are gone. There’s a timeline there now. So you try your best to do whatever you can to extend that period. But 
you really want to know, what else is there, that we can do to extend those times.” (Man, 38 years, CKD stage 3) 
Pro-active 
management 
“I never took the medication without knowing what it was or what the side effects were.…. I have even come back and said to the doctor, ‘this is crap I’m changing, what else can 
you give me?’ Especially with the blood pressure medication, I have always been very proactive about that.” (Woman, 27 years, CKD stage 3) 
“A lot of GPs [general practitioners] have got their favourite medications for one reason or another. It pays to shop around if you’ve got a blood pressure problem unless you are 
dead lucky and strike a good one [physician]. If you know you’ve got a problem you’ve got to be pro-active.” (Man, 72 years, CKD stage 2) 
“The diabetes association put out a magazine and one of the articles talked about grape seed. I bought it and my levels [of k idney function] stopped dropping. My nephrologist 
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Theme Quotations 
doesn't believe in it but I'm not willing to stop taking it to find out.” (Man, 70 years, CKD stage 3) 
Optimism “You’ve been dealt this blow, what can I do about it? I think the first thing is to be very positive in your own mind…and not sit in the corner and sulk it out… sitting in the corner is 
only going to pull you down. You get on with life and you enjoy it, because you never know whether tomorrow is your first day or your last...” (Woman, 66 years, CKD stage 3) 
 “My wife says, get on with it and enjoy yourself…. We've both had cancer, so we just do what we can and we ignore it.” (Man, 71 years)  
“Hearing what my doctor said: live life as normal and live life to the fullest. Just control your blood pressure, maintain a healthy diet and take your medicine and you should have 
a normal life. I still have goals ahead of me.” (Man, 33 years, CKD stage 3)  
Feeling normal “I don't want to know about it.  I know I've got it.  I'll put it in the back drawer, go on with my life.  When it gets serious, then I'll open that box up and start reading up on it more, 
because things change so much.  Dialysis machines have changed dramatically, techniques, drugs.  So I don't know a lot about it at the moment, because it's not really affecting 
me that much at all.” (Man, 51 years, CKD stage 4) 
“I wouldn’t say I was concerned when it hasn’t really impacted the family... When I have a blood test, the only thing not normal is my creatinine, everything else is in the normal 
range. So, I don’t think it impacts on me at the moment because I feel fine and I play tennis, I walk and I do things so I don’t really feel I’m sick.” (Woman, 60 years, CKD stage 3) 
“Was I scared? No not at all, I have no physical discomfort, I have no loss of concentration, I sleep well, I have ravenous appetite, so I was rather unconcerned, and I still am.” 
(Man, 75 years, CKD stage 3) 
Blame and 
resentment 
“It wasn't a total shock and it's probably one of the more fortunate versions of kidney disease. It sets in later in life and doesn't knock you over straight away. One of the problems 
of being younger at the time I was a bit resentful of the fact that I was sick at all and perhaps blamed my parents in some part of me.  It's alright, I don't feel too bad now.” (Man, 
39 years) 
Knowledge gaps 
Prioritize practical 
advice 
“Basically what we need to know is: what it is, how it works…. Obviously it's an impairment of some kind, but impairment of what? What part of the kidney? What we can do?” 
(Man, 62 years) 
“I think what is missing from most of these [brochures] is - WHY? They tell you about it but they don’t give you the reason why it’s like this.” (Man, 38 years, CKD stage 3) 
“I want to get some mind and body help. How do you get in touch with people with similar conditions and those sorts of things? Some of this stuff [in brochures] for me, it’s a bit 
more ideas as opposed to practical advice.” (Woman, 27 years, CKD stage 3) 
Limited access to 
information 
 
“When my husband was diagnosed with this prostate problem, the specialist had two books there [clinic] about the disease. Here you are, take it away, read it, I'll see you next 
week; make a note of your questions. Maybe you could actually have them at the urologist clinics.” (Woman, 58 years, CKD stage 4) 
“I think if you were going to publicize anything to do with polycystic kidneys, even though she [other participant] doesn't think it would help, I think it would help if it  was published 
in something like Cleo, or Cosmopolitan, or the magazines that young people read - or even on Triple J [radio station] or something like that.” (Woman, 57 years, CKD stage 3) 
“The hospital should do a CD or DVD with information about the kidneys. Then you go home and watch it comfortably in your lounge room.” (Man, 75 years, CKD stage 3) 
“Education for GPs. Whenever I've picked up any information pamphlets, it's always been in association with a renal centre in a hospital. It's not generally available [in the 
community].” (Woman, 76 years, CKD stage 5) 
Perplexing 
pathology results 
“I understand the function of the kidneys.  I understand the general progression of it, so a goodly amount.  But still each period when I get renal function tests, it's still a bit of a 
mystery when those numbers come out and you're sort of looking and think well I'm glad they mean something to you doc.” (Man, 39 years) 
“To tell you the truth, I don’t know. She [physician] always says ah you went up 2 points. Next time, ah, too bad you went down 5. But, I don’t know what point she is talking 
about.” (Man, 75 years, CKD stage 3) 
“When I do get my blood tests I don't know what anything of them [results] are. All I know is that I've things there that are highlighted in black, but I don't know what it is.  If they 
put it into words what it is, then I'd know. ” (Man, 69 years, CKD stage 3) 
Diagnostic 
ambiguity 
“I don’t even know like how you’re supposed to know your kidney function. Do you guys know how it works?” (Woman, 21 years, CKD stage 1) 
 “I always thought anyone on a [dialysis] machine must have had polycystic kidneys.”  (Man, 51 years, CKD stage 4) 
“It wasn’t till about 2 years ago, until I fully understood and I’ve had the kidney disease from the age of 15, what exactly my [k idney] function was and I got a fright. No one had 
ever told me.” (Man, 38 years, CKD stage 3) 
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Figure 5.1. Schematic diagram of themes 
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Chapter 6 Educational interventions for patients with early stage 
chronic kidney disease: a systematic review 
 
6.1 Abstract  
 
Background: Preventing the progression of chronic kidney disease (CKD) to end-stage kidney disease 
and minimising the risk of cardiovascular events and other complications is central to the management 
of CKD. Patients’ active participation in their own care is critical but may be limited by their lack of 
awareness and understanding of CKD. We aimed to evaluate educational interventions for primary and 
secondary prevention of CKD. 
 
Methods: Systematic review. Electronic databases were searched to December 2014 for Randomised 
and non-randomised studies of educational interventions for people with CKD. Primary outcomes 
included Knowledge, self-management, quality of life and clinical endpoints Study quality assessed 
using the Cochrane Collaboration risk of bias tool.  
 
Results: Twenty-five studies, 12 trials and 13 observational studies, involving 5,345 participants were 
included. Risk of bias was high in most studies. Interventions were multifaceted, including face-to-face 
teaching (25 studies), written information (19 studies) and telephone follow-up (13 studies). Nineteen 
studies involved one-on-one patient/educator interaction and 13 incorporated group sessions. Nine 
studies showed improved outcomes for quality of life, knowledge and self-management; eight had 
improved clinical endpoints; and two studies showed improvements in both patient reported and 
clinical outcomes. Characteristics of effective interventions included teaching sessions that were 
interactive - workshops/practical skills (12/14 studies); integrated negotiated goal setting (9/12 
studies); involved groups of patients (11/13 studies), their families (4/4 studies) and a multidisciplinary 
team (6/6 studies); and had frequent [weekly (4/5 studies) or monthly (7/7 studies)] 
participant/educator encounters. 
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Conclusions: Interactive, frequent, and multifaceted educational interventions that include both 
individual and group participation appear to improve knowledge, self-management and patient 
outcomes. 
 
6.2 Introduction  
 
Individuals with chronic kidney disease (CKD) have an increased risk of cardiovascular events 
including myocardial infarction, stroke, heart failure and peripheral vascular disease, as well as the risk 
of progression to end-stage kidney disease (ESKD), and early death [1-11]. The 1999 – 2008 National 
Health Survey showed that up to 90% of participants with two to four markers of CKD, including 
hyperkalemia, hyperphosphatemia, acidosis, increased blood urea nitrogen, albuminuria, anemia and 
hypertension, were unaware of their disease when surveyed [12]. Similarly patients with more 
advanced stages of CKD also showed poor knowledge regarding their treatment options [13].  
 
In addition to older age, lower socioeconomic status and level of education, risk factors associated 
with CKD include smoking, hypertension and a sedentary lifestyle [14, 15]. Patient education about 
these risk factors for CKD and its management to ensure effective primary and secondary prevention is 
widely accepted as an essential element of the care of people with CKD [16-20]. Systematic reviews, 
focused on diet and fluid management, have shown that educational interventions may be effective in 
pre-dialysis and dialysis patients [21] and self-management programs in stages 1-4 CKD have shown 
some improvement in knowledge and quality of life [22]. However, previous systematic reviews were 
primarily focused on dialysis patients, or were limited to self-management interventions, rather than 
educational interventions more broadly.  
The aim of our study was to evaluate the effectiveness of education interventions for patients with 
early stage CKD, including their effects on knowledge, and clinical outcomes, and then to identify the 
characteristics of the more effective educational interventions. 
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6.3 Methods  
 
We conducted a systematic review reported in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) [23]. 
 
Selection criteria 
 
We included randomized controlled trials (RCTs) and non-randomized studies on educational 
interventions for the primary and secondary prevention and management of CKD. Although the 
population of interest was patients with Stages 1-3 CKD, due to the limited number of studies with this 
specific population, we also included studies that had included those with Stages 4-5 CKD patients. 
Those studies that included only Stage 5 CKD, 5-T or 5-D were excluded. Interventions targeting 
conditions such as diabetes or hypertension were included only if they were in the context of CKD 
prevention and management. Citations were not excluded on the basis of language.  
 
Literature search 
 
Medical Subject Heading (MeSH) terms and text words for CKD were combined with MeSH terms 
and text words related to health education, patient education, self-care, health promotion, primary and 
secondary prevention, disease progression and risk factors (Table D1). We searched MEDLINE (1946 
to Week 4 December 2014), Embase (1996 to 30 December 2014), CINAHL (1982 – 30 December 
2014), The Cochrane Library (December 2014), and reference lists of relevant articles and reviews. 
Studies were first screened according to title and abstract. Those that did not satisfy the inclusion 
criteria were excluded. Full-text articles were retrieved and assessed for eligibility by two independent 
reviewers (PLV and MH).   
 
Data extraction and critical appraisal 
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Study characteristics relevant to the population, intervention, comparator and outcomes, as well as 
sample size, study setting and duration were extracted and tabulated.  
 
The risk of bias was performed using the Cochrane tool for randomized studies [24] and the Cochrane 
Effective Practice and Organisation of Care (EPOC) Review Group criteria [25] for controlled before-
and-after studies. The risk of bias criteria as described in Ramsay et al. [26] as well as EPOC [25] were 
used for assessment of the interrupted time series studies. The bias domains included in the assessment 
were: reporting bias (completeness of outcome reporting); attrition (incomplete outcome data); 
detection (blinding of investigators and outcome assessors); performance (blinding of participants); 
and selection bias (random sequence generation and allocation concealment) [24]. Other criteria were 
included in the assessment of controlled before-and-after and interrupted time series studies. PLV and 
MH assessed the studies independently and any disagreements were resolved by discussion. 
 
Synthesis of results 
 
A detailed analysis of the intervention characteristics was made using a taxonomy framework for 
educational interventions including setting (one-on-one, group), delivery style (face-to-face, 
telecommunication, written), teaching method (didactic, goal setting, situational), intensity (frequency, 
number of episodes, duration), content and personnel [27].  
 
Due to the heterogeneity in the interventions and outcomes, a formal meta-analysis could not be 
performed. The effect size for primary outcomes and their p-values, unless reported in the study, were 
calculated from the data provided using Review Manager (RevMan5) software (version 5.2.11) and 
expressed as relative risk or mean difference for dichotomous and continuous outcomes respectively. 
An intervention was considered effective if it had at least one primary outcome that was significantly 
improved in the intervention group compared to the control or from baseline in observational studies.  
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6.4 Results  
 
Literature search and study characteristics 
 
The initial search yielded 2,240 citations, from which we identified 25 eligible studies (n = 5,345 
participants) (Figure 6.1). Studies (Table 6.1) were conducted in Canada [28-31], Taiwan [32-38], 
Australia [39-41], Spain [42-44], China [45], Japan [46], The Netherlands [47], The United States of 
America [48, 49], Brazil [50], South Korea [51], and New Zealand [52]. There were 12 (48%) 
randomized trials, including six (50%) that were multi- centre studies [28-30, 38, 40, 47]. Of the 13 
non-randomized studies, which included one retrospective cohort, five controlled before and after and 
seven interrupted time series studies, eight (62%) were conducted in a single centre [35, 42-45, 48, 49, 
51]. The median number of participants was 80 (range 19 [42] to 1,056 [51]) and the median study 
duration was 12 months (range 3 months [39] to 20 years [29]). Four studies (16%) included CKD 
Stages 1-3 [35, 37, 38, 52]; eight studies (32%) Stages 1-4 CKD [28, 31, 33, 40, 41, 46, 47, 51] and 13 
(52%) studies included Stages 1-5 CKD [29, 30, 32, 34, 36, 39, 42-45, 48-50]. 
 
Risk of bias assessment (Figure 6.1; Table D2) 
 
The reporting of both randomized and non-randomized studies was relatively incomplete. For trials, 
the methods for randomization and allocation concealment were either not defined or unclear in four 
(33%) [28, 29, 31, 33] and eight (67%) trials respectively [28-31, 33, 38, 40, 50]. There was a high risk 
of bias for blinding as participants were blinded in only one [30] (8%) trial and outcome assessors 
were blinded in four (33%) studies [30, 40, 41, 47]. High risk of incomplete outcome data was present 
in five (42%) trials [29, 33, 38, 40, 50] as was selective reporting [29, 31, 38, 40, 50].  
 
Five observational studies showed a high risk for selection bias (42%) [34, 36, 48, 49, 51] and nine 
(75%) studies showed a high risk for detection bias [35-37, 42-44, 46, 49, 51]. There was a low risk of 
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bias for selective reporting in 11 studies (92%) [34-37, 42-44, 46, 49, 51, 52]. Six interrupted time 
series studies (86%) did not pre-specify the shape of the intervention [35, 37, 42-44, 52] and in one 
(14%) study this was also unclear [46]. The criteria for baseline outcome measurements, baseline 
characteristics and protection against contamination, had either low or unclear risk of bias.  
  
Characteristics of the interventions (Table 6.2; Table D3a, Table D3b) 
 
Mode of delivery: Nineteen studies (76%) provided a one-on-one (patient and educator) setting while 
52% also provided a group setting. Only 16% of studies included the family or support person. 
Interventions were multifaceted and included face-to-face teaching (100%), conducted patient 
telephone follow-up (52%) and provided written material (76%). The teaching method was a 
combination of mainly didactic lessons (84%) and negotiated goal-setting (48%), where decisions 
regarding care were shared between provider and patient. Nineteen interventions (76%) also 
incorporated situational problem solving [35, 42, 43, 45] and interactive strategies such as skills 
coaching, patient group discussion [35, 42-45], patient mentors [42, 44] and interactive educational 
sessions [34].     
 
Intensity: The range of intervention frequencies varied from weekly to a once-only event, with most 
being a combination of interactions (32%) [30, 32-36, 39, 40]. Many interventions had multiple 
components that had different frequencies. For example,  many studies evaluated a primary, one-off, 
intervention that consisted of a slide lecture or counselling session [30, 32, 33, 35, 36, 39, 40], but also 
included a  secondary intervention such as telephone follow up [30, 32, 36, 39, 40], active exercise 
[33], patient consultations [35], or workshops [32, 35, 36] which were delivered multiple times.  The 
number of these teaching episodes ranged from one to 16. Nine studies (36%) included between one 
and five sessions and six studies (24%) incorporated six to ten sessions. Duration per teaching episode 
lasted between 60 and 90 minutes for 32% of studies, and the amount of time spent on telephone 
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follow-up or patient consultations was variable. The majority of interventions were delivered over 
three to twelve months. 
 
Content:  Fifteen studies (60%) included interventions related to nutritional counselling, with 15 others 
also focused on lifestyle modification such as weight management and smoking cessation. Fourteen 
(56%) included education about kidney disease pathology and treatment and 13 (52%) involved 
various practical skills such as blood pressure monitoring, food preparation, nutritional needs and 
medication adherence. Only four studies included management of psychosocial issues [35, 43, 44, 48].   
 
Educator: Studies generally included a nephrologist and/or a nurse as the primary educator, but allied 
health professionals such as dietitians and social workers were also involved. Nurses were involved in 
72% of studies, nephrologists in 17 (68%) and dietitians in 14 (56%) studies. Patient volunteers or 
mentors were involved in six (24%) studies [32, 34, 42-45].    
 
Effects of the interventions (Table 6.3; Figure 6.2; Table D4) 
 
The domains measured and reported and the instruments used were very heterogeneous. Primary 
outcomes included both patient reported outcomes: quality of life (QoL) (16% of studies), 
psychosocial function (8%), knowledge (28%), self-management (20%) and lifestyle modification 
(12%); as well as clinical end-points – estimated glomerular filtration rate (eGFR) (32%), dialysis 
commencement (20%), survival (20%), blood pressure (28%) and biochemical markers (32%).  
 
Evaluation of patient reported outcomes was done using a variety of questionnaires (data available 
upon request) such as the Kidney Disease questionnaire [29, 30]; Kidney Disease Quality of Life – SF 
[28, 39]; World Health Organisation quality of life questionnaire [35, 46], the Medical Outcomes 
Studies 36-item Short Form health survey (SF-36) [30, 47], the Kidney Knowledge Survey [49] and 
many others. Other instruments were used for measuring medication adherence, fatigue, depression, 
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anxiety, exercise and behaviour modification. Some outcomes such as, nutritional status, symptoms of 
CKD, cognitive function and vitality were measured in multiple different ways. Psychosocial function 
was assessed with measures of emotional state, anxiety, coping mechanisms and depression. 
Knowledge was measured in terms of knowledge about the disease, treatment and prevention. Self-
management outcomes included self-efficacy, medication adherence and self-care and lifestyle 
modification included measures of dietary changes primarily protein intake, physical activity and 
smoking. Clinical outcomes were evaluated using blood tests, blood pressure monitoring and other 
measures such as event incidence.  
 
Most studies reported more than two primary outcomes. There were nine (36%) studies that showed 
significant improvements for Quality of life (QoL) [33, 39], psychosocial function [43, 44], knowledge 
[42, 43, 51], self-management and life-style modification [33, 37, 38, 50]. While clinical endpoints 
significantly improved in eight (32%) studies: survival [32, 34, 47], dialysis [30, 34, 36, 48], eGFR 
[32], blood pressure [45, 47] and biochemical markers [45, 47, 48, 52]; two (8%) studies demonstrated 
improvement in both patient and clinical outcomes [29, 46]. A significant reduction in QoL for the 
intervention group was reported in one study [35] and five studies had no significant changes [28, 31, 
40, 41, 49]. 
 
Overall, there were 19 studies where outcomes were significantly improved in the intervention group 
or from baseline post intervention. Eight of these were trials which showed improved outcomes for: 
QoL [33, 39], knowledge [29], survival [29, 32, 47], dialysis [29, 30], lifestyle modification [33, 38, 
50], eGFR [32], blood pressure and biochemical markers [47]. Whilst 11 non-randomized controlled 
studies had improved outcomes for: psychosocial function [43, 44], knowledge [42, 43, 51], self-
management [37, 46], survival [34], dialysis [34, 36, 48], blood pressure [45] and biochemical markers 
[45, 46, 48, 52].  
 
Characteristics of effective interventions 
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Common features of the interventions with improved outcomes (Figure 6.2, Table D4) included 
teaching sessions that involved groups of patients 11/13 studies (85%) [32-34, 36, 37, 42-45, 48, 51]; 
4/4 studies (100%) included the patient’s family [42, 43, 45, 48]; 12/14 studies (86%) were interactive, 
running workshops and teaching practical skills [32-34, 36-38, 42-45, 50, 51]; and 9/12 (75%) of 
studies integrated negotiated goal setting [32, 33, 37-39, 46, 48, 51, 52]. Effective interventions had 
frequent participant / educator encounters: 4/5 studies had weekly (80%) [32, 33, 37, 45] and 7/7 
studies had monthly (100%) encounters [30, 32, 34, 36, 39, 44, 50]; they also had between six and ten 
teaching episodes, 6/6 studies (100%) [42-46, 52] and included a multidisciplinary team including 
patient volunteers/mentors, 6/6 studies (100%) [32, 34, 42-45]. 
 
6.5 Discussion  
 
We identified twenty-five studies that evaluated a broad range of educational interventions and 
outcomes for patients with CKD Stages 1-5. Significant but inconsistent improvements were detected 
mainly for quality of life, psychosocial function, knowledge, self-efficacy, lifestyle modification 
(exercise and diet), mortality, dialysis commencement and biochemical (serum albumin, proteinuria, 
haemoglobin) outcomes. Very few studies showed improvement in estimated glomerular filtration rate 
and blood pressure. Intervention components which appeared most likely to be effective involved a 
group and patient family setting; include practical skills, workshops and goal setting that is negotiated 
with the patient; conduct frequent patient / educator encounters; and involved a multidisciplinary team 
including patient volunteers or mentors.  
 
All studies reported on more than one outcome and most had a combination of significant 
improvements and non-significant results. Possible explanations for the negative or no change in 
outcome measures may be due to: study design (small sample size, short study duration); inappropriate 
use of evaluation tools; or inadequate intervention to meet patient’s needs. There was a high risk of 
bias for blinding of participants, personnel and assessors as well as unclear risk for selection bias 
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particularly allocation concealment that may have led to an over-estimate of the effects of the 
interventions in question [53, 54]. This was also present in the non-randomized studies with high risk 
for selection bias, attrition and detection bias. Using the appropriate evaluation questionnaire to 
measure the desired outcomes is important. For example, for the interventions measuring exercise, one 
study used a self-management questionnaire which failed to report on exercise outcomes [31]. While 
another study used three evaluation instruments with one specific for reporting on exercise behaviour 
[33].  
 
Another possible reason for inconsistencies in improved outcomes may be due to inadequate patient 
awareness and understanding. Patients with early stage CKD may be largely asymptomatic and be less 
aware of issues regarding complications and disease progression. As a consequence they may assign a 
lower priority to education compared to individuals with later stage CKD [16]. Providing education 
and information that is relevant to the patient’s actual and perceived stage of CKD may enhance 
learning and improve outcomes. Care also needs to be taken with regard to cultural sensitivity as 
indicated in one of the studies on medication and self-management [40]. Patients of Greek, Italian and 
Vietnamese background were recruited and although they were given written material in their own 
language and interpreter services were used, almost 50% withdrew or were lost to follow-up, which 
may have led to bias, and of uncertain effects.   
 
Previous reviews have reported on educational interventions for pre-dialysis and dialysis patients 
which focus on CKD management [21, 55]. Most of these studies were conducted with dialysis 
patients and as a result the interventions focused on improving diet, fluid management, modality 
choices and access placement. One of the reviews addressed similar outcomes to our study and also 
conducted a quality assessment of the individual studies but used the Jadad risk of bias scale [21]. The 
Jadad scale for RCTs covers three items: randomization, blinding (patients and assessors) and attrition 
[56]. A more recent review included five studies on self-management interventions for Stage 1-4 CKD 
patients [22]. Thus the number of studies addressing early stage CKD has been limited. The poor 
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quality of educational interventions for CKD and for chronic disease patients is well known [21, 57], 
however, no study has identified the intervention characteristics and components using a taxonomy 
framework.  
 
The strengths of this review are that it included randomized and non-randomized educational 
interventions for patients with Stages 1-5 CKD. Study risk of bias was assessed using accepted 
instruments [24, 25]. To facilitate the analysis across heterogeneous studies, we undertook an in-depth 
analysis of the intervention characteristics [58]  using a taxonomy framework which has been 
previously used in educational interventions for patients with diabetes [27]. Although this study relates 
to the CKD population, our findings are likely to be relevant for educational interventions in patients 
with other chronic diseases. 
 
Limitations were also evident. Due to the heterogeneity of the interventions and outcomes measured, a 
formal meta-analysis could not be done. For the same reason, we were not able to statistically evaluate 
the effects of the outcome reporting bias. Also, protocols for the included studies were not available, 
so we were not able to determine the frequency of outcome reporting bias   
 
Current guidelines for early CKD suggest early education focusing on the management of risk factors 
to delay progression as well as information tailored to the stage of CKD to allow patients to make 
informed decisions [59-61].  Patient education should be encouraged at the primary health care level 
via a model of care delivery [62] that facilitates partnership among nephrologists, general physicians 
and allied health care professionals. At a secondary care level, this process could be facilitated by a 
nurse or health educator who would refer patients to other providers as required. Further research is 
needed to develop high quality educational interventions that address the educational needs of patients 
with early stage CKD. Attention should focus on study design to minimize risk of bias and 
intervention characteristics to improve effectiveness. There is also a need to standardize outcome 
measures and evaluation methods to facilitate comparison between studies.  
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Interventions were directed at improving quality of life, psychosocial function, knowledge and self-
management; as well as clinical measures including survival, dialysis and biochemical markers. 
Significant improvements in outcomes were detected but there were inconsistencies across studies. 
Educational interventions can help improve patient outcomes, however the development of well-
designed studies that include effective interventions which are: multifaceted, group based, interactive 
and involve a multidisciplinary team, are needed. 
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Table 6.1 Characteristics of included studies   
Study  N Participants (CKD 
Stage) 
Setting Intervention Comparator Primary outcomes Study duration 
(months) 
Randomized controlled trials 
Binik et al 
(1993)[29] 
†
 
 
204 (4-5)  Multicentre, 
Canada 
Individually administered slide-
lecture, print material given 
plus psychosocial interview 
Usual care as per hospital 
program (varied across 
centres) 
Dialysis commencement; 
quality of life; long-term 
knowledge; survival 
102 ± 86.76 
(mean ± SD)  
Devins et al 
(2003)[30] 
297 (4-5) Multicentre, 
Canada 
Individually administered slide-
lecture, print material given 
plus psychosocial interview 
Usual care as per hospital 
program (varied across 
centres) 
Time to dialysis therapy 
 
18 
Campbell et 
al (2008)[39] 
56 (4-5)  Single centre, 
Australia 
Individualized nutritional 
counselling and regular follow-
up 
Usual care (generic  
education) 
Nutritional status and 
quality of life 
3 
Barrett et al 
(2011)[28] 
 
474 (3-4), between 40 and 
75 years of age, 
recruited from the 
community 
Multicentre, 
Canada 
Usual care by General 
Practitioner plus care provided 
by a nurse and  nephrologists 
use of protocols  
Usual care by General 
Practitioner 
Surrogate endpoint 
targets: BP, biochemical 
markers, medication 
adherence. Quality of life 
24  
Chen et al 
(2011)[32] 
54 (3-5), between 18 and 
80 years of age  
Single centre, 
Taiwan 
Interactive individualized 
education sessions depending 
on patients’ stage of CKD. 
Print material and dietary 
advice given 
Usual care as per hospital 
program, print material 
given  
Improved eGFR and 
number of 
hospitalizations.  
12 
Flesher et al 
(2011)[31] 
 
 
40 (3-4), older than 19 
years of age  
 
Single centre, 
Canada 
Individual dietary counselling; 
group nutrition class; CKD 
cooking classes; and exercise 
program 
Usual care for CKD Cardiovascular risk 
factors; progression of 
CKD; self-efficacy and 
self-management,  
12 
Van Zuilen et 
al (2012)[47]
  
‡
 
788 (2-4), older than18 
years of age  
 
 
Multicentre,  
The 
Netherlands 
Multifactorial care provided by 
a nurse practitioner and 
nephrologist. Use of treatment 
guidelines and interviews  
Usual care provided by 
Physician only. Treatment 
guidelines also used 
MI, stroke and CV 
mortality. Composite renal 
endpoint of death, ESRD, 
and increase in serum 
creatinine 
68.4 (median) 
Kao et al 
(2012)[33] 
94 eGFR ≥15 
ml/min/1.73m
2
,  
Single centre, 
Taiwan 
Group education lecture, 
individual exercise program 
based on patient’s stage of 
change according to TTM. 
Not specified   Exercise behaviour 
Depression 
Fatigue status 
3 
Williams et al 
(2012)[41]  
80 (3-4), with Type 1 or 2 
diabetes, on 
antihypertensive 
medication 
Single centre, 
Australia 
 
Individualized medication self-
management including 
medication review and 
motivational DVD 
Usual care as per 
nephrology and diabetes 
outpatients’ clinics 
Blood pressure control 
and medication 
adherence 
 
12  
Williams et al 
(2012)[40]  
78  (2-4), CALD patients, 
≥18 years of age with 
Type 1 or 2 diabetes 
and CVD.  
Multicentre, 
Australia 
Individualized medication self-
management including 
medication review and DVD. 
Translated print material given 
Usual care through 
outpatients’ clinics and 
primary care 
Medication self-efficacy 
and adherence. 
12 
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Study  N Participants (CKD 
Stage) 
Setting Intervention Comparator Primary outcomes Study duration 
(months) 
Paes-Barreto 
et al 
(2013)[50] 
89 (3-5), 18 years of age 
or over  
Single centre, 
Brazil 
Intense counselling involving 
dietary program and nutrition 
education  
Normal counselling 
involving dietary program 
only 
Reduced protein intake  
Adherence to low protein 
diet 
5 ± 1.5 
Teng et al 
(2013)[38] 
160 eGFR ≥ 30 
ml/min/1.73m
2
, 20 
years of age or older 
Multicentre, 
Taiwan 
Targeted lifestyle modification 
program based on the Trans-
Theoretical Model.  
Standard education about 
diet and exercise plus 
information booklet 
Diet modification 
Exercise behaviour 
Knowledge about CKD 
12 
Non-randomized studies 
Slowik et al 
(2001)[48] 
114 eGFR <30mL/min, or 
expected dialysis 
within 12 to 24 months 
Single centre, 
USA 
Multidisciplinary education 
program. Basic CKD education 
to patient groups. Advanced 
education about renal 
replacement therapy given to 
individuals.  
Control group not enrolled 
in education program  
Albumin levels and 
vascular access type  
Not specified 
Gutiérrez et 
al (2007)[43] 
24 (4-5), not on dialysis Single centre, 
Spain 
Group education workshops 
with discussions. 
Multidisciplinary care with a 
psycho-educational team and a 
patient support team.  
Pre-intervention 
measures 
Able to resolve problems  
Ability to control fear 
Improved knowledge  
6 
Yen et al 
(2008)[35] 
 
66 (3), over 18 years of 
age  
Single centre, 
Taiwan 
Multidisciplinary education on 
CKD management, health 
promotion and prevention. 
Workshop and individual 
consultations. 
Pre-intervention 
measures  
Knowledge of disease 
Quality of life 
Physiological indicators 
(biochemical markers) 
12 
Gutiérrez et 
al (2009)[44] 
41 (4-5), pre-dialysis 
patients  
Single centre, 
Spain 
Group education based on 
nursing interventions to 
evaluate psychological 
outcomes. Print material given.  
Pre-intervention 
measures 
Coping ability, control of  
fear and anxiety levels 
9 
Wu et al 
(2009)[34] 
573 
 
(3-5), between 18 and 
80 years of age 
Multicentre, 
Taiwan. 
Interactive multidisciplinary 
dialysis education (MPE). 
Education topics varied 
according to CKD stage. 
Usual care Dialysis initiation 
All-cause mortality 
12  
Jia et al 
(2012)[45] 
302 (3-5)  Single centre, 
China 
Multidisciplinary group and 
individual education based on 
CKD, dietary skills and 
motivational activities. 
Education ≥ 12 hours. 
Similar program as 
intervention group 
education but reduced 
exposure, < 12 hours. 
Progression of CKD 
(decrease GFR, initiation 
of dialysis, or 
transplantation) 
≥ 3  
Aguilera 
Flórez et al 
(2012)[42] 
19 (4-5)  Single centre, 
Spain 
Multidisciplinary group 
education encompassing CKD 
management, psychological 
issues, lifestyle changes and 
self-management 
Pre-intervention 
measures 
Improved knowledge 
about CKD and its 
management. 
3.5 
Choi et al 61 (3-4), 20 years of age Single centre, Face-to-face self-management Usual care Knowledge of disease 2 
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Study  N Participants (CKD 
Stage) 
Setting Intervention Comparator Primary outcomes Study duration 
(months) 
(2012)[51] or over, not on RRT South Korea program and reinforcement Self-care practice 
Physiological indicators 
for kidney function 
Kazawa and 
Moriyama 
(2013)[46] 
30 (3-4), with diabetic 
nephropathy.  
Multicentre, 
Japan 
Multidisciplinary self-
management skills acquisition 
program – one-on-one patient 
education, goal setting 
Pre-intervention 
measures 
Self-management and 
behaviour modification 
6  
Lin et al 
(2013)[37] 
37 (1-3a), 18 years of age 
or older 
Multicentre, 
Taiwan 
CKD self-management 
program based on self-
regulation theory. Includes 
education and self-regulation 
activities 
Pre-intervention 
measures 
Self-efficacy and self-
management behaviour 
1.25 
Wright 
Nunes et al 
(2013)[49] 
556 (1-5), 18 years of age 
or over. 
Single centre, 
USA 
Physician delivered 1-page 
educational worksheet during 
clinic visits 
Usual care (historical 
cohort group) 
Knowledge about kidney 
disease 
18 
Walker et al 
(2014)[52] 
§
 
52 (2), >18 years of age, 
with diabetes and / or 
hypertension 
Multicentre, 
New Zealand 
An education and 
implementation program of 
individualized care plans   
Pre-intervention 
measures 
Proteinuria (albumin / 
creatinine ratio) 
12 
Chen et al 
(2013)[36] 
1056 (4-5), 20 – 80 years of 
age. 
Multicentre, 
Taiwan 
Multidisciplinary care based on 
K/DOQI guidelines and pre-
ESRD care program. 
Usual care Dialysis initiation 
Mortality  
36 
Abbreviations: SD – standard deviation; eGFR – estimated glomerular filtration rate; BP – blood pressure; MI – myocardial infarct; CV – cardiovascular; ESRD – end-stage renal disease; TTM – 
Transtheoretical Model; DVD – digital versatile disc; CVD – cardiovascular disease; CALD – culturally and linguistically diverse; RRT – renal replacement therapy. 
Note: 
† 
Binik[29] has an extended study, results are reported in Devins et al[63] 
‡
 Van Zuilen[47] has an extended follow-up study, some results are reported in Peeters et al[64] 
§ 
Walker[52] was written first but published after the second Walker et al[65] paper 
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Table 6.2 Characteristics of the education interventions  
Characteristics Randomized controlled 
studies (n=12) (%) 
Non-randomized 
studies (n=13) (%) 
Setting   
One-on-one 12 (100) 7 (54) 
Group 3 (25) 10 (77) 
Patient with family 0 (0) 4 (31) 
Delivery technique   
Face-to-face (slide-lectures, counselling, interviews) 12 (100) 13 (100) 
Telecommunication [phone, DVD] 7 (58) 6 (46) 
Written 11 (92) 8 (62) 
Other (medication charts, patient diary) 2 (17) 5 (38) 
Teaching method   
Didactic 9 (75) 12 (92) 
Goal-setting – dictated 4 (33) 2 (15) 
Goal-setting – negotiated (self-management) 7 (58) 5 (38) 
Situational problem solving (practical skills) 3 (25) 6 (46) 
Other (support group discussions, workshops) 2 (17) 8 (62) 
Frequency of interventions   
Once only 5 (42) 3 (23) 
Weekly 3 (25) 3 (23) 
Fortnightly 3 (25) 3 (23) 
Monthly 4 (33) 3 (23) 
3
rd
 – 6
th
 monthly 2 (17) 4 (31) 
Unspecified / Unclear 1 (8) 1 (8) 
Quantity of teaching episodes (n)   
1 - 5 6 (50) 3 (23) 
6 - 10 0 (0) 6 (46) 
>10 1 (8) 0 (0) 
Unspecified / Unclear 5 (42) 4 (31) 
Duration per episode (minutes)   
<60 1 (8) 0 (0) 
60 - 90 3 (25) 5 (38) 
91 – 150 0 (0) 3 (23) 
Variable duration 5 (42) 4 (31) 
Unspecified / Unclear 5 (42) 4 (31) 
Total duration of intervention (months)   
< 3  1 (8) 3 (23) 
3 ≥ ≤ 12  6 (50) 5 (38) 
13 > ≤ 24  2 (17) 0 (0) 
Unspecified / Unclear 3 (25) 5 (38) 
Content   
Kidney physiology / pathology / treatment 3 (25) 11 (85) 
Diet and kidney failure 3 (25) 11 (85) 
Pharmacological and medical protocols 2 (17) 0 (0) 
Nutrition counselling / dietician advice 5 (42) 10 (77) 
Lifestyle modification (weight / smoking) 5 (42) 10 (77) 
Exercise program / information / participation 5 (42) 4 (31) 
Medication management / adherence 5 (42) 8 (62) 
Self-management skills 6 (50) 7 (54) 
Self-monitored blood pressure 3 (25) 2 (15) 
Self-management nutritional needs 4 (33) 2 (15) 
Guideline implementation 1 (8) 1 (8) 
Psychosocial / psychological adaptation 0 (0) 4 (31) 
Educator   
Social worker 2 (17) 5 (38) 
Nephrologist 6 (50) 11 (85) 
Dietician 5 (42) 9 (69) 
Nurse 7 (58) 11 (85) 
General practitioner 2 (17) 1 (8) 
Patient volunteers / mentors 1 (8) 5 (38) 
Other (health educator, research assistant,  
interpreter,  pharmacist,  physiotherapist) 
5 (42) 4 (31) 
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Table 6.3 Effect size for primary outcomes  
Primary outcome Study Intervention Control Risk Ratio  
[95%CI] 
Mean Difference 
[95%CI] 
P – value 
[ ]* 
Direction 
Quality of life / Psychosocial function        
Quality of life measured with EQ-5D  Van Zuilen[47] - - - - [0.79] ↔ 
Global quality of life - mean (±SD)  Yen[35] 2.6 (0.8) 3.1 (0.6) - -0.50 [-0.74, -0.26] <0.001 ↓ 
Depression - adjusted mean (±SD)  Kao[33] 8.99  (1.21) 9.95 (1.19) - -0.96 [-1.45, -0.47] <0.001 ↑ 
Fatigue - adjusted mean (±SD)  Kao[33] 48.75 (2.82) 51.76 (2.80) - -3.01 [-4.15, -1.87] <0.001 ↑ 
Improved nutritional status  Campbell[39] - - - - < 0.01 ↑ 
Symptoms of CKD - (mean change for scores)
 
 Campbell[39] 
†
 - - - 7.1 [0.1, 14.1] [0.05] ↔ 
Cognitive functioning - (mean change for scores)
 
 
Campbell[39] 
†
 
- - - 14.6 [5.4, 23.7] [0.003] ↑ 
Vitality (difference in mean change for scores)  Campbell[39]
 †
 - - - 12.0 [4.6, 19.5] [0.002] ↑ 
Social function - problem solving  Gutierrez[43] - - - - [<0.001] ↑ 
Emotional function – control of fear  Gutierrez[43] - - - - [<0.001] ↑ 
Coping: decrease in stress - mean (±SD)  Gutierrez[44] 3.4 (0.9) 1.3 (0.5) - 2.10 [1.78, 2.42] <0.001 ↑ 
Seeks information about illness - mean (±SD)  Gutierrez[44] 3.7 (0.9) 2.3 (0.90) - 1.40 [1.01, 1.79] <0.001 ↑ 
Seeks information to reduce fear - mean (±SD)  Gutierrez[44] 3.6 (0.9) 2.2 (0.9) - 1.40 [1.01, 1.79] <0.001 ↑ 
Controls fear response - mean (±SD)  Gutierrez[44] 3.5 (1.0) 1.7 (0.5) - 1.80 [1.46, 2.14] <0.001 ↑ 
State-Trait Anxiety Inventory – mean (±SD)  Gutierrez[44] 16.8 (10.6) 24.8 (11.7) - -8.00 [-12.83, -3.17] <0.001 ↑ 
Knowledge        
About CKD and treatment - score (±SD)  Binik[29] 2.62 (2.47) -0.26 (2.06) - 2.88 [2.21, 3.55] <0.001 ↑ 
About renal function - mean (±SD)  Yen[35] 84.2 (6.0) 85.6 (6.0) - -1.40 [-4.10, 1.30] 0.18 ↔ 
About renal disease and medical treatment 
(score)  
Gutierrez[43] 3.7 2.0 - - [<0.001] ↑ 
About CKD and management (mean score)  Aguilera[42] 9.3 7.0 - - [0.01] ↑ 
About CKD management – mean (±SD)  Choi[51] 15.41 (2.32) 11.40 (3.82) - 4.01 [2.42, 5.60] <0.001 ↑ 
About renal protection Teng[38] - - - - 0.20 ↔ 
Kidney Knowledge Survey – general score 
Wright 
Nunes[49] 
- - - - 0.5 ↔ 
Self-management / lifestyle modification        
Dietician involvement (%) Barrett[28] 21 13 - - [0.09] ↔ 
Physical activity (%) Van Zuilen[47] 62 58 - 3.8 [-1.30, 8.90] [0.15] ↔ 
Smoking (%) Van Zuilen[47] 14 14 - 0.0 [-0.01, 0.01] [0.73] ↔ 
Self-efficacy scale score - mean (±SD)  Kazawa[46] 80.9 (9.0) 77.8 (9.2) - 3.10 [-1.51, 7.71] 0.19 [0.01] ↑ 
Exercise behaviour modification - adj mean (±SD)  Kao[33] 12.82 (2.75) 10.38 (2.73) - 2.44 [1.33, 3.55] <0.001 ↑ 
Medication adherence (%) Williams[41] 58.4 66 - - [0.16] ↔ 
Medication adherence  Williams[40] - - - - >0.05 ↔ 
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Primary outcome Study Intervention Control Risk Ratio  
[95%CI] 
Mean Difference 
[95%CI] 
P – value 
[ ]* 
Direction 
Self-efficacy behaviour (mean score) Lin[37] 231.78 218.48 - 13.55 [2.63, 24.48] [0.01] ↑ 
Self-management behaviour (mean score) Lin[37] 88.68 87.45 - - [0.66] ↔ 
Self-care practice – mean (±SD) Choi[51] 3.88 (0.41) 3.85 (0.42) - 0.03 [-0.18, 0.24] 0.78 ↔ 
Adherence to low protein diet – n (%) 
Paes-
Barreto[50] 
29 (69) 22 (47.8) 1.41 [0.98, 2.03] - 0.06 ↔ 
Change in protein intake 
Paes-
Barreto[50] 
- - - - 0.04 ↑ 
Diet lifestyle behavioural change Teng[38] - - - - 0.001 ↑ 
Exercise lifestyle behavioural change Teng[38] - - - - 0.08 ↔ 
Clinical endpoints        
Survival        
Survival from time of intervention (mean years)  Devins[63] 
‡
 9.36 7.96 HR 1.32 [1.00, 1.74] - [0.05] ↔ 
Survival after initiation of dialysis (mean years) 
 
Devins[63] 
‡
 6.52 5.67 HR 1.35 [1.02, 1.78] - [0.04] ↑ 
MI, stroke, CV mortality – rate/1000 person-years  Van Zuilen[47] 21.3 23.8 HR 0.90[0.58, 1.39] - [0.63] ↔ 
Death, ESRD, 50% SCr increase - events/n  Peeters[64] 
§
 180/395 208/393 0.86 [0.75, 0.99] - 0.04 ↑ 
All-cause mortality – events/n (%) Wu[34] 5/287 (1.7) 29/286 (10) 0.17 [0.07, 0.44] - <0.001 ↑ 
Hospitalization – events/n (%) Chen[32] 5/27 (18.5) 12/27 (44.47) 0.42 [0.17, 1.02] - 0.06 [<0.05] ↑ 
Mortality – events/n (%) Chen[36]  17/528 (3.2) 30/528 (5.7) 0.57 [0.32, 1.01] - 0.05 ↔ 
Dialysis        
Time from intervention to dialysis start - mean 
(±SD)  
Binik[29] 14.9 (12.44) 10.3 (11.78) - 4.60 [1.05, 8.15] 0.01 ↑ 
Patients starting dialysis – events/n (%) Devins[30] 89/149 (59.7) 106/148 (71.6) 0.83 [0.71, 0.98] - 0.03 ↑ 
Patients requiring dialysis – events/n (%) Wu[34] 40/287 (13.9) 123/286 (43) 0.32 [0.24, 0.44] - <0.001 ↑ 
Fistula placement – events/n (%) Slowik[48] 25/57 (43) 8/57 (14) 3.13 [1.54, 6.33] - 0.001 ↑ 
Patients starting dialysis – events/n (%) Chen[36]  46/528 (8.7) 21/528 (4.0) 2.19 [1.33, 3.62] - 0.002 ↑ 
eGFR        
eGFR decline 4 ml/min/1.73m
2
 – events/n (%) Barrett[28] 28/238 (11.8) 23/236 (9.7) 1.21 [0.72, 2.03] - 0.48 ↔ 
MDRD (ml/min/1.73m
2
)  Van Zuilen[47] 36.6 35.8 - 0.82 [-0.14, 1.78] [0.10] ↔ 
eGFR (ml/min/1.73m
2
) - mean (±SD)  Chen[32] 29.11 (20.3) 15.72 (10.67) - 13.39 [4.74, 22.04] 0.004 ↑ 
eGFR (10% reduction) – events/n (%) Flesher[31] 19/23 (82.6) 8/17 (47.1) 1.76 [1.03, 3.01] - 0.04 [0.21] ↔ 
eGFR (ml/min) – mean (±SD) Jia[45] 37 (16) 38 (15) - -1.00 [-4.50, 2.50] 0.58 ↔ 
eGFR (ml/min/1.73m
2
) - mean (±SD)  Yen[35] 41.2 (11.7) 42.1 (10.6) - -0.90 [-4.71, 2.91] 0.64 ↔ 
eGFR (ml/min/1.73m
2
) – mean (±SD)  Kazawa[46] 34.8 (15) 33.2 (11.6) - 1.60 [-5.19, 8.39] 0.64 [0.40] ↔ 
Change in eGFR – mean (±SD) Choi[51] -0.37 (5.81) -0.06 (4.89) - -0.31 [-3.00, 2.38] 0.82 ↔ 
Blood pressure        
BP  130/80 (mmHg) – events/n (%) Barrett[28] 81/128 (63.2) 64/136 (47) 1.34 [1.08, 1.68] - 0.01 [0.76] ↔ 
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Primary outcome Study Intervention Control Risk Ratio  
[95%CI] 
Mean Difference 
[95%CI] 
P – value 
[ ]* 
Direction 
Mean systolic BP (mmHg)  Van Zuilen[47] 132 135 - -3 [-4.51, -1.49] [<0.001] ↑ 
Mean diastolic BP(mmHg)  Van Zuilen[47] 77 79 - -2 [-2.88, -1.12] [<0.001] ↑ 
Reduced systolic BP by 13 mmHg and diastolic BP 
by 8 mmHg – events/n (%) 
Flesher[31] 14/23 (60.9) 3/17 (17.6) 3.45 [1.17, 10.14] - 0.02 [0.07] ↔ 
Systolic BP reduction (mmHg) – mean [95%CI:]  Williams[41] -6.9 [-13.8,0.02] -3.0 [-8.4,2.4] - - [0.37] ↔ 
Diastolic BP reduction (mmHg) - mean [95%CI:]  Williams[41] -2.25 [-5.2,0.7] -3.1 [-5.9, -0.3] - - [0.68] ↔ 
Systolic BP (mmHg) – mean (±SD)  Jia[45] 128 (15) 131 (15) - -3.00 [-6.39, 0.39] 0.08 [0.05] ↔ 
Diastolic BP (mmHg) - mean (±SD)  Jia[45] 72 (9) 77 (10) - -5.00 [-7.16, -2.84] <0.001 [0.03] ↑ 
Systolic BP (mmHg) - mean (±SD)  Yen[35] 141.9 (15.9) 141.5 (16.0) - 0.40 [-5.04, 5.84] 0.89 ↔ 
Diastolic BP (mmHg) - mean (±SD)  Yen[35] 84.7 (7.6) 84.2 (8.3) - 0.50 [-2.22, 3.22] 0.72 ↔ 
Systolic BP (mmHg) - mean (±SD)  Kazawa[46] 130 (14.4) 134.1 (18.4) - -4.10 [-12.46, 4.26] 0.34 [0.59] ↔ 
Diastolic BP (mmHg) - mean (±SD)  Kazawa[46] 69.6 (10) 72.2 (11.5) - -2.60 [-8.05, 2.85] 0.35 [0.44] ↔ 
Biochemical markers        
LDL<2.5 (mmol/L) – events/n (%) Barrett[28] 78/122 (63.9) 76/128 (59.4) 1.08 [0.89, 1.31] - 0.46 [0.74] ↔ 
HbA1c  7.0% in diabetics – events/n (%) Barrett[28] 40/49 (81.6) 43/52 (82.7) 0.99 [0.82, 1.18] - 0.89 [0.76] ↔ 
Hb  105 (g/L) – events/n (%) Barrett[28] 125/128 (97.7) 130/136 (95.6) 1.02 [0.98, 1.07] - 0.35 [0.64] ↔ 
Low-density lipoprotein - mean (mmol/L)  Van Zuilen[47] 2.39 2.50 - -0.11 [-0.18, -0.03] [0.01] ↑ 
HbA1c in diabetics (%) Van Zuilen[47] 7.0 7.1 - 0.10 [-0.08, 0.28] [0.25] ↔ 
Urinary protein (25% reduction) – events/n (%) Flesher[31] 12/23 (52.2) 8/17 (47.1) 1.11 [0.59, 2.10] - 0.75 [0.54] ↔ 
Albumin level on dialysis start (µg/dL) – mean 
(±SD)  
Slowik[48] 3.9 (0.7) 3.5 (0.6) - 0.40 [0.16, 0.64] 0.001 [<0.05] ↑ 
Haemoglobin (g/L) - mean (±SD)  Jia[45] 119 (26.6) 115.6 (21.2) - 3.60 [-1.80, 9.0] 0.20 [0.03] ↑ 
Serum albumin (g/L) - mean (±SD)  Jia[45] 43.3 (3.78) 40.9 (4.01) - 2.40 [1.52, 3.28] <0.001 [0.04] ↑ 
Serum creatinine - mean (±SD)  Yen[35] 2.1 (0.7) 2.1 (0.5) - 0.00 [-0.21, 0.21] 1.00 ↔ 
HbA1c (%) - mean (±SD)  Kazawa[46] 6.3 (0.9) 6.6 (1.1) - -0.30 [-0.81, 0.21] 0.25 [0.04] ↑ 
Decrease in proteinuria (ACR) (mg/mmol/month) Walker[52] - - - - 0.002 ↑ 
Abbreviations: EQ-5D – European Quality of Life-5 Dimensions; SD - standard deviation; CKD – chronic kidney disease; MI – myocardial infarction; CV – cardiovascular; ESRD – end-stage renal disease; SCr – serum 
creatinine; eGFR- estimated Glomerular Filtration Rate; MDRD – Modification of Diet in Renal Disease formula; BP – Blood Pressure; 95%CI – 95% confidence interval; LDL – Low Density Lipoprotein; HbA1c – glycated 
haemoglobin; Hb – haemoglobin; ACR – albumin / creatinine ratio 
Note: [ ]* = p-values provided by the respective studies, which have been calculated using a number of statistical tests including, Fisher’s exact test[31], Friedman test[46], adjusted for baseline measurements[28], two-group T-
test and chi-square statistics[48]. These may differ from the P value calculated in this assessment. 
†
Difference in mean change as provided in the study. 
‡ 
Cox proportional hazards as provided by Devins et al[63], this study was an extension of Binik et al[29].  
§ 
Results provided by Peeters et al[64], this was an extension of the van Zuilen et al[47] study. 
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a) 
 
b) 
 
c) 
 
Figure 6.1 Combined risk of bias for each study type – a) randomised controlled trials; b) controlled before 
and after studies; and c) interrupted time series 
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a) 
 
b) 
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c) 
 
Figure 6.2 Characteristics of interventions where a significant improvement in at least one primary 
outcome was reported in a study. The proportion shown is for the number of studies that included the 
specific characteristic for:  a) mode of delivery b) intensity c) content / educator. 
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Chapter 7 Discussion and Conclusions 
 
7.1 Summary of findings 
 
Management of chronic kidney disease (CKD) is complex. Since the kidneys are involved in 
detoxifying the blood, urine production, blood pressure management, bone homeostasis, red blood cell 
production and maintenance of the acid base balance in the body [1], their impairment will affect a 
series of bodily functions and organs. During the initial stages of the disease (Stages 1-3a) the patient 
can be asymptomatic and they may be unaware of it. However in the later stages (Stages 3b-5) patients 
will require medication to lower their blood pressure and lipids, and they may also require anti-platelet 
therapy, vitamin D supplements and uric acid lowering therapy [2]. Patients with CKD are at higher 
risk of dying from heart attacks and cardiovascular disease [3], and also more likely to have other 
comorbidities such as diabetes and hypertension [4, 5].   
 
Chapter 3 
 
Guidelines for early CKD provided recommendations for the detection of the disease, medical 
management, lifestyle modification and education. However some discrepancies surfaced relating to 
recommendations for diagnostic testing of eGFR, blood pressure and glucose targets, protein and 
albumin excretion, treatment of hypertension and proteinuria, and dietary protein intake. 
Recommendations for health promotion and education were noted but were unsupported with tools or 
specific strategies for implementation. The guidelines were found to be comprehensive and consistent 
in scope, but their methodologies varied. Differences between the recommendations may be attributed 
to the methodology used and the evidence available at the time. 
 
Chapter 4 
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The modifiable risk factors for CKD include hypertension, diabetes, obesity and smoking, while the 
non-modifiable factors include age, family history and being of Aboriginal/ Torres Strait Islander 
descent or other ethnic minority.  Participants in our study were aware of most modifiable risk factors 
but not of the non-modifiable ones. They also considered alcohol and inadequate fluid intake as risk 
factors for CKD. Participants believed that consequences for people with CKD would be less severe 
than for those with diabetes, or cardiovascular disease (CVD). These findings may help illustrate 
participants’ ‘invisible’ perceptions about CKD, as many demonstrated limited understanding of the 
risk factors and comorbidities associated with CKD.  
 
Chapter 5 
 
The diagnosis of CKD was very difficult for patients to comprehend. Participants were not generally 
aware of the effects of CKD progression, its multiple comorbidities and often felt overwhelmed, 
confused and unable to control their condition. Many had fears and anxieties about the future, 
including dialysis and premature mortality. Participants were willing to be proactive in their own 
healthcare, but they had limited confidence in disease management due to lack of knowledge about 
their condition, or strategies to improve their outcomes. They requested early, comprehensive and 
practical information that focussed on learning about kidney function, dietary advice, medication 
safety, and managing multiple co-morbidities.  
 
Chapter 6 
 
Educational interventions for patients with early stage CKD are uncommon and little is known about 
their effectiveness or quality. In our study we were able to evaluate 25 interventions for patients with 
CKD Stages 1-5. Results for quality of life, psychosocial function, knowledge, self-efficacy, lifestyle 
modification (exercise and diet), mortality, dialysis commencement and biochemical (serum albumin, 
proteinuria, haemoglobin) outcomes, showed significant but inconsistent improvements. Interventions 
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that involved a group and patient-family setting, included practical skills, workshops and goal setting, 
enabled frequent patient / educator encounters, and incorporated a multidisciplinary team including 
patient volunteers or mentors, appeared most likely to be effective. 
  
Studies evaluated on multiple outcomes and most had a combination of significant and minor 
improvements. Study design (small sample size, short study duration), inappropriate use of evaluation 
tools, or inadequate intervention to meet patients’ needs might be possible explanations for no change 
or negative outcome measures. The risk of bias for blinding of participants, personnel and assessors 
was high, and the risk for selection bias particularly allocation concealment was unclear; this may have 
led to an over-estimate of the effects of the interventions in question [6, 7]   
 
7.2 Strengths and limitations 
 
Chapter 3 
 
Our study is the first to systematically review clinical practice guidelines for CKD. The AGREE II 
instrument was used to appraise the guidelines with satisfactory agreement between two reviewers 
who were affiliated with the KHA-CARI guideline group.  This may be seen as a geographical bias 
however, the AGREE II instrument is solely focussed on guideline development and the reporting of 
methodology, making this bias unlikely. Due to resource limitations, the non-English guidelines 
included in the review were not assessed for methodological rigour.  
 
Chapters 4 and 5 
 
We have shown how patients’ perceive the risks and comorbidities associated with CKD compared to 
diabetes and cardiovascular disease. Patients’ attitudes, beliefs and thoughts about the risk factors of 
CKD, comorbidities, and future health were also analysed. In addition, we were able to identify their 
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information needs, priorities and the reasons underpinning their preferences for information and 
treatment. However, there were some limitations. The sample size was small, which was probably 
attributed to the difficulty in recruiting patients with early stage CKD. Many did not consider they 
were at risk nor believed they had kidney disease. Although the study was cross-sectional and non-
English speaking participants were excluded, those from different ethnic populations were included. 
Nevertheless, the transferability of our findings may be particularly limited for patients of culturally 
and linguistically diverse backgrounds. 
 
Chapter 6 
 
The systematic review on education interventions for patients with Stages 1-5 CKD included both 
randomized and non-randomized studies. We used the Cochrane Collaboration risk of bias tools, 
which are accepted and validated instruments to  assess the quality of the studies [8, 9].[8, 9] Due to 
the heterogeneity of the interventions, an in-depth analysis of the intervention characteristics was 
conducted [10] using a taxonomy framework, previously used in educational interventions for patients 
with diabetes [11]. The interventions and outcomes measured were varied and therefore a formal meta-
analysis could not be done. Even though the study relates to the CKD population, our findings are 
likely to be relevant for educational interventions in patients with other chronic diseases.  
 
7.3 Comparison with other studies 
 
Chapter 3 
 
Recommendations for the detection of early CKD in terms of the risk factors, appeared to be reflective 
of current epidemiological data supporting the association between obesity, hypertension, 
cardiovascular disease, and chronic kidney disease [12, 13]. All guidelines reported angiotensin 
converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) for the treatment of 
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hypertension as first line therapy, however there were explicit inconsistencies in the regimens 
recommended. While some guidelines recommended ACEi and ARB as monotherapy, others 
recommended both as combination therapy. Combination therapy has been shown to increase the risk 
of cardiovascular death, hypotension, renal dysfunction and hyperkalaemia [14, 15].  This evidence 
was not available at the time of guideline development for most of the guidelines. Inconsistencies were 
also found in the recommendations for glucose control, where the HbA1c target ranged from 6.5 - 
7.5% and protein restriction. Evidence suggests that intensive glucose lowering is associated with 
complications such as hypoglycaemia [16, 17]. There was also no conclusive evidence that protein 
reduction would delay CKD progression [18, 19]. 
 
Chapters 4 and 5 
 
Although participants had received information about CKD, the majority still had limited knowledge 
about the disease, related risk factors and comorbidities. Almost half thought alcohol intake and about 
three quarters believed inadequate fluid intake were risk factors for CKD. These are similar to results 
from previous studies where participants thought that alcohol misuse caused kidney disease [20, 21]. 
Patients appeared to regard diabetes and CVD as more serious conditions than CKD. They consistently 
indicated higher event rates for stroke, heart attack and death when associated with diabetes and CVD. 
However evidence indicates that individuals with earlier stages of CKD are at significantly increased 
risk of CVD, independent of other CVD risk factors [22]. In another study, patients also identified 
diabetes and hypertension as the main risk factors for CKD, but unlike our study, their beliefs related 
to diabetes and CVD associated complications were not evaluated [23]. 
 
Many participants felt that learning about their condition commenced too late. They believed the onset 
of CKD could have been delayed if they had been more aware of the effects of having diabetes and 
hypertension, and wished they had managed them better.  Previous studies have identified similar 
issues where patients perceive their disease to be less threatening in the initial stages compared to 
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those with advanced disease. Their perceived knowledge improved as the disease progressed [24, 25]. 
These studies have identified patients’ knowledge gap about CKD, however, their perceptions about 
CKD-related co-morbidities were not assessed. 
 
Like other studies, we have found that not only did patients want more information about CKD and the 
associated risk factors, they also wanted to be educated about dietary changes, medication safety, 
better patient-physician communication and more public awareness [26-30]. Although patients 
recognised it was important to ask questions and be involved in shared-decision making [31, 32], they 
felt intimidated and unable to formulate questions during consultations. They also sensed there was no 
opportunity to ask questions due to the limited time allocated.  
 
Chapter 6 
 
Previous reviews on CKD educational interventions have mainly involved studies for the management 
of pre-dialysis and dialysis patients [33, 34]. Thus outcomes focused on diet, fluid management and 
renal replacement therapy. One of the reviews addressed similar outcomes to our study. It also 
conducted a quality assessment of the individual studies but used a different risk of bias scale which 
only covers three risk of bias domains; randomization, blinding and attrition [34, 35]. A more recent 
review on interventions for Stage 1-4 CKD patients included only five studies on self-management 
[36], indicating the limited number of studies addressing early stage CKD. The poor quality of 
educational interventions for CKD and for chronic disease patients is well documented [34, 37]. 
Furthermore, no study has used a taxonomy framework to highlight intervention characteristics and 
components.  
 
7.4 Implications for practice 
 
Chapter 3 
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Although there were some inconsistencies with the guideline recommendations, clinicians should 
continue to use guidelines as the basis for clinical management. The guidelines were developed 
systematically and based on the best available evidence at the time. However they need to be updated 
regularly so that any new evidence can be integrated into patient care. Such is the case for the use of 
ACEi and ARB as first line therapy versus combination therapy for blood pressure management. New 
evidence for blood pressure targets suggests that a target below 125/75 to 130/80mmHg provides no 
extra benefit than a target of <140/90 for patients with CKD [38].  
 
Chapter 4 
 
In our study, it was evident that participants had limited awareness about risk factors and 
comorbidities, even though 40% of them had been diagnosed for over five years. Therefore, it is 
necessary for patients to be educated during the early stages of the disease. An education program 
needs to be implemented which meets patients’ needs and allows patient learning barriers to be 
identified and addressed. Educational interventions that are based on a health care model or theory 
may facilitate the learning process as they can help address patients’ beliefs and barriers to managing 
their disease [39, 40].  Public awareness about CKD can also be improved by promoting awareness 
programs and by encouraging patients and their families to access information from consumer based or 
nephrology organisations such as Kidney Health Australia (KHA) [41], the National Institute of 
Diabetes and Digestive and Kidney Diseases (NIDDK) [42]. 
 
Chapter 5 
 
The diagnosis of CKD can have a detrimental psychosocial impact on patients [31, 43]. They can feel 
overwhelmed by prognostic uncertainty, lifestyle changes, hopelessness and loss of control. Health 
care providers should encourage open communication, acknowledge patients’ concerns, suggest 
positive coping mechanisms, and provide access to psychosocial support. Both patient support and 
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self-management education have been shown to improve patient health outcomes and treatment 
satisfaction [44, 45]. The development, dissemination and implementation of educational resources are 
necessary to facilitate patient education. At the same time, increasing awareness amongst primary 
health care providers is also necessary. The nephrology community could facilitate regular CKD 
workshops and training, and other common and inherited autoimmune renal diseases. 
 
Participants voiced their concerns about the lack of knowledge related to dietary needs and medication 
safety. For this reason we believe it is imperative that newly diagnosed patients receive dietary advice 
including practical recommendations such as recipes and medical information that focuses on possible 
side-effects, drug interactions and clear explanation of their direct benefit in CKD prevention. 
Information about CKD should be accessible in the primary healthcare setting particularly targeted at 
individuals with risk factors for CKD including diabetes and hypertension.  
 
To allow patients to make informed decisions about their care, education needs to be promoted at the 
primary health care level via a model of care [46] that allows collaboration among nephrologists, 
primary care physicians and allied health care professionals. A CKD patient care pathway may be 
useful for implementing strategies to increase patient awareness of CKD, promote self-management 
skills and patient education. The pathway would be initiated by the General Practitioner who would 
identify patients at high risk of developing CKD and those who have Stages 2-3 CKD (eGFR 90-30). 
The intervention would promote adequate screening, follow-up and education of patients and would 
involve a multidisciplinary team of health care professionals. 
 
7.5 Implications for research 
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Based on our assessment, guidelines scored consistently low in the applicability domain. This domain 
refers to the barriers and facilitators to implementation, provision of advice or tools to implement 
recommendations, potential resource implications, and provision of auditing and/or monitoring criteria 
[47]. To improve guideline uptake and implementation, we recommend that guidelines identify 
facilitators and barriers to consider additional resources such as quality indicators, algorithms, links to 
manuals, economic evaluations and cost analysis. We also suggest that guideline developers facilitate 
active consumer involvement in guideline development, and incorporate topics and outcomes that 
patients believe are important. 
 
Chapter 4 
 
Studies have shown that patients with hypertension were not any more aware that this was a risk factor 
for CKD compared to patients with normal blood pressure (3.3% versus 2.7%, respectively P=not 
significant). However, patients with diabetes did have greater awareness of the risk of developing 
CKD compared to those without diabetes (P<0.001) [21]. We suggest that research should aim to 
improve patient learning by addressing their learning needs and capabilities. Interventions that include 
dietary modification, medication adherence, self-management and education about risk factors and 
comorbidities should be considered.  
 
Chapters 5 and 6 
 
Further research is needed to develop high quality educational interventions that address the 
educational needs of patients with early stage CKD. It is recommended that these interventions be 
multifaceted [34, 48, 49], and incorporate interactive educational sessions with supplementary printed 
material such as an educational booklet or digital medium such as a DVD. Attention should focus on 
study design to minimize risk of bias and intervention characteristics to improve effectiveness. There 
is also a need to standardize outcome measures and evaluation methods to facilitate comparison 
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between studies. Outcome measures to consider include clinical parameters for renal function, blood 
pressure and glucose targets, patient knowledge, quality of life, psychosocial and behavioural factors. 
This is a research area I would like to consider and develop as a post doctorate. 
 
7.6 Conclusions 
 
The guidelines for the prevention, detection and management of CKD were evaluated for quality, 
comprehensiveness and scope. Although comprehensive, we identified some implicit and explicit 
discrepancies across guidelines in regards to detection of CKD, targets for management of risk factors 
and dietary intake of protein. This thesis also provides an in-depth assessment of patients’ awareness, 
education needs and beliefs about CKD. Patients are not aware of the interaction between kidney 
disease and developing a heart or stroke and many perceived diabetes and CVD as more threatening to 
life compared to CKD. Participants lacked knowledge about the signs and symptoms of CKD and for 
many it was difficult to believe they had the disease due to its initial asymptomatic nature. 
Development of comprehensive educational resources including practical lifestyle recommendations, 
combined with active multidisciplinary and physician engagement in prevention, are likely to promote 
patient satisfaction. Educational interventions facilitated improvements in outcomes, but these were 
inconsistent across studies. There is a need for the development of well-designed studies that include 
effective interventions that are multifaceted, group based, interactive and involve a multidisciplinary 
team. 
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Table A2. Search strategy  
 
Medline search 1948 to November Week 3 2011  
1. Kidney diseases/ 
2. Renal insufficiency/ 
3. exp renal insufficiency, chronic/ 
4. Kidney disease$.ti. 
5. (chronic kidney or chronic renal).ti. 
6. Or/1-5 
7. exp guideline/ 
8. Guideline$.ti 
9. (guideline or practice guideline).pt 
10. Or/7-9 
11. 6 and 10 
12. Or/1-3 
13. 7 or 9 
14. 12 and 13 
 
Embase search 1980 to 2011 week 50  
1. exp Chronic kidney disease/ 
2. exp Kidney failure/ 
3. exp Chronic kidney failure/ 
4. Pre-dialysis or predialysis.ti 
5. Kidney disease$.ti 
6. Or/1-5 
7. practice guideline.ti 
8. Guideline$.ti 
9. 7 or 8 
10. 6 and 9 
 
Nephrology societies searched 
 
Nephrology society Source  
Asia Pacific   
Australian and New Zealand Society of Nephrology www.nephrology.edu.au 
Hong Kong Society of Nephrology www.hksn.org 
Japanese Society of Nephrology www.jsn.or.jp/en/ 
The Korean Society of Nephrology www.ksn.or.kr/english 
Taiwan Society of Nephrology www.tsn.org.tw 
Bangladesh Renal Society / Kidney Foundation Bangladesh  www.kidneybangla.org 
Chinese Society of Nephrology No website access 
Indian Society of Nephrology www.isn-india.com 
Indonesian Society of Nephrology No website access 
Malaysian Society of Nephrology www.msn.org.my/index.jsp 
Nepal Society of Nephrology No website access 
Nephrology Society of Thailand www.nephrothai.org 
Pakistan Society of Nephrology No website 
Philippine Society of Nephrology www.psn.ph;  www.mypsn.org 
Singapore Society of Nephrology www.ssn.org.sg 
Sri Lankan Society of Nephrology No website 
Latin America  
Latin American Society of Nephrology and Hypertension (SLANH)  www.slanh.org 
Venezuelan Society of Nephrology www.svnefrologia.org 
Peruvian Society of Nephrology www.spn.pe 
*Argentinian society of Nephrology www.san.org.ar 
Brazilian society of Nephrology www.sbn.org.br 
Cuban society of Nephrology www.sld.cu/sitios/nefrologia 
Mexican Society of Nephrology and Transplantation No website 
Uruguayan society of Nephrology www.nefrouruguay.com  
*Chilean society of nephrology www.sociedaddenefro.cv.cl;  www.nefro.cl 
Paraguayan society of Nephrology www.spn.org.py 
Sociedad Boliviana de nefrologia 
La Paz society of Nephrology (Bolivia) 
No website for Bolivia but yes for La Paz 
www.galenored.com/sopanefro 
Sociedad Ecuatoriana de nefrologia No website 
Colombian Association of nephrology and hypertension www.asocolnef.com 
Sociedad Panamena de nefrologia No website 
Sociedad Dominicana de nefrologia No website 
Sociedad Hondurena de nefrologia No website 
Sociedad Nicaraguense de nefrologia No website 
Sociedad Puertorriquena de nefrologia No website 
Sociedad Costarricense de nefrologia No website 
Appendix A 
157 
Nephrology society Source  
Nephrolgy and hypertension Association of El Salvador www.medicosdeelsalvador.com;www.nefrologiaelsalvador.
com 
Sociedad Guatemalteca de nefrologia No website 
North America  
Canadian Society of Nephrology www.csncn.ca 
American Society of Nephrology www.asn-online.org 
Europe  
European Renal Association www.era-edta.org 
Albanian Society of Nephrology No website 
Algerian Society of Nephrology, Dialysis and Transplantation www.sandt.asso.dz 
Austrian Society of Nephrology www.nephro.at 
Belarus Society of Nephrology No website 
Belgian Society of Nephrology www.bvn-sbn.be  
Society of Nephrology, Dialysis and Kidney Transplantation in 
Bosnia and Herzegovina 
www.undt.ba 
Bulgarian Society of Nephrology www.bgnephrology.com 
Croatian Society for Nephrology, Dialysis and Transplantation www.hdndt.org 
Cypriot Society of Nephrology No website 
Czech Society of Nephrology www.nefrol.cz 
Danish Society of Nephrology www.nephrology.dk 
The Egyptian Society of Nephrology & Transplantation www.esnonline.net 
Estonian Society of Nephrology No website 
Macedonian Society of Nephrology, Dialysis, Transplantation & 
Artificial Organs 
www.nephrologia.org.mk  
Finnish Society of Nephrology www.terveysportti.fi/kotisivut/sivut.koti?p_sivusto=580 
* French Society of Nephrology www.soc-nephrologie.org 
Dialysis, Nephrology & Kidney Transplantation Union of Georgia www.dntunion.ge/en 
German Society of Nephrology www.dgfn.eu 
Hellenic Society of Nephrology www.ene.gr 
Hungarian Society of Nephrology www.nephrologia.hu 
Icelandic Renal Association No website 
Irish Nephrology Society www.nephrology.ie  
The Israeli Society of Nephrology and Hypertension www.isnh.org.il 
* Italian Society of Nephrology www.sin-italy.org 
Latvian Nephrologist Association No website 
Lebanese Society of Nephrology & Hypertension www.lsnh.org    
Lithuanian Nephrology, Dialysis & Transplantation Association www.lndta.lt 
Moldavian Society of Nephrology and Urology No website 
Montenegrin Society of Nephrology No website 
Moroccan Society of Nephrology www.nephro-maroc.ma/index.action  
* Dutch Federation of Nephrology www.nefro.nl 
Norwegian Society of Nephrology www.nephro.no 
Polish Society of Nephrology www.PTNefro.org 
Portuguese Society of Nephrology www.spnefro.pt 
Romanian Society of Nephrology No website 
Russian Society of Nephrology www.nephro.ru 
Scottish Society of Nephrology www.show.scot.nhs.uk 
Serbian Association of Nephrology www.kns2010.org/kontakt  
Slovak Nephrological Society www.nefro.sk  
Slovenian Society of Nephrology www.nephro-slovenia.si 
Spanish Society of Nephrology www.senefro.org 
Swedish Society of Nephrology www.njur.se 
Swiss Society of Nephrology www.nephro.ch 
Tunisian Nephrological Society www.nephro-tn.org  
Turkish Society of Nephrology www.tsn.org.tr 
The Renal Association (UK) www.renal.org 
Ukrainian Nephrology Association www.nephrology.kiev.ua  
Africa No website 
South African renal society www.sa-renalsociety.org  
African Association of Nephrology www.afran.net 
Nigerian Association of Nephrology www.nanephrology.org 
Sudanese society of kidney diseases and transplantation www.sskdt.com  
Kenya renal association www.kenyarenal.org 
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Table A3. AGREE II Instrument: domains and definitions 
Domain Content No. of 
items 
Scope and purpose Addresses the overall aim of the guideline, the specific clinical questions 
and the target patient population 
3 
Stakeholder involvement Addresses the extent to which the guideline represents the views of its 
intended users (relevant professional groups, patients, target users 
defined, piloting among target users) 
3 
Rigour of development Addresses the process used to collect and synthesize the evidence, the 
methods to formulate the recommendations, process for updating the 
guidelines, external review 
8 
Clarity and presentation Addresses the language and format of the guideline (recommendations 
are specific and unambiguous, different options for management are 
presented, key recommendations are identifiable, tools for application are 
available) 
3 
Applicability Addresses the likely organisational, behavioural, and cost implications of 
applying the guideline, key criteria for monitoring and/or audit purposes 
4 
Editorial independence Addresses the independence of the recommendations and 
acknowledgement of possible conflict of interest from the guideline 
development group 
2 
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Item B1 – Participant survey  
 
 
Age: ______    Male / Female 
 
Please read the following questions and circle the answer in the scale provided.  
 
a) Consider 100 people who have type 2 diabetes, for more than 5 years. How many people do you think 
will develop: 
 
 
 
 Comments: _________________________________________________________________ 
___________________________________________________________________________ 
___________________________________________________________________________ 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
 
1. Kidney 
3. Heart attack 
0 100 50 70 90 30 10 20 40 60 80 
2. Stroke 
0 100 50 70 90 30 10 20 40 60 80 
0 100 50 70 90 30 10 20 40 60 80 
4. Cancer 
0 100 50 70 90 30 10 20 40 60 80 
0 100 50 70 90 30 10 20 40 60 80 
5. Death 
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b) Consider 100 people over the age of 50, who have moderate kidney damage (eGFR 30-59 mL/min), for 
5 years. How many people do you think will develop: 
 
 
 
 
 
Comments: _________________________________________________________________ 
___________________________________________________________________________ 
___________________________________________________________________________ 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
 
 
   
1. Heart attack 
3. Cancer 
0 100 50 70 90 30 10 20 40 60 80 
2. Stroke 
0 100 50 70 90 30 10 20 40 60 80 
0 100 50 70 90 30 10 20 40 60 80 
4. Death 
0 100 50 70 90 30 10 20 40 60 80 
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c) Consider 100 people over the age of 50, with cardiovascular disease, for 10 years. How many people 
do you think will develop: 
 
 
 
Comments: _________________________________________________________________ 
___________________________________________________________________________ 
___________________________________________________________________________ 
___________________________________________________________________________ 
___________________________________________________________________________ 
  
1. Heart attack 
3. Kidney disease 
0 100 50 70 90 30 10 20 40 60 80 
2. Stroke 
0 100 50 70 90 30 10 20 40 60 80 
0 100 50 70 90 30 10 20 40 60 80 
4. Cancer 
0 100 50 70 90 30 10 20 40 60 80 
0 100 50 70 90 30 10 20 40 60 80 
5. Death 
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d) What factors can increase your chances of developing chronic kidney disease?  Tick your answers. 
 
 
 
 
 
Comments: _________________________________________________________________ 
___________________________________________________________________________ 
___________________________________________________________________________ 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
 
 
 
1. Family history of kidney disease 
2. Over 60 years of age 
3. High blood pressure 
4. Obesity  
5. Alcohol consumption 
6. Aboriginal or Torres Strait                   
    Islander 
7. Diabetes 
8. Over 50 years of age 
9. Cancer 
10. Smoking 
11. Inadequate fluid intake 
12. Other (please specify)  
13. Other (please specify) 
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Table C1: Running sheet for focus groups 
 
Topic Question Guides 
Introduction  Welcome and thank participants for attending 
 Introduce yourself (facilitator) and other study researchers present during the session. 
(State your workplace and affiliations) 
 Introduce the study: who is involved, types of participants, recruiting centres, the 
purpose of the study and intentions.  
 Remind participants that the study consists of:  
1. Voluntary participation; leave at any time; discuss issues privately. 
2. Confidential; nothing is traced back to you. 
3. Free to agree or disagree with other’s opinions. 
4. Respectful and considerate of one another. 
5. Ask questions but answer not guaranteed.  
6. Discussion will be recorded; transcribed and analysed later on. 
Ice breaker As the participants introduce themselves, they should provide an answer to ‘ice breaker’ 
question provided by the facilitator. Example of a question: What is the one thing you really 
enjoy doing? 
Experiences  
 
 
We’ll start off this session by discussing your experiences since your diagnosis.  
The following questions were used by the facilitator to stimulate discussion about 
participants’ experiences at the time of diagnosis and since then. 
1. How did you react or what were your initial thoughts and feelings when you were told 
you have kidney disease? 
2. How did you find out that you had kidney disease? Did you have any signs / 
symptoms? 
3. What sorts of things were you told about kidney disease? 
4. Has kidney disease made an impact on your day-to-day living? How? 
The facilitator can engage others into the conversation by asking questions such 
as: 
1. Do people agree? 
2. Anyone have anything else to add/say? 
3. Any other opinions/experiences that we haven’t discussed?  
Current concerns The following questions were sued to stimulate discussion about the participants’ 
major concerns. 
1. Do you have any concerns about the short-term and long-term future?  
2. Are you concerned about any long-term impacts of chronic kidney disease?  
3. How has your diagnosis affected your family?  
4. How are you coping (physically, emotionally, psychologically)? Do you get any 
support? (examples, services, financial, community nurse)  
Current 
knowledge 
The following prompt questions were used to stimulate discussion about what 
participants know about kidney disease and about what they would like to know.  
1. Would anyone like to share what they know? 
2. What do you know about chronic kidney disease? (diagnosis, prevention, treatment, 
lifestyle impact) 
3. When you were diagnosed - What sorts of things did you want to know? Have you been 
given this information? 
4. Is there anything else you would like to know about CKD? Any questions that have not 
been answered? 
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Topic Question Guides 
Suggestions for 
patient education 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The following prompt questions were used to discuss participant’s ideas and 
opinions about patient education and available services.  
1. What kind of information do you think is important to people with CKD?  
2. Where do you go to get your information? 
Ormandy
1
 (2008) topics – use as Prompts 
1. CKD information 
2. Renal replacement therapy 
3. Physical symptoms and body image 
4. Complications of both disease and treatment 
5. Family and social life 
6. Work and finance 
7. Diet and fluid restriction 
8. Medication 
9. Tests and blood results 
10. Psychological impact 
11. Other patients’ experiences 
12. Patient organizations 
13. Service provision 
3. Who should be educating patients? (GP, nephrologist, nurse) 
4. In what format should the information/education be given? Lectures / seminars; 
pamphlets; DVD; internet site? 
5. Do you think you would benefit from listening to and speaking with patients who have 
more advanced kidney disease? How do you think this will affect you? 
6. Do you ask your doctor any questions? Why/Why not  
These questions were used to prompt discussion about behavior modification and 
lifestyle changes. 
7. What do you think are the things that motivate people to make life style changes to 
improve their health?  
8. What do you think are the things that stop people from making life changes?  
Evaluation of 
current resources 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Participants were shown various information resources, which they evaluated and 
gave feedback on.   
The following questions were used to stimulate discussion for improving current 
resources or developing one.  
Evaluation 
1. Which resource do you think is the best one? Which is the most attractive to you?  
2. Does it make you want to read it? Is it easy/hard to read? Is it interesting? Is it 
motivating or boring? Is it easy or difficult to understand? 
Improvement 
3. What can be done to improve these publications/resources? E.g. Less writing? More 
writing? More pictures? 
4. Should we include a question and answer section?  
5. Should we include a section that advises on the type of questions you should be asking 
your doctor? 
6. Should we include some form of track record sheet, which will be managed by you? 
Close  Thank participants and give out reimbursements.  
 
1. Ormandy P. Information topics important to chronic kidney disease patients: a systematic review. Journal of 
Renal Care. 2008;34(1):19-27. 
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Table C2 Kidney disease information  
 
Organization Type Title  Web source 
Kidney Health 
Australia 
Pamphlet (2008) Kidneys & Blood Pressure www.kidney.org.au 
Pamphlet (2008) Kidney & Urinary Health 
Pamphlet (2008) Kidneys & Diabetes 
Handbook (2008) Living with reduced kidney function – a 
handbook for self-management of chronic 
kidney disease 
North West Dialysis 
Service 
Pamphlet (2007) “I have kidney failure” What does that 
mean? 
www.mh.org.au 
Pamphlet (2007) Treatment for Chronic Kidney Failure and 
End Stage Kidney Failure 
New South Wales 
Department of Health 
– Aboriginal Vascular 
Health Program 
Pamphlet (2004) Kidney disease – What is it? http://www.health.nsw.gov
.au/pubs/bhc.asp Pamphlet (2004) Blood pressure – Keepin’ it under control 
Pamphlet (2004) Heart disease – Know your risks 
Pamphlet (2004) Stroke – Early warning signs 
South Sydney 
Western Area Health 
Service  
Booklet   Kidney failure & treatment options – 
Information for patients & families 
Renal Resource 
Centre 
Booklet (2009) Eating Out: A Guide for Chronic Kidney 
Disease Patients 
www.renalresource.com 
Pamphlet (2004) Glomerulonephritis 
Pamphlet (2006) Understanding and Preventing Renal 
Bone Disease 
National Kidney 
Foundation 
Pamphlet (2004) What you need to know about Anemia 
and Chronic Kidney Disease 
www.kidney.org 
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Table D1. Search strategies 
 
Ovid MEDLINE(R) 1946 to 31 December 2014  
Search line # Searches Results 
1 exp Health Promotion/ 55,447 
2 exp Health Education/ 136,638 
3 exp Education/ 625,763 
4 exp Patient Education as Topic/ 70,911 
5 exp Self Care/ 40,543 
6 or/1-5 697,196 
7 exp Renal Insufficiency/ 126,833 
8 exp Renal Insufficiency, Chronic/ 84,668 
9 chronic kidney disease.tw. 17,991 
10 chronic renal disease.tw. 2,492 
11 or/7-10 134,891 
12 exp primary prevention/ or exp secondary prevention/ 127,673 
13 disease progression/ 105,532 
14 prevention of progression.tw. 308 
15 exp risk factors/ 574,942 
16 or/12-15 787,077 
17 6 and 11 and 16 273 
18 exp Health Knowledge, Attitudes, Practice/ 74,403 
19 education.tw. 267,654 
20 or/1-5,18-19 855,899 
21 11 and 16 and 20 555 
 
 
Embase 1996 to 31 December 2014 
Search line # Searches Results 
1 exp health promotion/ 60,320 
2 exp health education/ 181,685 
3 exp adult education/ or exp education/ or exp patient education/ 749,765 
4 education.tw. 281,327 
5 exp self care/ 40,217 
6 exp attitude to health/ 65,731 
7 or/1-6 901,583 
8 exp chronic kidney disease/ 34,894 
9 chronic kidney disease.tw. 31,097 
10 exp primary prevention/ 24,623 
11 exp secondary prevention/ 16,224 
12 exp disease course/ 1,803,810 
13 prevention of progression.tw. 423 
14 exp risk factor/ 579,349 
15 or/10-14 2,282,002 
16 exp kidney disease/ 466,647 
17 8 and 9 and 16 23,571 
18 7 and 15 and 17 671 
Appendix D 
167 
CINAHL 1982 to 31 December 2014 
Search line # Search Terms Results 
S16 S7 AND S11 AND S15  919 
S15 S12 OR S13 OR S14   248,785 
S14 (MH "Risk Factors+")   75,320 
S13 (MH "Disease Progression")   16,571 
S12 (MH "Preventive Health Care+") OR (MH "Primary Health Care")   165,747 
S11 S8 OR S9 OR S10   29,686 
S10 "chronic kidney disease.tw"   0 
S9 (MH "Kidney Diseases+")   29,686 
S8 (MH "Renal Insufficiency+") OR (MH "Renal Insufficiency, Chronic+")   15,278 
S7 S1 OR S2 OR S3 OR S4 OR S5 OR S6   180,380 
S6 (MH "Attitude to Health+")   71,116 
S5 (MH "Adult Education")   819 
S4 (MH "Self Care+")   24,935 
S3 (MH "Patient Education+")   47,331 
S2 (MH "Health Education+")   75,340 
S1 (MH "Health Promotion+")   32,040 
 
 
The Cochrane Library December 2014 
Search line # Searches Results 
1 
"renal insufficiency":ti,ab,kw or "chronic kidney":ti,ab,kw or "chronic 
kidney 
insufficiency":ti,ab,kw or "chronic renal insufficiency":ti,ab,kw or 
"chronic renal":ti,ab,kw 
(Word variations have been searched) 
4,580 
2 
"pre-dialysis":ti,ab,kw or "predialysis":ti,ab,kw or "CKD":ti,ab,kw or 
"CRD":ti,ab,kw 
(Word variations have been searched) 
1,578 
3 
"health promotion":ti,ab,kw or "health education":ti,ab,kw or "patient 
education":ti,ab,kw 
or "education":ti,ab,kw or "self care":ti,ab,kw (Word variations have 
been searched) 
33,569 
4 "health information":ti,ab,kw (Word variations have been searched) 635 
5 #1 or #2 5,090 
6 #3 or #4 33,968 
7 #5 and #6 85 
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Table D2. Risk of bias for individual studies 
a). Randomized controlled studies 
Bias criteria 
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T
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[3
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Random sequence generation 
(selection bias)             
Allocation concealment 
(selection bias)             
Blinding of participants and 
personnel (performance bias)             
Blinding of outcome 
assessment (detection bias)             
Incomplete outcome data 
(attrition bias)             
Selective reporting (reporting 
bias)             
 
b) Controlled before and after studies 
Bias criteria 
W
u
[3
4
] 
S
lo
w
ik
[4
8
] 
C
h
e
n
[3
6
] 
C
h
o
i[
5
1
] 
W
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N
u
n
e
s
[4
9
] 
Random sequence generation (selection bias) 
     
Allocation concealment (selection bias) 
     
Baseline outcome measurements similar 
     
Baseline characteristics similar 
     
Incomplete outcome data (attrition bias) 
     
Knowledge of allocated interventions (detection bias) 
     
Protected against contamination 
     
Selective reporting (reporting bias) 
     
 
c) Interrupted time series 
Bias criteria 
Y
e
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5
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A
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W
a
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e
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5
2
] 
Intervention independent of other changes 
       
Shape of intervention effect pre-specified 
       
Intervention unlikely to affect data collection 
       
Primary outcome assessed blindly or measured objectively 
       
Incomplete outcome data addressed (attrition bias) 
       
Selective reporting (reporting bias) 
       
 
 
 
Low risk 
 
Unclear risk 
 
High risk 
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Table D3a. Characteristics of educational interventions for randomized controlled studies 
Intervention 
B
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Setting             
One-on-one ● ● ● ● ● ● ● ● ● ● ● ● 
Group    ● ● ●       
Patient with family             
Delivery method             
Face-to-face (slide-lectures, counselling, interviews) ● ● ● ● ● ● ● ● ● ● ● ● 
Telecommunication [phone, DVD]   ●  ● ● ● ● ●  ●  
Written   ● ● ● ● ● ● ● ● ● ● ● 
Other (medication charts, patient diary)        ● ●    
Teaching method             
Didactic  ● ● ● ● ● ● ● ●  ●  
Goal-setting – dictated ●       ● ● ●   
Goal-setting – negotiated (self-management) ●   ● ● ● ● ●    ● 
Situational problem solving (practical skills) ●     ●      ● 
Other (support group discussions, workshops)     ●      ●  
Frequency of interventions             
Once only  ● ●   ● ●  ●    
Weekly    ● ● ●       
Fortnightly       ● ● ●    
Monthly   ●  ●  ●    ●  
3
rd
 - 4
th
 monthly ●           ● 
Unspecified / Unclear          ●   
Quantity of teaching episodes (n)             
Number 5 1 1 16  1     5 4 
Unspecified / Unclear     ●  ● ● ● ●   
Duration per episode             
Minutes  75 90   90     20  
Variable duration   ● ●    ● ●  ●  
Unspecified / Unclear ●    ●  ●   ●  ● 
Total duration of intervention             
Days  1           
Months 20  18   3 3 3 3  5 12 
Unspecified / Unclear    ● ●     ●   
Content             
Kidney physiology / pathology / treatment  ● ●  ●        
Diet and kidney failure  ● ●  ●        
Pharmacological and medical protocols ●  ●          
Nutrition counselling / dietician advice     ● ●  ●   ● ●  
Lifestyle modification (weight / smoking) ●  ●  ●     ●  ● 
Exercise program / information / participation ●   ●  ●    ●  ● 
Medication management / adherence ●    ●   ● ● ●   
Self-management skills ●   ● ●  ● ● ●    
Self-monitored blood pressure    ●    ● ●    
Self-management nutritional needs    ●   ●    ● ● 
Guideline implementation           ●   
Psychosocial / psychological adaptation             
Provider             
Social worker  ● ●          
Nephrologist ●  ●  ●   ● ● ●   
Dietician    ● ●  ● ●   ●  
Nurse ●   ● ●   ● ● ●  ● 
General practitioner ●         ●   
Patient volunteers / mentors     ●        
Other (health educator, research assistant,  
interpreter,  pharmacist,  physiotherapist) 
 
●  ●  ●   ●  
 ● 
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Table D3b. Characteristics of educational interventions – non-randomized studies 
Characteristics 
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Setting              
One-on-one ●      ● ●  ● ● ● ● 
Group ● ● ● ● ● ●  ● ● ●   ● 
Patient with family   ● ●  ●  ●      
Delivery method              
Face-to-face (slide-lectures, counselling, 
interviews) 
● ● ● ● ● ● ● ● ● ● ● ● ● 
Telecommunication [phone, DVD] ● ●     ● ● ●    ● 
Written  ● ●  ● ●  ● ●    ● ● 
Other (medication charts, patient diary, 
checklist) 
     ●   
● ● ● ●  
Teaching method              
Didactic ● ● ● ● ● ● ● ●  ● ● ● ● 
Goal-setting – dictated      ●     ●   
Goal-setting – negotiated (self-management)       ● ● ● ●  ●  
Situational problem solving (practical skills)  ● ● ●  ●   ● ●    
Other (support group discussions, workshops) ● ● ● ● ● ●   ●    ● 
Frequency of interventions              
Once only  ●      ●  ●    
Weekly      ●   ●    ● 
Fortnightly   ●    ●     ●  
Monthly ●    ●        ● 
3
rd
 – 4th monthly ● ●  ●         ● 
Unspecified / Unclear           ●   
Quantity of teaching episodes (n)              
Number  1 7 8 6 8 8  5 3  6  
Unspecified / Unclear ●       ●   ●  ● 
Duration per episode              
Minutes  150 90 120 120 90 60  90 90    
Variable duration  ●     ● ●  ●    
Unspecified / Unclear ●          ● ● ● 
Total duration of intervention              
Days   7           
Months  12  6 6  6  1 2  12  
Unspecified / Unclear ●     ●  ●   ●  ● 
Content              
Kidney physiology / pathology / treatment ● ● ● ● ● ● ● ●  ● ●  ● 
Diet and kidney failure ● ● ● ● ● ● ● ●  ● ●  ● 
Pharmacological and medical protocols              
Nutrition counselling / dietician advice  ● ● ● ● ● ● ● ●    ● ● 
Lifestyle modification (weight / smoking) ● ● ● ● ● ● ●    ● ● ● 
Exercise program / information / participation  ● ●  ●  ●       
Medication management / adherence ● ● ●    ● ●   ● ● ● 
Self-management skills   ●   ● ● ● ● ●  ●  
Self-monitored blood pressure       ●     ●  
Self-management nutritional needs      ●    ●    
Guideline implementation       ●        
Psychosocial / psychological adaptation  ●  ● ●   ●      
Provider              
Social worker ● ●  ●    ●     ● 
Nephrologist ● ● ● ● ● ● ● ●  ● ●  ● 
Dietician ● ● ● ●  ● ● ●  ●   ● 
Nurse ● ● ● ● ● ● ● ●  ●  ● ● 
General practitioner            ●  
Patient volunteers / mentors ●  ● ● ● ●        
Other (health educator, research assistant,  
interpreter,  pharmacist,  physiotherapist) 
    ●  ●  ● 
   ● 
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Table D4 Studies with significant results and their characteristics  
Intervention characteristics Studies with 
significant  results 
Total number of studies  Proportion (%) 
Setting    
  Patient with family 4 4 100 
  Group 11 13 85 
  One-on-one 14 19 74 
Delivery method    
Written 15 19 79 
Telecommunication [phone, DVD] 10 13 77 
Face-to-face (lectures, counselling, interviews) 19 25 76 
Other (medication charts, patient diary) 4 7 57 
Teaching technique    
Other (support group discussions, workshops) 9 10 90 
Situational problem solving (practical skills) 7 9 78 
Didactic 16 21 76 
Goal-setting – negotiated (self-management) 9 12 75 
Goal-setting – dictated 2 6 33 
Frequency of interventions    
Monthly 7 7 100 
Weekly 4 5 80 
Once only 6 8 75 
Fortnightly 4 6 67 
3
rd
 – 6
th
 monthly 4 6 67 
Unspecified / Unclear 1 2 50 
Quantity of teaching episodes (n)    
6 - 10  6 6 100 
1 - 5 7 9 78 
Unspecified / Unclear 6 9 67 
Duration per episode    
<60 1 1 100 
60 - 90 8 8 100 
Unspecified / Unclear 7 9 78 
91 – 150 2 3 67 
Variable duration 4 9 44 
Total duration of intervention    
< 3  4 4 100 
Unspecified / Unclear 6 8 75 
3 ≥ ≤ 12  6 11 55 
13 > ≤ 24  1 2 50 
Content    
Nutrition counselling / dietician advice 13 15 87 
Kidney physiology / pathology / treatment 12 14 86 
Diet and kidney failure 12 14 86 
Self-management nutritional needs 5 6 83 
Lifestyle modification (weight / smoking) 12 15 80 
Psychosocial / psychological adaptation 3 4 75 
Self-management skills 9 13 69 
Exercise program / information / participation 6 9 67 
Medication management / adherence 8 13 62 
Pharmacological and medical protocols 1 2 50 
Self-monitored blood pressure 2 5 40 
Provider    
Patient volunteers / mentors 6 6 100 
Social worker 6 7 86 
Dietician 11 14 79 
Other (educator, pharmacist, physiotherapist) 7 9 78 
Nurse 13 18 72 
Nephrologist 12 17 71 
General practitioner 2 3 67 
 
